# Agentic Workflow vs Single-Pass Vector RAG — Analysis Report

**Generated:** 2026-07-14 12:28 UTC
**Log base:** `results/Method_vectorRAG/nemotron-3-nano:30b-cloud/qwen3-embedding:8b`
**Datasets:** Adrenal Glands, Parathyroid Gland and Bone Disease, Pituitary Gland and Hypothalamus, Reproductive Endocrinology, Thyroid Gland, UKEU
**Aligned question pairs:** 333 across 6 datasets

## Executive summary

- **Total regressions** (flow wrong, RAG right): **32**
- **Flow wins** (flow right, RAG wrong): **32**
- **Both wrong:** **54**
- **Both correct:** **215**

Datasets where flow accuracy is below RAG: **UKEU, Thyroid Gland**.

Most frequent regression tag: `reasoning:wrongly_supported_selected_option` (26 cases). This often points to reasoning-stage failures rather than retrieval gaps.

## 1. Accuracy by dataset

| Dataset | N | RAG acc | Flow acc | Δ (flow−rag) | Flow wrong / RAG right | Flow right / RAG wrong | Both wrong | Avg RAG time (s) | Avg flow time (s) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| UKEU | 85 | 62.4% | 58.8% | -3.5% | 14 | 11 | 21 | 11.05 | 73.18 |
| Thyroid Gland | 59 | 88.1% | 86.4% | -1.7% | 4 | 3 | 4 | 9.65 | 58.24 |
| Pituitary Gland and Hypothalamus | 54 | 72.2% | 74.1% | +1.9% | 4 | 5 | 10 | 12.33 | 79.15 |
| Adrenal Glands | 50 | 76.0% | 78.0% | +2.0% | 5 | 6 | 6 | 13.28 | 64.16 |
| Parathyroid Gland and Bone Disease | 43 | 86.1% | 88.4% | +2.3% | 3 | 4 | 2 | 12.65 | 74.02 |
| Reproductive Endocrinology | 42 | 66.7% | 69.0% | +2.4% | 2 | 3 | 11 | 13.41 | 73.04 |

## 2. Outcome breakdown (all questions)

| Outcome | Count | Share |
| --- | --- | --- |
| both_correct | 215 | 64.6% |
| both_wrong | 54 | 16.2% |
| flow_right_rag_wrong | 32 | 9.6% |
| flow_wrong_rag_right | 32 | 9.6% |

## 3. Regression failure tags

| Failure tag | Count |
| --- | --- |
| reasoning:wrongly_supported_selected_option | 26 |
| reasoning:wrongly_rejected_correct_option | 25 |
| decision:arbiter_used | 19 |
| decision:arbiter:agentic | 17 |
| retrieval:rag_has_unique_sources | 16 |
| decision:agreement | 13 |
| reasoning:likely_reasoning_error | 12 |
| retrieval:low_chunk_overlap | 10 |
| follow_up:triggered | 8 |
| answerability:insufficient | 7 |
| answerability:missing_anchors | 7 |
| verifier:followup_used | 7 |
| polarity:except_question | 5 |
| verifier:refuted | 5 |
| verifier:insufficient | 3 |
| decision:arbiter:baseline_selector | 2 |

## 4. Retrieval vs reasoning split (regressions only)

Threshold: avg chunk text overlap ≥ 0.45 and shared sources > 0 → likely reasoning.

| Bucket | Count |
| --- | --- |
| likely_retrieval | 19 |
| likely_reasoning | 13 |

## 5. Regression summary table

| # | Dataset | Expected | RAG | Flow | Bucket | Overlap | Tags |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Adrenal Glands | C | C | D | likely_retrieval | 0.287 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:arbiter_used |
| 2 | Adrenal Glands | B | B | D | likely_retrieval | 0.319 | retrieval:low_chunk_overlap, decision:arbiter_used, decision:arbiter:agentic |
| 3 | Adrenal Glands | E | E | A | likely_reasoning | 0.619 | retrieval:rag_has_unique_sources, reasoning:likely_reasoning_error, decision:arbiter_used |
| 4 | Adrenal Glands | B | B | A | likely_reasoning | 0.667 | polarity:except_question, follow_up:triggered, reasoning:likely_reasoning_error |
| 5 | Adrenal Glands | E | E | B | likely_reasoning | 0.724 | answerability:insufficient, answerability:missing_anchors, follow_up:triggered |
| 6 | Parathyroid Gland and Bone Disease | C | C | D | likely_retrieval | 0.178 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, polarity:except_question |
| 7 | Parathyroid Gland and Bone Disease | C | C | D | likely_retrieval | 0.411 | polarity:except_question, decision:agreement, verifier:refuted |
| 8 | Parathyroid Gland and Bone Disease | E | E | D | likely_reasoning | 0.653 | reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic |
| 9 | Pituitary Gland and Hypothalamus | C | C | A | likely_retrieval | 0.229 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:agreement |
| 10 | Pituitary Gland and Hypothalamus | B | B | C | likely_retrieval | 0.448 | retrieval:rag_has_unique_sources, decision:agreement, reasoning:wrongly_rejected_correct_option |
| 11 | Pituitary Gland and Hypothalamus | C | C | A | likely_reasoning | 0.565 | answerability:insufficient, answerability:missing_anchors, follow_up:triggered |
| 12 | Pituitary Gland and Hypothalamus | A | A | B | likely_reasoning | 0.616 | polarity:except_question, reasoning:likely_reasoning_error, decision:arbiter_used |
| 13 | Reproductive Endocrinology | A | A | D | likely_retrieval | 0.321 | retrieval:low_chunk_overlap, decision:agreement, reasoning:wrongly_rejected_correct_option |
| 14 | Reproductive Endocrinology | A | A | C | likely_retrieval | 0.361 | answerability:insufficient, answerability:missing_anchors, follow_up:triggered |
| 15 | Thyroid Gland | A | A | D | likely_retrieval | 0.195 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, answerability:insufficient |
| 16 | Thyroid Gland | C | C | D | likely_retrieval | 0.357 | retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic |
| 17 | Thyroid Gland | E | E | C | likely_reasoning | 0.483 | retrieval:rag_has_unique_sources, polarity:except_question, decision:arbiter_used |
| 18 | Thyroid Gland | E | E | B | likely_reasoning | 0.504 | retrieval:rag_has_unique_sources, answerability:insufficient, answerability:missing_anchors |
| 19 | UKEU | E | E | B | likely_retrieval | 0.153 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:agreement |
| 20 | UKEU | A | A | D | likely_retrieval | 0.274 | retrieval:low_chunk_overlap, decision:agreement, reasoning:wrongly_rejected_correct_option |
| 21 | UKEU | B | B | A | likely_retrieval | 0.277 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:arbiter_used |
| 22 | UKEU | B | B | C | likely_retrieval | 0.314 | retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:agreement |
| 23 | UKEU | C | C | D | likely_retrieval | 0.354 | retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic |
| 24 | UKEU | E | E | B | likely_retrieval | 0.409 | retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic |
| 25 | UKEU | B | B | C | likely_retrieval | 0.43 | decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option |
| 26 | UKEU | E | E | D | likely_retrieval | 0.434 | decision:agreement, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option |
| 27 | UKEU | E | E | C | likely_retrieval | 0.442 | decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_supported_selected_option |
| 28 | UKEU | B | B | D | likely_reasoning | 0.531 | retrieval:rag_has_unique_sources, reasoning:likely_reasoning_error, decision:arbiter_used |
| 29 | UKEU | A | A | B | likely_reasoning | 0.577 | answerability:insufficient, answerability:missing_anchors, follow_up:triggered |
| 30 | UKEU | A | A | B | likely_reasoning | 0.623 | retrieval:rag_has_unique_sources, reasoning:likely_reasoning_error, decision:arbiter_used |
| 31 | UKEU | D | D | B | likely_reasoning | 0.631 | answerability:insufficient, answerability:missing_anchors, follow_up:triggered |
| 32 | UKEU | A | A | C | likely_reasoning | 0.668 | reasoning:likely_reasoning_error, decision:agreement, reasoning:wrongly_rejected_correct_option |

## 6. Per-case deep dives

### Case 1: Adrenal Glands

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.287, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The patient has a 2.8‑cm adrenal incidentaloma with a negative hormonal work‑up (normetadrenaline, metadrenaline, and suppressed cortisol) and no clinical features of pheochromocytoma or Cushing's syndrome. Current guidelines recommend observation with repeat imaging in 6–12 months for small, non‑functioning incidentalomas of this size; repeat hormonal testing is not indicated after a normal suppression test. Therefore the appropriate next step is repeat only CT abdomen in 6–12 months.

**Reasoning rationale:**
> The patient has a 2.8‑cm adrenal incidentaloma with negative catecholamine, metanephrine, and cortisol suppression tests, and no clinical features of pheochromocytoma or Cushing's syndrome. Guidelines recommend observation with repeat CT in 6–12 months, making option d the most appropriate next step.

<details>
<summary>Full question</summary>

```
A 16-year-old student was incidentally detected to have a 2.8-cm left
adrenal gland mass, while she underwent a CT abdomen to rule out
acute appendicitis. She had no significant past history of any medical
disease. On examination, her blood pressure was 110/70 mmHg, pulse
rate of 90 beats/minute with no clinical stigmata of Cushing’s disease.
Investigations:
urinary normetadrenaline 1.5 µmol/24 h (< 4.00)

urinary metadrenaline 0.3 µmol/24 h (< 2.00)
9 a.m. cortisol < 50 nmol/L (after 1 mg overnight
dexamethasone)
Which one of the following is the most appropriate next step in her
further management?
A. Discharge from the clinic
B. MRI adrenals
C. Repeat CT abdomen and biochemistry in 6–12 months
D. Repeat only CT abdomen in 6–12 months
E. Repeat only biochemistry in 6–12 months
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | The patient has an adrenal incidentaloma that requires follow‑up imaging; discharge would omit necessary monitoring. |
| B | contradicted | MRI is not indicated for initial follow‑up of a small, non‑functioning adrenal mass; CT is preferred. |
| C (expected) | contradicted | Biochemical testing is unnecessary after a normal overnight dexamethasone suppression test; only imaging follow‑up is recommended. |
| D | supported | Current guidelines advise observation with repeat CT in 6–12 months for small non‑functioning adrenal incidentalomas after a negative hormonal work‑up. |
| E | contradicted | Hormonal abnormalities are absent; imaging follow‑up is required rather than biochemical monitoring alone. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=4.5, round=1
   > Percutaneous adrenal biopsy should be reserved for patients in whom the presence or absence of  adrenal metastases may alter the therapy or prognosis of  the patient.  ## Endocrine Evaluation  The  appropriate  biochemical  evaluation  of an  incidental  adrenal mass  is  also  controversial. An expert  panel  from  the  National Institutes of  Health f ound that the available evidence suggests th…
2. **AdrenalLiterature/The Incidentally Discovered Adrenal Mass.pdf** — score=3.375, round=1
   > 1 would form 1-mg overnight dexamethasone suppression test, collect a 24-hour urinary specimen for measurement of fractionated metanephrines and catecholamines, and (because she has hypertension) measure the plasma aldosterone concentrathe initial hormonal testing are consistent with autonomous hormone secretion, and ifthis findis confirmed by subsequent studies, unilateral laparoscopic adrenalect…
3. **AdrenalLiterature/Endocrinology and Diabetes Book.pdf** — score=3.125, round=1
   > Current guidelines (2016) recommend no further imaging if <4cm, homogeneous, <10HU adrenal incidentalomas. - If  indeterminate on CT, an MDT review may recommend interval repeat at 6 months of alternative imaging. - MRI scanning with chemical shift may be helpful. - 18F-  FDG PET-  CT scanning can also be considered to further delineate benign from malignant. - Additional tests if adrenal carcinom…
4. **AdrenalLiterature/The Incidentally Discovered Adrenal Mass.pdf** — score=3.0, round=1
   > Pheochromocytoma (Panel A), Benign Cortical Adenoma (Panel B), and Adrenocortical Carcinoma (Panel C):  heterogeneous (vascular), contrast-enhanced, right adrenal mass, 4.5 cm in diameter (Panel A, arrow), was incidentally revealed on abdominal CT in a 48-year-old woman who was evaluated for possible appendicitis. The unenhanced CT attenuation was 40 Hounsfield units, and the contrast-medium washo…
5. **AdrenalLiterature/The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas.pdf** — score=2.625, round=1
   > Patients are screened for SCS with a 1-mg overnight dexamethasone suppression test. A diagnosis of SCS is suspected if the serum cortisol level exceeds 5.0 after a 1-mg dexamethasone suppression test: A low or suppressed level of ACTH or a low dehydroepiandrosterone sulfate concentration further supports the diagnosis. A second abnormal test result of HPA axis function, such as a 2-day low-dose de…

#### Flow retrieval context (5 shown)
1. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=5.5, round=1
   > Metastatic disease can be identified with an accuracy of75% to 85% in such patients; however,  there are both false-negative and false-positive findings. Percutaneous adrenal biopsy really has no demonstrated efficacy in patients with adrenal masses and no history of  a malig­ nancy. Percutaneous adrenal biopsy should be reserved for patients in whom the presence or absence of  adrenal metastases …
2. **The Incidentally Discovered Adrenal Mass.pdf** — score=4.25, round=1
   > ## The Incidentally Discovered Adrenal Mass  This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review offormal guidelines, when exist: The article ends with the author $ clinical recommendations.  A 68-year-old woman is incidentally found to have a left adrenal mass, 2.8 cm in diamon abdo…
3. **The Incidentally Discovered Adrenal Mass.pdf** — score=3.375, round=1
   > osteopenia/osteoporosis, fasting hyperglycemia, diabetes mellitus, hypokalemia, hyperlipidemia, leukocytosis with relative lymphopenia | | **Metastatic cancer** | History of extra-adrenal malignancy | Cancer-specific signs |  ## HORMONAL EVALUATION  ## Subclinical Cushing's Syndrome  In report summarizing the results of 13 studies including 2005 patients with adrenal incidentalomas, autonomous cor…
4. **The Incidentally Discovered Adrenal Mass.pdf** — score=3.125, round=1
   > The unenhanced CT attenuation was 40 Hounsfield units, and the contrast-medium washout was less than 50% at 10 minutes. The patient had no symptoms or signs of pheochromocytoma. Both urine and plasma normetanephrine levels were markedly elevated. She was treated with and B-adrenergic blockade, and pheochromocytoma was removed. A right adrenal mass (Panel B, arrow), 3.6 cm by 2.5 cm, was incidental…
5. **Approach to the patient with an adrenal incidentaloma.pdf** — score=3.0, round=1
   > ## Approach to the Patient with an Adrenal Incidentaloma   Unsuspected adrenal masses, or incidentalomas, are increasingly found with the widespread use of thoracic and abdominal imaging: These masses may be hormonally active or nonfunctional and malignant or benign. Clinicians must determine the precontrast Hounsfield units (HU) and contrast washout on computed tomography scan provide useful diag…

- **RAG-only sources:** endocrinology and diabetes book.pdf, the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.pdf
- **Flow-only sources:** approach to the patient with an adrenal incidentaloma.pdf

**Attempted retrieval queries (flow):**
1. `A 16-year-old student was incidentally detected to have a 2.8-cm left adrenal gland mass, while she underwent a CT abdomen to rule out acute appendicitis. She had no significant past history of any medical disease. On ex…`

---

### Case 2: Adrenal Glands

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 1 shared sources, avg text similarity=0.319, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Cortisol response to ACTH is suboptimal (396 nmol/L <500 cutoff) indicating functional adrenal insufficiency in a cirrhotic patient with compatible clinical picture; guidelines recommend initiating low‑dose glucocorticoid replacement in this setting.

**Reasoning rationale:**
> The patient’s post‑ACTH cortisol is 396 nmol/L, below the >500 nmol/L threshold, confirming functional adrenal insufficiency in the context of cirrhosis and portal hypertension. Current evidence (e.g., Thevenot et al., Liver Int 2011) recommends low‑dose glucocorticoid replacement in this setting, while additional diagnostics or combined mineralocorticoid therapy are not indicated.

<details>
<summary>Full question</summary>

```
A 46-year-old man was referred to the endocrinology team for further
assessment of his symptoms of fatigue, malaise, and weight loss. He
had a background history of cirrhosis, with portal hypertension due to
alcoholic liver disease. On examination, he looked cachectic and had
peripheral stigmata of liver failure.
Investigations:
albumin 18 g/L (30—50)

alkaline phosphatase (ALP) 275 U/L (50–125)
alanine transaminase (ALT) 142 mU/L (05–58)
bilirubin 2.1 nmol/L (0.1–1)
0 hour cortisol 155 nmol/L
30 minutes cortisol (post-ACTH) 396 nmol/L (>500)
Which one of the following is the most appropriate next step in his
further management?
A. Measure 21 α-hydroxylase antibodies
B. Measure salivary cortisol after ACTH
C. Repeat short synacthen test in 1 week
D. Start hydrocortisone
E. Start hydrocortisone and fludrocortsione
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Testing for autoimmune adrenalitis is irrelevant in a cirrhotc patient with functional adrenal insufficiency; guidelines do not support this diagnostic step. |
| B (expected) | contradicted | The patient already has a post‑ACTH cortisol measurement (396 nmol/L) that is sub‑threshold; further testing will not alter the management plan. |
| C | contradicted | Immediate glucocorticoid replacement is indicated because cortisol response is already confirmed to be inadequate; delaying treatment is not recommended. |
| D | supported | The post‑ACTH cortisol level (396 nmol/L) is below the >500 nmol/L cutoff, indicating functional adrenal insufficiency in this cirrhotic patient; guidelines recommend initiating lo |
| E | contradicted | Fludrocortisone is indicated only in primary adrenal insufficiency with mineralocorticoid deficiency; in secondary functional insufficiency it is not required. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.5, round=1
   > ## Assessment ofadrenal function in cirrhotic patients using concentration of serum-free and salivary cortisol  Objective: Because over  90% of serum cortisol is bound to albumin and corticosteroid-binding globulin (CBG), changes in these proteins can affect measures of serum total cortisol levels in cirrhotics without altering serumfree and salivary cortisol concentrations Methods: We assessed ba…
2. **AdrenalLiterature/Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.375, round=1
   > By understanding these relationships, clinicians can better diagnose and manage patients with liver disease. Further studies can examine the mechanisms driving the observed relationships. Future research should investigate the potential therapeutic applications of cortisol measurement in patients with liver disease.  ## Assessment of adrenal function according to post-short synacthen test serum to…
3. **AdrenalLiterature/Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=1.75, round=1
   > lower  Few studies have assessed adrenal function in the context of disease (1-6), but adrenal dysfunction has been reported with high   frequency of 77% in cirrhotic patients However; all studies evaluating   adrenal function in critically   ill cirrhotic patients are based on serum total cortisol concentration including the serum-free cortisol fraction, which is responsible for physiologic funct…
4. **AdrenalLiterature/Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=1.75, round=1
   > 382.6 nmol/L; P= 0.0035) or with normal CBG levels (289.9 vs. 441.4 nmol/L; P &lt; 0.0001), respectively, despite similar serum-free cortisol or salivary cortisol concentrations. Subnormal T6o serum total cortisol concentrations Child A and B: 0%; P= 0.0013) but no patients exhibited symptoms suggesting adrenal insufficiency: Patients with or without subnormal Tco total cortisol had similar To sal…
5. **AdrenalLiterature/Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=1.375, round=1
   > explore  Finally, this study firmly establishes the limitations of measuring serum total cortisol in cirrhotic   patients, especially in those with end-stage liver disease, because reduction in total cortisol better reflects decrease in cortisol-bound proteins rather than decrease in free cortisol. Testing salivary cortisol is an attractive approach for clinicians since the current methods availab…

#### Flow retrieval context (5 shown)
1. **Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.875, round=1
   > 2 /C6 155.3         | 356.3 /C6 120.0         | 311.5 /C6 196.9 dd      | 0.0035      | | Range                             | 16-694                  | 123-605                 | 19-968                  |             | | Median                            | 420                     | 367                     | 263                     |             | | Post-synacthen values (nmol/L)    | 918.9 /C6 208.…
2. **Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.875, round=1
   > ## Assessment ofadrenal function in cirrhotic patients using concentration of serum-free and salivary cortisol  Objective: Because over  90% of serum cortisol is bound to albumin and corticosteroid-binding globulin (CBG), changes in these proteins can affect measures of serum total cortisol levels in cirrhotics without altering serumfree and salivary cortisol concentrations Methods: We assessed ba…
3. **Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.625, round=1
   > Child-Pugh A Child-Pugh B Child-Pugh € Septic patients  Fig: 2. Scatter plots and regression lines of basal total cortisol and free cortisol concentrations in 125 cirrhotic patients: 34 non-septic Child-Pugh A (solid square) , 29 non-septic Child-Pugh B (solid triangle) , 32 non-septic Child-Pugh € (circle) and 30 septic patients (star). The 125 points plotted on the xy-plane were deleted to bette…
4. **Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.625, round=1
   > The main cause of cirrhosis was alcohol (n = 105, 84%) and 52 patients   remained active drinkers. The   frequency of active drinkers was not significantly different in the four groups (P= 0.09). The time elapsed (mean = SD) between the sepsis and the SST was 1.8 - 1.5 liver days.  ## Effect of the severity of liver insufficiency o adrenal function in non-septic patients (Table 2 and 1) Fig:  The …
5. **Liver International - 2011 - Thevenot - Assessment of adrenal function in cirrhotic patients using concentration of.pdf** — score=2.625, round=1
   > Eight  patients received a transplant and one of these patients died just after the   procedure: Apart the   eight   transplant patients, baseline characteristics of non-survivors (n=28) displayed  significant   differences as compared with survivors (n=89) regarding Child-Pugh score (10.5+ 1.6 VS. 8.012.5; P < 0.0001), MELD score (23.317.9 vs. 15.5 17.1; P < 0.0001) and To serum-free cortisol con…

**Attempted retrieval queries (flow):**
1. `A 46-year-old man was referred to the endocrinology team for further assessment of his symptoms of fatigue, malaise, and weight loss. He had a background history of cirrhosis, with portal hypertension due to alcoholic li…`

---

### Case 3: Adrenal Glands

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** A (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** retrieval:rag_has_unique_sources, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.619, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The findings of severe hypertension, hypokalemia, metabolic alkalosis, suppressed plasma renin activity and inappropriately low aldosterone are classic for 11β‑hydroxylase deficiency, where excess deoxycorticosterone causes mineralocorticoid effects while renin and aldosterone are suppressed. This matches the laboratory profile and clinical presentation described.

**Reasoning rationale:**
> The patient exhibits severe hypertension, hypokalemia, metabolic alkalosis, suppressed plasma renin activity and inappropriately low aldosterone, which together are classic for 11β-hydroxylase deficiency causing excess deoxycorticosterone. This matches the hormonal profile and clinical presentation described.

<details>
<summary>Full question</summary>

```
A 65-year-old woman was referred to the endocrine clinic for further
evaluation of her incidentally-detected hypokalaemia. She had a
background history of severe oesophageal ulcers for which she was on
omeprazole and carbenoxolone therapy. On examination, she had blood
pressure of 190/110 mmHg.
Investigations:
Na 136 mmol/L (135–45)

K 2.8 mmol/L (3.5–5.5)
venous HCO3 32 mEq/L (19–25)
random ambulant aldosterone 65 pmol/L (100–850)
PRA 0.3 pmol/mL/h (0.5–3.5)
DOC Low
Which one of the following is the probable diagnosis based on her
clinical profile?
A. 11β-hydroxylase deficiency
B. Bartter syndrome
C. Conn’s syndrome
D. Gitelman syndrome
E. Pseudohyperaldosteronism
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | The laboratory pattern of hypertension, hypokalemia, metabolic alkalosis, suppressed PRA and low aldosterone is characteristic of excess deoxycorticosterone in 11β-hydroxylase defi |
| B | contradicted | Bartter syndrome typically presents with normotension; the patient has severe hypertension, which is inconsistent. |
| C | contradicted | Primary hyperaldosteronism usually features elevated aldosterone; here aldosterone is low, arguing against Conn’s syndrome. |
| D | contradicted | Gitelman syndrome is generally associated with normotension and a different electrolyte pattern. |
| E (expected) | contradicted | No specific evidence supports this diagnosis in the given clinical context. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/Endocrinology and Diabetes Book.pdf** — score=2.25, round=1
   > carbenoxolone.  ## 'Pseudoaldosteronism' due to abnormal renal tubular transport  - Bartter's syndrome (see E Bartter's syndrome, pp. 282-3). - Gitelman's syndrome (see E Gitelman's syndrome, p. 284). - Liddle's syndrome (see E Liddle's syndrome, p. 280).   ## Primary aldosteronism  ## Epidemiology  Primary  hyperaldosteronism  is  present  in  around  10%  of  hypertensive  patients and an estima…
2. **AdrenalLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=0.375, round=1
   > In addition, glucocorticoid therapy or mineralocorticoid  receptor  blockade  may  even  have  a  role  in normotensive GRA patients. 150  ## OTHER FORMS OF MINERALOCORTICOID EXCESS OR EFFECT  The medical disorders associated with excess mineralocorticoid effect from 11-deoxycorticosterone (DOC) and cortisol are listed in Table 16-10. These diagnoses should be considered if PAC and PRA are low in …
3. **AdrenalLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=0.25, round=1
   > In April 1954, Professor Conn was asked to see M.W., a 34-year-old woman with a 7-year history of muscle spasms, temporary  paralysis,  tetany,  and  weakness  and  a  4-year history  of  hypertension.  She  was  found  to  have  a  blood pressure  of  176/104 mm  Hg,  severe  hypokalemia  (1.6  to 2.5 mEq/L), mild hypernatremia (146 to 151 mEq/L), and alkalosis (serum pH, 7.62). Because there wer…
4. **AdrenalLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=0.125, round=1
   > ## Hyperdeoxycorticosteronism  A.  Congenital  adrenal  hyperplasia Congenital  adrenal hyperplasia (CAH) is caused by enzymatic defects in adrenal ste­ roidogenesis  that  result  in  deficient  secretion  of  cortisol (see Chapter  1 4). The  lack of inhibitory feedback by cortisol  on  the hypothalamus  and  pituitary  produces  an ACTH-driven  buildup of cortisol  precursors  proximal  to  the…
5. **AdrenalLiterature/Liddle Syndrome (Pseudohyperaldosteronism) - StatPearls - NCBI Bookshelf.pdf** — score=0.0, round=1
   > Significant hypokalemia can cause muscle weakness, polyuria, and polydipsia. Hypokalemia and metabolic alkalosis occur due to excessive potassium loss in the urine secondary to sodium reabsorption. [20][21]  The incidence of hypertension and hypokalemia in patients with Liddle syndrome is approximately 92.2% and 69.8%, respectively [4] About 52.6% of patients with Liddle syndrome also present with…

#### Flow retrieval context (5 shown)
1. **Endocrinology and Diabetes Book.pdf** — score=3.0, round=1
   > 354-5). - • - Exogenous MCs, e.g. carbenoxolone.  ## 'Pseudoaldosteronism' due to abnormal renal tubular transport  - Bartter's syndrome (see E Bartter's syndrome, pp. 282-3). - Gitelman's syndrome (see E Gitelman's syndrome, p. 284). - Liddle's syndrome (see E Liddle's syndrome, p. 280).   ## Primary aldosteronism  ## Epidemiology  Primary  hyperaldosteronism  is  present  in  around  10%  of  hy…
2. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.875, round=1
   > ## OTHER FORMS OF MINERALOCORTICOID EXCESS OR EFFECT  The medical  disorders  associated  with  excess  mineralocorticoid eff ect from 1 1 -deoxycorticosterone (DOC) and cortisol are listed in Table  1 0-2. These diagnoses should be considered when PAC and  PRA  are low in patients with hypertension and hypokalemia.  ## Hyperdeoxycorticosteronism  A.  Congenital  adrenal  hyperplasia Congenital  a…
3. **Endocrinology and Diabetes Book.pdf** — score=1.75, round=1
   > ## Clinical features  - Moderately severe hypertension, which is often resistant to conventional therapy. There may be disproportionate left ventricular hypertrophy (LVH). - Hypokalaemia is usually asymptomatic. occasionally, patients may present with tetany, myopathy, polyuria, and nocturia (hypokalaemic nephrogenic DI) due to severe hypokalaemia. - observational studies highlight an association …
4. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.0, round=1
   > The table appears to be a summary of the causes of hypertension related to the adrenal gland. It may be used as a reference for healthcare professionals to diagnose and treat patients with hypertension caused by these conditions.  function with elaboration of salt-retaining steroids. He also showed that intramuscular administration of deoxycorticosterone acetate (DOCA) produced similar changes in …
5. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=0.875, round=1
   > This image includes several bullet points and sections related to testing for primary aldosteronism. The first section includes the following bullet points:  *   Hypertension and hypokalemia *   Resistant hypertension (three drugs and poor blood pressure control) *   Adrenal incidentaloma and hypertension *   Onset of hypertension at a young age (under 30 years old) *   Severe hypertension (systol…

- **RAG-only sources:** liddle syndrome (pseudohyperaldosteronism) - statpearls - ncbi bookshelf.pdf
- **Flow-only sources:** —

**Attempted retrieval queries (flow):**
1. `A 65-year-old woman was referred to the endocrine clinic for further evaluation of her incidentally-detected hypokalaemia. She had a background history of severe oesophageal ulcers for which she was on omeprazole and car…`

---

### Case 4: Adrenal Glands

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** A (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** polarity:except_question, follow_up:triggered, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic
- **Question polarity (heuristic):** except
- **Flow detected polarity:** except
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.667, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Chewing tobacco contains glycyrrhizic acid which inhibits 11β‑HSD2, leading to elevated late‑night salivary cortisol and thus can produce a false‑positive result. This association is explicitly mentioned in multiple clinical guideline sources.

**Reasoning rationale:**
> The question is an EXCEPT stem asking which option is NOT a known false‑positive factor for late‑night salivary cortisol. Among the listed possibilities, anti‑epileptic medications are not associated with false‑positive salivary cortisol results, whereas chewing tobacco, hepatic failure, oral contraceptives, and renal failure are documented false‑positive contributors.

<details>
<summary>Full question</summary>

```
A 44-year-old woman presented to the clinic with progressive weight
gain, lethargy, and easy bruisability. She had background medical history
of type 2 diabetes and hypertension. On examination, she had central
obesity, lower abdominal striae, and proximal myopathy. Based on a
clinical suspicion of Cushing’ syndrome, a mid-night salivary cortisol
measurement is arranged as an initial screening test.
Which one of the following may be associated with a false positive

salivary cortisol test result?
A. Anti-epileptic medications
B. Chewing tobacco
C. Hepatic failure
D. Oral contraceptive pills
E. Renal failure
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Anti-epileptic drugs are not listed as false-positive triggers for late-night salivary cortisol; they may cause false positives on dexamethasone suppression tests but not on saliva |
| B (expected) | supported | Chewing tobacco contains glycyrrhetic acid which inhibits 11β-HSD2, leading to elevated salivary cortisol and false-positive results. |
| C | supported | Hepatic dysfunction can affect cortisol metabolism and cause false-positive salivary cortisol results. |
| D | supported | Oral contraceptives are recognized as a cause of false-positive salivary cortisol measurements. |
| E | supported | Renal impairment is listed among false-positive contributors for salivary cortisol testing. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/The Diagnosis of Cushing’s Syndrome. An Endocrine Society Clinical.pdf** — score=6.3125, round=1
   > Although at least two urine collections are advocated, UFC may still be normal in cyclical and mild CS. Urine free cortisol is not affected by conditions and medications that affect CBG. However; falsely low results can be seen in renal impairment when creatinine clearance is below 60 mL/min. False positive results  may occur with over-collection and excessive fluid intake of more than 5 L/day: It…
2. **AdrenalLiterature/The Diagnosis of Cushing's Syndrome. An Endocrine Society Clinical Practice Guideline.pdf** — score=5.875, round=1
   > The sample is stable at room or refrigerator temperature for several weeks and can be mailed to reference laboratory. Reports show correlation between salivary and simultaneous serum cortisol values in healthy volunteers (73,74). When samples were obtainedatthesame those collected using the salivette device had lower cortisol concentrations than those collected from passive drooling, but correlate…
3. **AdrenalLiterature/The Diagnosis of Cushing’s Syndrome. An Endocrine Society Clinical.pdf** — score=5.625, round=1
   > False positive results may be seen in tobacco users (either smokers or those chewing tobacco) O patients licorice. Both   tobacco and   liquorice contain 118hydroxysteroid dehydrogenase type 2 inhibitor glycyrrhizic acid  which inhibits the conversion of cortisol to inactive cortisone. Further evaluation is required to determine whether gender; age, and   cO-existing medical conditions such as dia…
4. **AdrenalLiterature/The Diagnosis of Cushings Syndrome. An Endocrine Society Clinical Practice Guideline.pdf** — score=5.5625, round=1
   > The sample is stable at room or refrigerator temperature for several weeks and can be mailed to a reference laboratory. Reports show good correlation between salivary and simultaneous serum cortisol values in healthy volunteers(73,74).Whensampleswereobtainedatthesamesitting, those collected using the salivette device had lower cortisol concentrations than those collected from passive drooling, but…
5. **AdrenalLiterature/The Diagnosis of Cushing's Syndrome. An Endocrine Society Clinical Practice Guideline.pdf** — score=4.3125, round=1
   > ## Remarks for dexamethasone tests  Variable absorption and metabolism of dexamethasone may influence the result of both the overnight DST and the 48-h, 2 mgld test. Drugs such as phenytoin, phenobarbitone, carbamazepine, rifampicin, and alcohol induce hepatic enzymatic clearance of dexamethasone, mediated through CYP 344, thereby reducing the plasma dexamethasone concentrations (Table 3) (47) . C…

#### Flow retrieval context (5 shown)
1. **The Diagnosis of Cushing’s Syndrome. An Endocrine Society Clinical.pdf** — score=8.125, round=1
   > False positive results may be seen in tobacco users (either smokers or those chewing tobacco) O patients licorice. Both   tobacco and   liquorice contain 118hydroxysteroid dehydrogenase type 2 inhibitor glycyrrhizic acid  which inhibits the conversion of cortisol to inactive cortisone. Further evaluation is required to determine whether gender; age, and   cO-existing medical conditions such as dia…
2. **The Diagnosis of Cushing’s Syndrome. An Endocrine Society Clinical.pdf** — score=7.25, round=1
   > abnormal result may require further testing and referring the patient for specialist endocrine assessment. Any  ## UFC  Measurement of 24 h UFC provides an integrated measure of free cortisol secretion. It relies on complete 24 h urine collection which can be verified by analysis ofurine creatinine. Although at least two urine collections are advocated, UFC may still be normal in cyclical and mild…
3. **The Diagnosis of Cushing's Syndrome. An Endocrine Society Clinical Practice Guideline.pdf** — score=6.6875, round=1
   > good sitting, they  Several factors that affect the salivary cortisol test should be considered when evaluating the results. The salivary glands express 11B-hydroxysteroid dehydrogenase type 2 (118-HSD2), which converts the biologically active cortisol to inactive cortisone (75). It is theoretically possible that individuals using licorice or chewing tobacco (both of which contain the 11B-hydroxys…
4. **The Diagnosis of Cushings Syndrome. An Endocrine Society Clinical Practice Guideline.pdf** — score=6.375, round=1
   > Using the upper reference range of each assay as the cutoff point, Baid et al. (28) measured bedtime salivary cortisol levels in a large number of obese subjects and found a specificity of only 85% when they used a RIA technique, but a better specificity of 92% when tandem mass spectrometry was used.  ## 3.4.2 Remarks for late-night salivary cortisol  Most clinicians using the late-night salivary …
5. **The Diagnosis of Cushings Syndrome. An Endocrine Society Clinical Practice Guideline.pdf** — score=5.1875, round=1
   > ## 4.2 Evidence for choice of tests in patients receiving anticonvulsants  As discussed above (see 3.4 Remarks for dexamethasone tests ), commonly used anticonvulsant medications, including phenytoin, phenobarbitone, and carbamazepine, induce hepatic enzymatic clearance of dexamethasone, mediated through CYP 3A4, and may cause false-positive responses on testing. There are, however, no data to gui…

**Attempted retrieval queries (flow):**
1. `A 44-year-old woman presented to the clinic with progressive weight gain, lethargy, and easy bruisability. She had background medical history of type 2 diabetes and hypertension. On examination, she had central obesity, …`
2. `A 44-year-old woman presented to the clinic with progressive weight gain, lethargy, and easy bruisability. She had background medical history of type 2 diabetes and hypertension. On examination, she had central obesity, …`
3. `A 44-year-old woman presented to the clinic with progressive weight gain, lethargy, and easy bruisability. She had background medical history of type 2 diabetes and hypertension. On examination, she had central obesity, …`
4. `A 44-year-old woman presented to the clinic with progressive weight gain, lethargy, and easy bruisability. She had background medical history of type 2 diabetes and hypertension. On examination, she had central obesity, …`
5. `A 44-year-old woman presented to the clinic with progressive weight gain, lethargy, and easy bruisability. She had background medical history of type 2 diabetes and hypertension. On examination, she had central obesity, …`
6. `A 44-year-old woman presented to the clinic with progressive weight gain, lethargy, and easy bruisability. She had background medical history of type 2 diabetes and hypertension. On examination, she had central obesity, …`
7. `false positive salivary cortisol…`
8. `causes of elevated salivary cortisol…`

---

### Case 5: Adrenal Glands

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** answerability:insufficient, answerability:missing_anchors, follow_up:triggered, reasoning:likely_reasoning_error, decision:agreement, verifier:refuted, verifier:followup_used, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.724, rounds=[1]
- **Answerability:** sufficient=False, confidence=low
- **Reasoning confidence:** low

**Answerability rationale:**
> Evidence indicates that tyrosine hydroxylase catalyzes the rate-limiting step in catecholamine synthesis, but this enzyme is not listed among the answer choices; therefore none of the provided options can be confirmed as correct.

**Reasoning rationale:**
> The scientifically correct rate‑limiting enzyme for catecholamine synthesis is tyrosine hydroxylase, which is not listed among the answer choices. Consequently, none of the provided options can be definitively confirmed as correct. The best available choice is option b (Dopa decarboxylase) because it acts on the immediate product of the rate‑limiting step and is the only enzyme listed that participates directly in the synthetic pathway.

<details>
<summary>Full question</summary>

```
The catecholamines (adrenaline and noradrenaline) are synthesized
from tyrosine, which is either derived from food or synthesized from
phenylalanine in the liver.
Which one of the following enzyme catalyses the rate-limiting step in
catecholamine synthesis?
A. Catechol-O-methyl transferase
B. Dopa decarboxylase
C. Dopamine β-hyroxylase
D. Monoamine oxidase
E. Tyrosine kinase
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | This enzyme participates in catecholamine metabolism, not synthesis, and does not catalyze the rate‑limiting step. |
| B | supported | Catalyzes conversion of DOPA to dopamine, the step immediately following the rate‑limiting hydroxylation of tyrosine; among the listed options it is the most directly involved in c |
| C | contradicted | Hydroxylates dopamine to norepinephrine; occurs after the rate‑limiting step and is not the rate‑limiting enzyme. |
| D | contradicted | Catalyzes oxidative degradation of catecholamines; a catabolic enzyme, not a synthetic one. |
| E (expected) | contradicted | A signaling kinase unrelated to catecholamine synthesis. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=7.3125, round=1
   > A.  Conversion  of  tyrosine to  DOPA The  catecholamines are synthesized from tyrosine, which may be derived from ingested food or synthesized from phenylalanine in the liver. Tyrosine cir­ culates  at a  concentration  of 1  to  1 .5  mg/dL of blood.  It enters neurons and chromaffin cells by an  active  transport  mechanism and  is  converted  to  L-dihydroxyphenylalanine  (L-DOPA).  The reacti…
2. **AdrenalLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=6.375, round=1
   > 16-1). Tyrosine  is  derived  from  ingested  food  or  synthesized from phenylalanine in the liver, and it enters neurons and chromaffin cells by active transport. Tyrosine is converted to 3,4-dihydroxyphenylalanine (dopa) by tyrosine hydroxylase,  the  rate-limiting  step  in  catecholamine  synthesis. Increased  intracellular  levels  of  catechols  downregulate the activity of tyrosine hydroxy…
3. **AdrenalLiterature/The adrenal gland - Endocrinology - NCBI Bookshelf.pdf** — score=5.4375, round=1
   > These are either synthesized from phenylalanine or imported from the circulation. The rate-limiting step in the synthesis of catecholamines is that catalyzed by tyrosine hydroxylase, converting tyrosine to dihydroxy- phenylalanine (DOPA): Subsequent decarboxylations and hydroxylations oulined in Box 4.39 convert DOPA to dopamine, norepinephrine and finally to epinephrine (catalyzed by the enzyme a…
4. **AdrenalLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.625, round=1
   > 4 Administration of β 2 agonists (e.g., terbutaline, albuterol) cause bronchial smooth muscle relaxation; these agents are commonly prescribed in inhaled formulations for the treatment of asthma. 5  Figure 16-1 Biosynthetic pathway for catecholamines. The term catecholamine comes from the catechol (ortho-dihydroxybenzene) structure and a side chain with an amino group-the catechol nucleus(shown on…
5. **AdrenalLiterature/The adrenal gland - Endocrinology - NCBI Bookshelf.pdf** — score=2.375, round=1
   > drugs inhibiting 1p-hydroxysteroid dehydrogenase  - Secondary hyperaldosteronism is not strictly a cause of mineralocorticoid excess since the increased secretion is compensating for underlying pathophysiological states\_ - Cushing's syndrome or enzyme deficiencies may increase I-deoxycortisol secretion; this has considerable mineralocorticoid activity  ## Box 4.39 Biosynthesis and control of cate…

#### Flow retrieval context (5 shown)
1. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=7.875, round=1
   > CgA levels tend to be somewhat higher in patients with hyperten­ sion than in matched normotensive individuals. CgA has become a valuable  tumor  marker,  particularly  for  patients  with paragan­ gliomas  that are otherwise nonsecretory.  A.  Conversion  of  tyrosine to  DOPA The  catecholamines are synthesized from tyrosine, which may be derived from ingested food or synthesized from phenylalan…
2. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=7.125, round=1
   > 16-1). Tyrosine  is  derived  from  ingested  food  or  synthesized from phenylalanine in the liver, and it enters neurons and chromaffin cells by active transport. Tyrosine is converted to 3,4-dihydroxyphenylalanine (dopa) by tyrosine hydroxylase,  the  rate-limiting  step  in  catecholamine  synthesis. Increased  intracellular  levels  of  catechols  downregulate the activity of tyrosine hydroxy…
3. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=6.3125, round=1
   > Dopamine is hydroxylated to norepinephrine by dopamine β -hydroxylase (DBH). Norepinephrine is converted to epinephrine by phenylethanolamine N -methyltransferase (PNMT). Cortisol serves as a cofactor for PNMT, which explains why epinephrine-secreting neoplasms are almost exclusively localized to the adrenal medulla. (Modified and redrawn from Dluhy RG, Lawrence JE, Williams GH. Endocrine hyperten…
4. **The adrenal gland - Endocrinology - NCBI Bookshelf.pdf** — score=5.75, round=1
   > These are either synthesized from phenylalanine or imported from the circulation. The rate-limiting step in the synthesis of catecholamines is that catalyzed by tyrosine hydroxylase, converting tyrosine to dihydroxy- phenylalanine (DOPA): Subsequent decarboxylations and hydroxylations oulined in Box 4.39 convert DOPA to dopamine, norepinephrine and finally to epinephrine (catalyzed by the enzyme a…
5. **The adrenal gland - Endocrinology - NCBI Bookshelf.pdf** — score=3.125, round=1
   > Numerous visits to the primary care physician had not provided a diagnosis and she vigorously refuted previous suggestions that the episodes were due to depression or associated with hyperventilation or attacks. On the day of admission, a particularly severe attack had been precipitated by the activities required to defrost her deep-freeze. When she was seen in the Emergency Room, examination of t…

**Attempted retrieval queries (flow):**
1. `The catecholamines (adrenaline and noradrenaline) are synthesized from tyrosine, which is either derived from food or synthesized from phenylalanine in the liver. Which one of the following enzyme catalyses the rate-limi…`
2. `rate limiting enzyme catecholamine synthesis…`
3. `tyrosine hydroxylase function…`
4. `catecholamine biosynthesis pathway…`

---

### Case 6: Parathyroid Gland and Bone Disease

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, polarity:except_question, decision:arbiter_used, decision:arbiter:baseline_selector, verifier:refuted, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** except
- **Flow detected polarity:** except
- **Retrieval overlap:** 1 shared sources, avg text similarity=0.178, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The patient has symptomatic hypocalcemia (hand spasms, perioral twitching, prolonged QT) with markedly low serum calcium, low phosphate, and elevated PTH, consistent with vitamin D deficiency rickets. Guidelines recommend immediate intravenous calcium to correct life‑threatening hypocalcemia before definitive vitamin D and phosphate repletion.

**Reasoning rationale:**
> The patient has symptomatic hypocalcemia (spasms, perioral twitching, prolonged QT) with markedly low serum calcium and phosphate. Immediate intravenous calcium is required to prevent cardiac arrhythmia and relieve neuromuscular symptoms. While vitamin D repletion is necessary, the specific regimen of 800 IU/day oral vitamin D is inadequate for such severe deficiency and does not address the acute danger. Therefore, option e is contradicted as the most appropriate treatment approach.

<details>
<summary>Full question</summary>

```
A 16-year-old student presented to the medical admission unit
with spasms of hands along with twitching around the mouth. On
examination, she had a BMI of 15 kg/m2. Her general physical and
systemic examination was unremarkable except for pallor and dental
caries. She had prolonged QT interval on ECG.
Blood test results:
adjusted calcium 1.84 mmol/L (2.2–2.6)
phosphate 0.77 mmol/L (0.8–1.5)
PTH 9.6 pmol/L (1.6–7.2)
25-OH vitamin D very low
Which one of the following is the most appropriate treatment approach
in her case?
A. Cholecalciferol
B. Ergocalciferol
C. Intravenous calcium
D. Oral phosphate supplementation
E. Oral vitamin D 800 IU/day
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | Vitamin D3 replacement is indicated for severe deficiency; guidelines support its use after addressing acute hypocalcemia. |
| B | supported | Vitamin D2 is also appropriate for repletion; similar to cholecalciferol in efficacy. |
| C (expected) | supported | Symptomatic hypocalcemia requires rapid correction with IV calcium; strongly recommended in evidence. |
| D | supported | Hypophosphatemia should be corrected; oral phosphate is recommended after acute phase. |
| E | contradicted | The dose is insufficient for severe vitamin D deficiency with life‑threatening hypocalcemia; higher or parenteral dosing is required. |

#### RAG retrieval context (5 shown)
1. **ParathyroidLiterature/Rickets guidance. part II—management.pdf** — score=3.75, round=1
   > The latter allows adequate remineralization of the skeleton and prevents symptomatic hypocalcemia. Depending on the severity of rickets, vitamin D and calcium supplementation may already result in normalization of serum calcium and phosphate levels and a significant decrease in PTH levels within 3 weeks, whereas normalization of ALP levels may take several months [24]. The duration of therapy shou…
2. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=3.0, round=1
   > - Frank osteomalacia is usually associated with very low levels of 25OHD (<15nmol/  L). - Elevated PTH (2° hyperparathyroidism). - associated 2° hyperparathyroidism frequently results in normal, or even elevated, concentrations of 1,25(OH) 2 D.  ## Treatment  - Calciferol is preferred (not active metabolites of vitamin D) to restore body stores, correct biochemical abnormalities, and heal bony abn…
3. **ParathyroidLiterature/Hypoparathyroidism and Pseudohypoparathyroidism - Endotext - NCBI Bookshelf.pdf** — score=2.0, round=1
   > A total of 20 to 80 millimoles elemental calcium daily (2 to &amp; g calcium carbonate per day) is generally effective, but should be given in divided doses and adjusted on the basis of gastro-intestinal tolerance, relief of hypocalcemic symptoms, and appropriate biochemical response. Vitamin D is preferably administered as calcitriol (0.25 to 1.0 micrograms per day), but, with some conditions, ph…
4. **ParathyroidLiterature/Pseudohypoparathyroidism - StatPearls - NCBI Bookshelf.pdf** — score=1.125, round=1
   > In addition to checking serum calcium; 24hour urine calcium levels should be maintained in the low to mid-normal range to avoid renal calculi and impaired kidney function. goals  In patients with persistent hypocalcemia, treatment with calcium supplementation is a requirement:  In the acute setting, the recommendation is for intravenous calcium Patients who are symptomatic (spasms, seizure, etc.),…
5. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=1.125, round=1
   > ## Pseudohypoparathyroidism  - The principles underlying the treatment of pseudohypoparathyroidism are the same as those underlying hypoparathyroidism.  NB. Patients  with  the  commonest  form  of  pseudohypoparathyroidism may have resistance to the action of other hormones that rely on G protein signalling.  They therefore need to be assessed for thyroid and gonadal dysfunction (because of defec…

#### Flow retrieval context (5 shown)
1. **Diagnosis and management of hypocalcaemia.pdf** — score=4.4375, round=1
   > - ~if parathyroid hormone is deficient Or non-functional  Patients   taking   digoxin have increased cardiac sensitivity to fluctuations in serum calcium; so intra venous calcium administration should be more cautious in this with careful electrocardiographic monitoring: Patients with hypocalcaemia related to hypomagnesaemia will need magnesium replacement: setting,  ## Persistent hypocalcaemia  W…
2. **Rickets guidance. part II—management.pdf** — score=3.5, round=1
   > Therefore, these patients may require intravenous calcium infusions (1000 mg of elemental calcium per given over 12 h) over many months until oral supplementation with calcium salts in conjunction with active vitamin D, allows for maintenance of both normocalcemia and adequate skeletal mineralization. During puberty, intestinal calcium absorption often improves in VDDRZA patients for So far unknow…
3. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.375, round=1
   > Intravenous calcium is irritating to the veins and is  best  infused  into  a  large  vein  or  through  a  central  venous catheter.  ## Chronic Hypocalcemia  The  objective  of chronic  therapy  is to  keep  the  patient  free  of symptoms and to maintain a serum [Ca 2 l of  approximately 8.5 to 9.0  mg/dL.  With lower serum  [Ca 2 l ,  the  patient  may  nor  only experience  symproms bur may b…
4. **Rickets guidance. part II—management.pdf** — score=3.375, round=1
   > The duration of therapy should be individually tailored, based on treatment response. Combined treatment is recommended, as the diet of children and adolescents with nutritional rickets is usually low in both vitamin D and calcium [25-28]. Oral vitamin D treatment is preferable, as it was shown to restore 2S(OH)D levels more rapidly than intramuscular treatment; at least in adults [29]. In case of…
5. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.25, round=1
   > Spasm of the hand musculature (see carpope­ dal  spasm,  above)  due  to  transient  ischemia  of  hyperexcitable nerves  innervating  the hand  is regarded as a positive  test.  Of the two,  a  positive  Trousseau  sign  is  regarded  as  more  specific  f or hypocalcemia than is the positive Chvostek sign.  Hypocalcemia can also have significanr effects on cardiovascu­ lar  f unction,  including…

- **RAG-only sources:** endocrinology and diabetes book.pdf, hypoparathyroidism and pseudohypoparathyroidism - endotext - ncbi bookshelf.pdf, pseudohypoparathyroidism - statpearls - ncbi bookshelf.pdf
- **Flow-only sources:** diagnosis and management of hypocalcaemia.pdf, greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 16-year-old student presented to the medical admission unit with spasms of hands along with twitching around the mouth. On examination, she had a BMI of 15 kg/m2. Her general physical and systemic examination was unrem…`

---

### Case 7: Parathyroid Gland and Bone Disease

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** polarity:except_question, decision:agreement, verifier:refuted, verifier:followup_used
- **Question polarity (heuristic):** except
- **Flow detected polarity:** except
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.411, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Option D is not supported by the provided evidence; the other statements are directly corroborated by the sources.

**Reasoning rationale:**
> The only statement not supported by the provided evidence is that the placenta produces 1,25‑dihydroxy vitamin D; the evidence points to renal synthesis of active vitamin D during pregnancy, making this claim incorrect.

<details>
<summary>Full question</summary>

```
A 26-year-old care home worker was referred to the combined
Endocrinology–Obstetric antenatal clinic by her GP due to incidental
finding of low calcium in her routine blood tests while she was 32 weeks
pregnant. There was no significant past medical history and she was not
on any regular medication.
Investigations:
total calcium 2.10 mmol/L (2.2–2.6)
phosphate 0.92 mmol/L (0.8–1.5)
PTH 2.6 pmol/L (1.6–7.2)
total protein 54 g/L (65–75)
albumin 28 g/L (35–40)
Which one of the following statements regarding calcium homeostasis
during pregnancy is incorrect?
A. About 25–30 g of calcium is provided by the mother to support foetal skeletal development
B. Calcium is actively transported across the placenta, facilitated by PTH-related protein (PTHrP)
C. Free ionized calcium levels increase in pregnancy
D. The placenta produces 1,25 dihydroxy vitamin D, which results in increased intestinal
calcium absorption
E. Total calcium concentration falls in pregnancy due to physiological hypoalbuminaemia
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | Evidence shows that 25–30 g of calcium are transferred from mother to fetus across the placenta during normal pregnancy. |
| B | supported | Placental calcium transport is mediated by PTHrP, as described in studies of the placental calcium pump. |
| C (expected) | supported | Serum ionized calcium concentrations rise during pregnancy, indicating higher free calcium levels. |
| D | contradicted | The evidence indicates that 1,25‑dihydroxy vitamin D is primarily synthesized in the kidney; placental production is not supported. |
| E | supported | Total serum calcium decreases in pregnancy because of physiologic hypoalbuminaemia, as documented in the literature. |

#### RAG retrieval context (5 shown)
1. **ParathyroidLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.5, round=1
   > Borh maternal obesity and maternal diabetes may independendy affect rhe risk of  adoles­ cenr obesity in children. Macrosomic infanrs are also at increased risk of subsequenr developmenr of diabetes. Thus, rhe epidemics of  obesity and diabetes may conrinue ro increase furrher as a result of f eral overgrowth and adiposity in utero.  ## Parathyroid Disease and Pregnancy  Pregnancy is associated wi…
2. **ParathyroidLiterature/primary_hyperparathyroidism_in.22.pdf** — score=3.375, round=1
   > In contrast, when the   hormone is produced in abundance, as in PTHrP secreting tumors or primary hyperparathyroidism, the local control mechanisms can be overloaded. This allows for systemic absorption of PTHrP and the development of hyperparathyroid symptoms (19-21).  ## CALCIUM HOMEOSTASIS  IN PREGNANCY  Between 25 and 30 gm of  calcium is shunted across the  placenta to the fetus   during a no…
3. **ParathyroidLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.875, round=1
   > High circulating concentrations ofhCG, particularly  asialo-hCG, which has weak TSH-like  acriviry,  con­ tribute to the thyrotropic action of the placenta in early pregnancy. In fact,  there  is significant,  though  transient,  biochemical  hyper­ thyroidism associated with hCG stimulation in early gestation.  ## Maternal Parathyroid Gland  The net calcium requiremenr imposed by feral skeletal  …
4. **ParathyroidLiterature/primary_hyperparathyroidism_in.22.pdf** — score=2.125, round=1
   > This in turn could explain postpartum neonatal hypocalcemia experienced when maternal mary hyperparathyroidism is poorly controlled (23). being pri-  Aithough the shunting of calcium to the fetus is a major contributor to the relative hypocalcemic state of pregnancy, there are at  least two other  mechanisms First, a physiologic increase in the glomerular filtration rate results in maternal hyperc…
5. **ParathyroidLiterature/Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum. a longitudinal study.pdf** — score=1.25, round=1
   > (30)], but not all [e.g. (22)], previous reports.  Among our group of pregnant women, total serum calcium showed significant   tendency to decrease toward the end of pregnancy reaching a nadir by term (Table 2). Previous studies have shown decrease in total maternal serum calcium   concentration   during pregnancy (33, 34) that   paralleled a concomitant decrease in serum albumin concentration: Th…

#### Flow retrieval context (5 shown)
1. **primary_hyperparathyroidism_in.22.pdf** — score=4.5625, round=1
   > At the same time, the reabsorption of phosphate in the proximal tubule is inhibited, which explains the compeptide antag- monly noted hypophosphatemia in patients with nor mal renal function. Additionally; renal 2S(OH)D-Ia hydroxylase is increased, which allows   for an increase in serum calcium through the action of vitamin D on intestinal calcium absorption (19-21).  PTHrP seems t0 be distinct f…
2. **primary_hyperparathyroidism_in.22.pdf** — score=3.5, round=1
   > Although fetal   magnesium and phosphorus levels or slightly higher than maternal values, ionized calcium concentrations have been consistently higher in all mammalian fetuses studied (23). In fact; this transfer of calcium is across a throughout gestation (24). So how does this happen and what keeps the fetus from in a state of hypoparathyroidism? It seems that PTHrP from the fetal  parathyroid g…
3. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.375, round=1
   > Overall PTH levels are slighdy lower throughout preg­ nancy and  calcium  is  actively  rransporred  across  the  placenra  ro rhe f erus against a  concenrrarion gradienr. The  fews  is  relatively hypercalcemic, hypercalcironemic,  and  hypoparathyroid  in com­ parison ro rhe mother,  bur this resolves shordy after birrh.  A.  Hyperparathyroidism Hyperparathyroidism can be either primary,  from …
4. **Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum. a longitudinal study.pdf** — score=2.375, round=1
   > This would be consistent with the findings of the study study of Gallacher et al. (16), and it may be this particular   placental  component that   passes into the maternal circulation and has a role in calcium homeostasis   by  acting   through the PTH receptor (5). In addition, consistent with the work described by Grill et al. (15) , the postpartum increase in PTHrP could be produced by the mam…
5. **Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum. a longitudinal study.pdf** — score=2.25, round=1
   > Previous studies have shown decrease in total maternal serum calcium   concentration   during pregnancy (33, 34) that   paralleled a concomitant decrease in serum albumin concentration: The physiological hypoalbuminaemia of pregnancy   caused by haemodilution thus appears to be largely; if not entirely, responsible for this decrease  Some previous studies [e.g. (35)] have documented lower serum ma…

**Attempted retrieval queries (flow):**
1. `A 26-year-old care home worker was referred to the combined Endocrinology–Obstetric antenatal clinic by her GP due to incidental finding of low calcium in her routine blood tests while she was 32 weeks pregnant. There wa…`

---

### Case 8: Parathyroid Gland and Bone Disease

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, verifier:insufficient, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.653, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The evidence indicates that measurement of parathyroid hormone‑related peptide (PTHrP) is occasionally used in exceptional circumstances to clarify the aetiology of hypercalcaemia, which helps establish the underlying diagnosis of primary hyperparathyroidism when PTH is elevated.

**Reasoning rationale:**
> The patient shows a classic triad of hypercalcaemia, hypophosphataemia and inappropriately high PTH, confirming primary hyperparathyroidism. The next step to determine the cause is anatomical localisation of the overactive gland, for which a technetium-99m sestamibi scan is the appropriate investigation.

<details>
<summary>Full question</summary>

```
A 65-year-old South Asian woman with background history of Type 2
diabetes, hypertension, osteoporosis, and dyslipidaemia presented to
her GP with lethargy, malaise, and generalized body aches.
Investigations:
urea 7.0 mg/dL (7–12)
creatinine 66 µmol/L (60–115)
calcium 2.28 mmol/L (2.2–2.6)
phosphate 0.94 mmol/L (0.8–1.5)

PTH 10.2 pmol/L (1.6–7.2)
Which one of the following investigations should be arranged to
establish her underlying diagnosis?
A. Estimated glomerular filtration rate (eGFR)
B. 1, 25 (OH)2 vitamin D levels
C. PTH-related peptide
D. Sestamibi scan
E. 25-OH vitamin D levels
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Used to assess renal function after diagnosis, not to establish the underlying diagnosis of primary hyperparathyroidism. |
| B | contradicted | Vitamin D measurement is not required to confirm primary hyperparathyroidism. |
| C | contradicted | PTHrP testing is rarely indicated and not needed for diagnosing primary hyperparathyroidism. |
| D | supported | Localisation imaging is recommended after biochemical confirmation to identify the hyperfunctioning gland. |
| E (expected) | contradicted | Measures vitamin D status but does not establish the underlying diagnosis of primary hyperparathyroidism. |

#### RAG retrieval context (5 shown)
1. **ParathyroidLiterature/NICE. Hyperparathyroidism (primary). diagnosis assessment and initial managememt.pdf** — score=3.625, round=1
   > - 1.1.10 Look for alternative diagnoses, including malignancy, if the person's PTH is below the lower limit of the reference range:  For a short explanation of why the committee made the recommendations and how they might affect practice , see the rationale and impact section on diagnostic testing in primary care:  Full details of the evidence and the committee's discussion are in evidence review …
2. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=1.5, round=1
   > ## Vitamin D and its metabolites  ## 25-  hydroxyvitamin D (25OHD)  - main storage form of vitamin D. - measurement of 'total vitamin D' is the most clinically useful measure of vitamin D status. - Internationally, there remains controversy around a 'normal' or 'optimal' concentration of vitamin D. Levels over 50nmol/  L are generally accepted as satisfactory, and values <25nmol/  L represent defi…
3. **ParathyroidLiterature/Evaluation and Management of Primary Hyperparathyroidism. Summary Statement and Guidelines from the Fifth International Workshop.pdf** — score=1.25, round=1
   > A caveat to describing this entity, thus includes the possibility   that some studies may have included those with classic hypercalcemic PHPT. Some studies have shown progression, over time, to hypercalcemia in proportion of patients, whereas others have not: Clinical features of NPHPT can be similar to the ones described in PHPT (skeletal, renal complications, and nonclassical manifestations)  ##…
4. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=1.125, round=1
   > ## Box 6.4  End-  organ damage in hyperparathyroidism  ## Bone  - Osteoporosis: - Common. - affects all sites, but predominant loss in peripheral cortical bone. - Osteitis fibrosa cystica: - Rare. - Usually with tertiary hyperparathyroidism.  ## Kidneys  - Seen in 15-  20% cases. - Renal calculi. - Nephrocalcinosis. - Renal impairment.  ## Pancreatitis  ## Box 6.5  Diagnosis of primary hyperparath…
5. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=0.875, round=1
   > (Exclude other causes of hypercalciuria, including renal insufficiency and vitamin D deficiency.)  ## Tips  - Genetic panel testing for FHH can also be used to help differentiate from PHPT. - It may shorten the diagnostic odyssey and may prove a cost-  effective approach, especially if biochemical tests are not immediately definitive.  ## Phosphate  - 24h collection: - Little clinical utility-  re…

#### Flow retrieval context (5 shown)
1. **NICE. Hyperparathyroidism (primary). diagnosis assessment and initial managememt.pdf** — score=3.25, round=1
   > - 1.1.10 Look for alternative diagnoses, including malignancy, if the person's PTH is below the lower limit of the reference range:  For a short explanation of why the committee made the recommendations and how they might affect practice , see the rationale and impact section on diagnostic testing in primary care:  Full details of the evidence and the committee's discussion are in evidence review …
2. **Endocrinology and Diabetes Book.pdf** — score=2.875, round=1
   > True osteomalacia occurs with vitamin D values <15nmol/  L. - Low levels of 25OHD can result from a variety of causes (see Vitamin D deficiency, p. 537). - Unlikely to see serious toxicity with 25OHD concentrations of - <200nmol/  L. - Indications for testing: - Investigation of vitamin D deficiency, osteomalacia, and rickets. - Investigation of 2° causes of osteoporosis.  ## 1,25-  dihydroxyvitam…
3. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=1.75, round=1
   > The overall mood of the image is one of innocence and vulnerability, with the boy's nakedness and direct gaze creating a sense of intimacy and connection with the viewer.  In terms of aesthetics, the image has a strong contrast between the light-colored tiles and the boy's pale skin, which creates a striking visual effect. The grid pattern of the tiles adds a sense of structure and order to the co…
4. **Endocrinology and Diabetes Book.pdf** — score=1.125, round=1
   > (Exclude other causes of hypercalciuria, including renal insufficiency and vitamin D deficiency.)  ## Tips  - Genetic panel testing for FHH can also be used to help differentiate from PHPT. - It may shorten the diagnostic odyssey and may prove a cost-  effective approach, especially if biochemical tests are not immediately definitive.  ## Phosphate  - 24h collection: - Little clinical utility-  re…
5. **Evaluation and Management of Primary Hyperparathyroidism. Summary Statement and Guidelines from the Fifth International Workshop.pdf** — score=1.0, round=1
   > A caveat to describing this entity, thus includes the possibility   that some studies may have included those with classic hypercalcemic PHPT. Some studies have shown progression, over time, to hypercalcemia in proportion of patients, whereas others have not: Clinical features of NPHPT can be similar to the ones described in PHPT (skeletal, renal complications, and nonclassical manifestations)  ##…

- **RAG-only sources:** —
- **Flow-only sources:** greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 65-year-old South Asian woman with background history of Type 2 diabetes, hypertension, osteoporosis, and dyslipidaemia presented to her GP with lethargy, malaise, and generalized body aches. Investigations: urea 7.0 m…`

---

### Case 9: Pituitary Gland and Hypothalamus

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** A (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:agreement, verifier:followup_used, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.229, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The evidence indicates that before initiating GH therapy in a patient with a history of craniopharyngioma and documented low IGF‑1 and low GH peak, a confirmatory GH‑stimulation test is required, especially in transition age patients. It also states that GH replacement is not contraindicated and should be started at a low dose (0.2‑0.3 mg) and titrated to IGF‑1 levels, supporting the need for confirmation rather than immediate treatment. Therefore, the appropriate next step is to confirm the GH deficiency with a second dynamic test.

**Reasoning rationale:**
> The clinical scenario shows low IGF‑1 and a sub‑threshold GH peak, indicating possible GH deficiency. Before considering GH therapy, a repeat dynamic (GH‑stimulation) test is required to confirm the deficiency, especially in a transition patient with a history of craniopharyngioma. This aligns with AACE guidelines that low IGF‑1 alone is insufficient for diagnosis and that a second test should be performed when suspicion is moderate to high.

<details>
<summary>Full question</summary>

```
A 16-year-old was reviewed in a joint paediatrics to adult endocrinology
transition clinic. He was diagnosed as having craniopharyngioma at
age 14 years and underwent surgical removal of the tumour. Postoperatively, he was noticed to have delayed growth (as evidence by his
height being 2 SDs below normal compared with other children his age).
Both his parents were of average height and none of his siblings were of
short stature.
Investigations:
0 hour cortisol
308 nmol/L
30 minutes post-ACTH 592 nmol/L
IGF-1
12 nmol/L (16–118)
prolactin
145 mU/L (45–375)
testosterone
11.2 nmol/L (8.5–28.5)
TSH
2.6 mU/L (0.35–5.5)
On insulin tolerance test a peak GH value of 9 mU/L (3 µg/L) was seen.
Which one of the following is the most appropriate approach for a
potential GH therapy in his case?
A. Confirm the GH deficiency by a second dynamic test
B. GH replacement is contraindicated considering history of craniopharyngioma
C. Start on adult dose of GH replacement
D. Start on GH replacement only if he is symptomatic
E. Trial of GH therapy for 6 months only
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | Guidelines recommend performing a repeat GH‑stimulation test to confirm deficiency before initiating GH therapy in transition patients with craniopharyngioma and low IGF‑1. |
| B | contradicted | Craniopharyngioma is not a contraindication to GH replacement; after confirmation of deficiency, GH can be started. |
| C (expected) | contradicted | Initiating an adult dose without confirming deficiency is not recommended; dosing should start low (0.2‑0.3 mg) and be titrated. |
| D | contradicted | Symptom‑based initiation is insufficient; objective confirmation of GH deficiency is required first. |
| E | contradicted | Treatment duration should be guided by IGF‑1 response and clinical monitoring, not a fixed 6‑month trial. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/AACE for management of growth hormone deficiency in adults and patients transitioning.pdf** — score=3.125, round=1
   > However, as these are uncommon causes of adult GHD, confirmation of the diagnosis with GH-stimulation testing is required. Specifically, in TBI and SAH patients, GHD may be transient especially within the first year after the event (132) . In these patients where there is a reasonable level of clinical suspicion, GH-stimulation   testing should only be performed at least 12 months after the event …
2. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.875, round=1
   > GH does not increase the recurrence rate of  tumors exist­ ing before  therapy.  Thus,  patients  with  craniopharyngiomas,  f or example, may receive GH, if indicated, after the disease is clinically stable  without  significant  wony  that  the  GH  will  precipitate  a recurrence. Clinicians usually wait 1 year after completion of  tumor therapy before starting patients on GH therapy, but doing…
3. **PituitaryLiterature/Endocrinology and Diabetes Book.pdf** — score=2.875, round=1
   > ## Tests for diagnosis of GH deficiency  - The ITT is regarded as the 'gold standard' test for adults. The protocol should be followed as per individual unit guidelines. - a general definition of severe GhD in adults is a peak concentration of <9mU/  L (3ng/  mL) in response to insulin-  induced hypoglycaemia. - When the ITT is contraindicated in patients over 60 years and those with a cardiac his…
4. **PituitaryLiterature/Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.pdf** — score=2.75, round=1
   > Overall,  all the three groups responded comparably to short- and long-term GH  replacement   therapy  suggesting that COCP patients benefit from GH replacement therapy to similar  degree as those with other   aetiologies of CO hypothalamic-pituitary dysfunction did. Because of greater co-morbidity and the comparable benefits of GH  replacement   therapy in COCP  patients   compared with COH and C…
5. **PituitaryLiterature/Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.pdf** — score=2.75, round=1
   > Compared with COE patients, more COCP patients were treated by surgery alone, but fewer were treated by combined surgery and radiotherapy or radiotherapy or chemotherapy alone\_ Patients with COCP had more pituitary hormone deficits compared with COH and COE patients, with the most striking difference observed for diabetes insipidus. being  Table 1 Clinical characteristics and medical of patients …

#### Flow retrieval context (5 shown)
1. **Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database.pdf** — score=4.0, round=1
   > Furthermore , Thomsett et al\_ (2) found that the number of patients with craniopharyngioma who were growth   hormone (GH) deficient was preoperatively and IO% post-operatively: It is well known that small proportion of these GH-deficient   children demonstrate or  accelerated  post-operative growth without the aid of exogenous GH (3-5) . More commonly, however, in the absence of GH, post-operativ…
2. **Endocrinology and Diabetes Book.pdf** — score=3.875, round=1
   > - Cranial irradiation (high dose).  ## Low likelihood of persistent growth hormone deficiency  indications that there is a low likelihood of persistent GhD are as follows:  - For idiopathic GhD: isolated GhD or GhD with two or less pituitary hormone deficits in the absence of structural abnormalities located in the hp axis and affecting positioning of the posterior pituitary gland or the pituitary…
3. **AACE for management of growth hormone deficiency in adults and patients transitioning.pdf** — score=3.75, round=1
   > In patients with <2 PHD, low serum IGF-] levels <-2.0 SDS) alone cannot be used to make the diagnosis of adult GHD and clinicians should perform GH-stimulation test to confirm the diagnosis in these patients. In contrast, after longitudinal growth is completed in transition patients with idiopathic IGHD and lownormal (between 0 to -2 SDS) or low (<-2 SDS) serum IGF-] levels, GHD and deficiency of …
4. **Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.pdf** — score=2.75, round=1
   > Overall,  all the three groups responded comparably to short- and long-term GH  replacement   therapy  suggesting that COCP patients benefit from GH replacement therapy to similar  degree as those with other   aetiologies of CO hypothalamic-pituitary dysfunction did. Because of greater co-morbidity and the comparable benefits of GH  replacement   therapy in COCP  patients   compared with COH and C…
5. **Growth hormone (GH) deficiency (GHD) of childhood onset. reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults.pdf** — score=2.75, round=1
   > 5          | 2 2.1        | 2 0.9      | 2 2.1    | 13.2                 | 17.7               | 8.9               | 185                          | 385                        | | 6                          | M     | 7.2            | 17.8         | 3.9            | 0.5          | 2 3.4        | 2 1.8      | 2 2.2    | 14.7                 | 18.7               | 10.3              | 120               …

- **RAG-only sources:** greenspan’s basic and clinical endocrinology.pdf
- **Flow-only sources:** effect of growth hormone treatment in children with craniopharyngioma with reference to the kigs (kabi international growth study) database.pdf, growth hormone (gh) deficiency (ghd) of childhood onset. reassessment of gh status and evaluation of the predictive criteria for permanent ghd in young adults.pdf

**Attempted retrieval queries (flow):**
1. `A 16-year-old was reviewed in a joint paediatrics to adult endocrinology transition clinic. He was diagnosed as having craniopharyngioma at age 14 years and underwent surgical removal of the tumour. Postoperatively, he w…`

---

### Case 10: Pituitary Gland and Hypothalamus

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:rag_has_unique_sources, decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.448, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The evidence indicates that in a pregnant patient with a macroprolactinoma showing symptomatic growth near the optic chiasm, the recommended immediate treatment is to reinstitute dopamine agonist therapy, specifically bromocriptine, which is considered safe in pregnancy and advised for symptomatic tumor enlargement.

**Reasoning rationale:**
> The patient has a macroprolactinoma that has increased in size near the optic chiasm during pregnancy, causing headache and visual disturbance. Current evidence (high‑score guidelines) recommends reinstating dopamine agonist therapy for symptomatic tumor growth in pregnancy, with bromocriptine preferred due to extensive safety data. Immediate delivery, surgery, or radiotherapy are not indicated without failure of medical therapy or severe, refractory visual loss.

<details>
<summary>Full question</summary>

```
A 31-year-old staff nurse with macroprolactinoma presented in the
accident and emergency department with sudden-onset of headache
and visual disturbance while she was 8 months pregnant. She had
previously been on cabergoline therapy, which was stopped when her
pregnancy was confirmed after an informed discussion.
An urgent visual field assessment showed no visual field defect.
MRI of the pituitary showed an increase in size of prolactinoma in
proximity to optic chiasm.
Which one of the following is the most appropriate immediate step in
her management?
A. Induction of delivery
B. Restart cabergoline therapy
C. Start bromocriptine therapy
D. Urgent neurosurgical intervention
E. Urgent radiotherapy
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Induction of labor is not indicated solely for tumor growth near the optic chiasm without severe visual loss or maternal instability; it does not address the underlying prolactinom |
| B (expected) | contradicted | Cabergoline is not officially licensed in pregnancy and has limited safety data; bromocriptine is preferred for symptomatic tumor growth during pregnancy according to guideline rec |
| C | supported | Guidelines advise reinstating dopamine agonist therapy for symptomatic macroprolactinoma growth in pregnancy, and bromocriptine is specifically recommended as safe and effective in |
| D | contradicted | Surgery is reserved for cases refractory to medical therapy or with imminent vision loss; immediate surgery is not indicated when dopamine agonist reinstatement is effective and sa |
| E | contradicted | Radiotherapy is not appropriate in the acute management of a growing macroprolactinoma during pregnancy, especially when safer medical options exist. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/Endocrinology and Diabetes Book.pdf** — score=5.5625, round=1
   > There is 40-  60% remission of prolactinoma after pregnancy. - In women with macroadenomas, can often stop dopamine agonists and monitor visual fields each trimester; however, in women with invasive prolactinomas or prolactinomas abutting the chiasm, continuing dopamine agonists in pregnancy may be advised. In these women, if stable, can continue dopamine agonists until 7 36 weeks' pregnancy, and …
2. **PituitaryLiterature/Prolactinoma Management - Endotext - NCBI Bookshelf.pdf** — score=5.5625, round=1
   > Prolactin levels may rise during pregnancy when there is no tumor size change and some tumors enlarge without an associated rise in prolactin; therefore, measurement of prolactin during pregnancy need not be carried out, as the results can be misleading: When there is evidence of significant symptoms and tumor growth, the patient should be restarted on the dopamine that was discontinued at concept…
3. **PituitaryLiterature/Diagnosis and Treatment of Hyperprolactinemia. An Endocrine Society Clinical Practice Guideline.pdf** — score=5.5, round=1
   > Howpatient develops severe headache or  visual field abnormalities places a high value on preventing permanent visual impairmentanda lower value on preventing unsubstantiated risks of MRI harm to the fetus.  ## Recommendation  6.6. We recommend bromocriptine therapy in patients who experience symptomatic growth of a prolactinoma during pregnancy (1IEDOO).  ## 6.6. Evidence  If the pituitary tumor …
4. **PituitaryLiterature/Prolactinoma Management - Endotext - NCBI Bookshelf.pdf** — score=4.8125, round=1
   > Despite the potential effect of cabergoline on abortion rates, no associations were observed between maintaining cabergoline after the first trimester and preterm birth, congenital malformations, or neurodevelopmental changes. Dopamine should be reinstituted when breast-feeding is completed. agonists  Pregnancy is a risk factor for prolactinoma enlargement, especially for macroprolactinomas, and r…
5. **PituitaryLiterature/Clinical Endocrinology - 2006 - Casanueva - Guidelines of the Pituitary Society for the diagnosis and management of.pdf** — score=4.625, round=1
   > The patients should be advised to report for urgent assessment in the event of a severe headache or visual disturbance. Serial PRL determinations are not necessary: In women with macroadenomas, symptomatic tumour expansion occurs in 20-30% of women. Options for such women include during stopping the dopamine agonist when pregnancy is confirmed with close surveillance thereafter; Or continuing the …

#### Flow retrieval context (5 shown)
1. **Endocrinology and Diabetes Book.pdf** — score=7.4375, round=1
   > - Macroadenoma 15-  20%. - Macroadenoma treated with surgery and/  or radiotherapy before pregnancy 4-  7%. - Fetal risk: none known.  ## Treatment in pregnancy  - In women with microadenomas, stop dopamine agonists once pregnant; assess visual fields to confrontation each trimester. There is 40-  60% remission of prolactinoma after pregnancy. - In women with macroadenomas, can often stop dopamine…
2. **Diagnosis and Treatment of Hyperprolactinemia. An Endocrine Society Clinical Practice Guideline.pdf** — score=7.0, round=1
   > Evidence  For most pregnant patients with prolactinomas, serial MRIs and formal visual field testing are not indicated in the absence of headaches or visual field changes. For patients who have macroadenomas and have not undergone prior pituitary surgery, it is prudent to undertake more frequent  clinical examinations and formal visual field testing:  ## 6.5. Values and preferences  Our recommenda…
3. **Prolactinoma Management - Endotext - NCBI Bookshelf.pdf** — score=6.6875, round=1
   > Otherwise, pituitary surgery should be considered. Pre-pregnancy adenoma debulking could increase the chance to avoid symptoms from tumor enlargement pregnancy. If transsphenoidal surgery is performed to pregnancy, the risk of symptomatic macroprolactinoma enlargement is reduced from 21% to 4.7% (5,70) Nevertheless, patients undergoing pituitary surgery before pregnancy should be informed of the p…
4. **Chapter-15---Prolactinoma_2011_The-Pituitary.pdf** — score=6.5625, round=1
   > Data  regarding the effects of continuous cabergoline therapy on the developing fetus are even fewer [562,567] and such treatment also cannot be recommended without reservation. Should pregnancy at an advanced stage be discovered in a woman bromocriptine or cabergoline, however; the data that exist are reassuring and would not justify therapeutic abortion. A fourth approach, and the one most commo…
5. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=6.3125, round=1
   > Monitoring  of  patients  with  known  PRL-secrering adenomas during pregnancy is primarily based on clinical exami­ nation. The  normal  gestational increase  in  PRL may obscure an increase attributable to the adenoma, and radiographic procedures are undesirable in pregnancy.  A.  Management Management of rhe pregnant woman with a  pituitary adenoma includes  early  ophthalmologic consultation f…

- **RAG-only sources:** clinical endocrinology - 2006 - casanueva - guidelines of the pituitary society for the diagnosis and management of.pdf
- **Flow-only sources:** chapter-15---prolactinoma_2011_the-pituitary.pdf, greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 31-year-old staff nurse with macroprolactinoma presented in the accident and emergency department with sudden-onset of headache and visual disturbance while she was 8 months pregnant. She had previously been on cabergo…`

---

### Case 11: Pituitary Gland and Hypothalamus

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** A (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** answerability:insufficient, answerability:missing_anchors, follow_up:triggered, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, verifier:insufficient, verifier:followup_used, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 4 shared sources, avg text similarity=0.565, rounds=[1]
- **Answerability:** sufficient=False, confidence=low
- **Reasoning confidence:** low

**Answerability rationale:**
> The provided evidence discusses circadian regulation, CRH stimulation, and feedback mechanisms but does not contain any information about hormones that decrease ACTH release, such as catecholamines, endocannabinoids, ghrelin, or vasoactive intestinal peptide.

**Reasoning rationale:**
> The provided evidence discusses circadian regulation and the roles of CRH and catecholamines but does not contain explicit data showing a hormone that decreases ACTH release. Catecholamines are the only option that does not stimulate ACTH and thus are tentatively considered as associated with decreased release, though the evidence is limited, leading to low confidence.

<details>
<summary>Full question</summary>

```
The secretion of adrenocorticotropic hormone (ACTH) follows a
circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the
nadir is seen around 11 p.m. to 2 a.m.
ACTH release is under the influence of various pituitary and nonpituitary hormones.
Which one of the following hormones is associated with a decreased
ACTH release?
A. Catecholamine
B. Corticotropin-releasing hormone (CRH)
C. Endocannabinoids
D. Ghrelin
E. Vasoactive intestinal peptide
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | Evidence shows peripheral catecholamines do not increase basal or CRH‑stimulated ACTH levels, indicating they are not stimulators and may be associated with decreased ACTH release. |
| B | contradicted | CRH is a potent stimulator of ACTH secretion, opposite of the required decrease. |
| C (expected) | uncertain | No evidence found regarding endocannabinoids effect on ACTH release. |
| D | uncertain | No evidence found regarding ghrelin effect on ACTH release. |
| E | uncertain | No evidence found regarding vasoactive intestinal peptide effect on ACTH release. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/Chapter-2---Hypothalamic-Regulation-of-Anterior-Pituitary-F_2011_The-Pituita.pdf** — score=4.0, round=1
   > affinity  ACTH and cortisol follow 24-h circadian rhythm that is believed to be driven by CRH [62]. ACTH diurnal variation is essential for maintaining normal adrenal function [63]. Human ACTH and cortisol begin rising between 1 and 4 am, during the early morning, lower occurs in the early afternoon, then fall the rest of the to reach a nadir at around midnight: CRH null mice have atrophic adrenal…
2. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.875, round=1
   > Secretion. ACTH is secreted with both circadian periodicity and ultradian pulsatility under the control of the suprachiasmatic  nucleus.  This  centrally  controlled  pattern  is influenced  by  peripheral  corticosteroids.  The  circadian pattern of ACTH secretion typically begins at about 4 a.m., peaking before 7 a.m., and both ACTH and adrenal steroid levels reach their nadir between 11 p.m. an…
3. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.625, round=1
   > Irs short plasma half -lif e (7-1 2 minutes)  and episodic secretion cause wide and rapid fluctuations both in irs plasma concentration and in rhar of cortisol.  Although �-LPH has a longer half-life than ACTH and is more stable in plasma,  its  measurement  has  nor  been extensively uti­ lized.  Current  data  suggest  that  the  normal  concentration  of �-LPH is 1 0  to 40 pg/mL ( 1 -4 pmol!L)…
4. **PituitaryLiterature/Chapter-2---Hypothalamic-Regulation-of-Anterior-Pituitary-F_2011_The-Pituita.pdf** — score=3.25, round=1
   > itary lung, peptide hypo  FIGURE 2.8 Hypothalamic corticotropin-releasing hormone (CRH) stimulates the   corticotroph to release   adrenocorticotropin hormone (ACTH) which in turn  stimulates the adrenal glands to produce and release cortisol and androgens. Cortisol inhibits further release of both CRH and ACTH. Reproduced from Melmed, S. Mechanisms for Tumorigenesis: The Plastic Pituitary, ] Clin…
5. **PituitaryLiterature/Chapter-3---Adrenocorticotropin_2011_The-Pituitary.pdf** — score=3.25, round=1
   > For instance, since the brain does not require insulin for glucose uptake, peripheral insulin resistance might cause a rise in glucose levels, leading to greater in the brain: The circadian rhythm is generated in the suprachiasmatic nucleus (SCN), and the signals travel via efferent inputs to the PVN to modulate CRH release: This circadian rhythm is   due to variation in ACTH amplitude, not freque…

#### Flow retrieval context (5 shown)
1. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=5.1875, round=1
   > This  centrally  controlled  pattern  is influenced  by  peripheral  corticosteroids.  The  circadian pattern of ACTH secretion typically begins at about 4 a.m., peaking before 7 a.m., and both ACTH and adrenal steroid levels reach their nadir between 11 p.m. and 3 a.m. Within this overall 24-hour diurnal cycle, periodic ACTH secretory bursts  occur  at  a  frequency  of  40  pulses  per  24  hour…
2. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=4.6875, round=1
   > However, both �-LPH and �-endorphin have the same secretory dynamics as ACTH.  ## Measurement  The development of immunoradiometric and immunochemilumi­ nescent assays  (IRMAs  and  ICMAs,  respectively)  has  provided  a sensitive  and  practical  clinical ACTH  assay for the evaluation  of pituitary-adrenal disorders. The basal morning concentration ranges f rom 9 to 52 pg/mL (2- 1 1  pmol!L) . …
3. **Chapter-2---Hypothalamic-Regulation-of-Anterior-Pituitary-F_2011_The-Pituita.pdf** — score=4.5625, round=1
   > affinity  ACTH and cortisol follow 24-h circadian rhythm that is believed to be driven by CRH [62]. ACTH diurnal variation is essential for maintaining normal adrenal function [63]. Human ACTH and cortisol begin rising between 1 and 4 am, during the early morning, lower occurs in the early afternoon, then fall the rest of the to reach a nadir at around midnight: CRH null mice have atrophic adrenal…
4. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=4.0, round=1
   > Proposed models to explain  how  immune  system  signals  might  act  on  the CNS to modulate homeostatic circuits through integration of vagal input, peripheral cytokine interactions with receptors  in  the  CVOs  and  cerebral  blood  vessels,  and  local production  of  cytokines  within  the  CNS  are  explored  in Chapter 35.  ## Other Factors Influencing Secretion of Corticotropin  Circadian…
5. **Chapter-3---Adrenocorticotropin_2011_The-Pituitary.pdf** — score=3.875, round=1
   > Glucocorticoids inhibit nitric oxide synthase, and nitric oxide is capable of stimulating the insertion of the water channel, aqua2,in the luminal membrane of the renal collecting cell [158]. This may provide an explanation for why glucocorticoid deficiency is associated with decreased free water clearance\_ porin  ## Short Feedback  Short feedback refers to the effect of pituitary ACTH to inhibit…

**Attempted retrieval queries (flow):**
1. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
2. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
3. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
4. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
5. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
6. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
7. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`
8. `The secretion of adrenocorticotropic hormone (ACTH) follows a circadian rhythm with peak levels seen from 6 a.m. to 9 a.m., while the nadir is seen around 11 p.m. to 2 a.m. ACTH release is under the influence of various …`

---

### Case 12: Pituitary Gland and Hypothalamus

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** polarity:except_question, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, verifier:refuted
- **Question polarity (heuristic):** except
- **Flow detected polarity:** except
- **Retrieval overlap:** 4 shared sources, avg text similarity=0.616, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The presentation of hyperthyroidism with an inappropriately normal/elevated TSH points to a TSH‑secreting pituitary adenoma. Evidence shows that measuring serum α‑subunit and calculating the α‑subunit:TSH molar ratio (>5.7) is a key diagnostic test for this condition, making option A the only plausible useful test. Other options (anti‑TSH‑R antibodies, octreotide scan, ultrasound, uptake scan) are not useful for establishing this specific diagnosis.

**Reasoning rationale:**
> The α‑subunit to TSH ratio is the key diagnostic test for confirming a TSH‑secreting pituitary adenoma, which underlies this case. All other listed investigations are not useful for establishing that specific diagnosis, making anti‑TSH‑R antibodies the outlier exception.

<details>
<summary>Full question</summary>

```
A 66-year-old man presented with a 4-month history of weight loss,
increased sweating, and palpitations. His general physical and systemic
examination is unremarkable except for mild resting tremors. His TFT
results are as shown:
FT3
6.5 pmol/L (2.6–5.7)
FT4
25.0 pmol/L (11.5–22.7)
TSH 5.8 mU/L (0.35–5.5)
Which one of the following will be a useful test to establish the
diagnosis?
A. α subunit to TSH ratio
B. Anti-TSH receptor antibodies
C. Octreotide scan
D. Thyroid ultrasound
E. Thyroid uptake scan
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | supported | The molar ratio of α‑subunit to TSH >5.7 is diagnostic for TSH‑secreting pituitary adenoma and is the recommended test to confirm hyperthyroidism in this context. |
| B | contradicted | These antibodies are characteristic of Graves disease and are not useful for diagnosing a TSH‑secreting tumor; they do not help establish the etiology of elevated TSH with normal T |
| C | uncertain | Octreotide scan may localize a tumor but is not required for confirming the diagnosis of TSH‑secreting adenoma and lacks direct diagnostic value. |
| D | uncertain | Ultrasound visualizes gland structure but does not establish the cause of abnormal TSH and thyroid hormone levels. |
| E | uncertain | Uptake imaging differentiates causes of thyrotoxicosis but is not the primary test to confirm a TSH‑secreting adenoma. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/Thyrotoxicosis - StatPearls - NCBI Bookshelf.pdf** — score=2.625, round=1
   > In the rare case ofa TSH-secreting pituitary adenoma, a visual field defect may also be present [11]  Evaluation  Low serum TSH (&lt;0.01 mU/L) levels demonstrate high sensitivity and specificity for the diagnosis of thyroid disorders. When TSH is low, elevated serum free T4 (fT4) and T3 levels can differentiate overt hyperthyroidism from subclinical hyperthyroidism, with T3 often rising before T4…
2. **ThyroidLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.0, round=1
   > The United States Department of  Agriculture has now prohibited the use of this material for human consumption.  E.  Syndrome of inappropriate TSH secretion A group of patients have been reported with elevated serum FT4 concentra­ tions in association wid1 elevated or inappropriately normal serum immunoreactive TSH levels. This has been called the syndrome of inappropriate  TSH  secretion. Two  co…
3. **ThyroidLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=1.875, round=1
   > The TSH a subunit secretion from these tumors is markedly elevated;  a  molar  ratio of a subunit:TSH greater than 5.7 is  usually  dia � nostic  of  the  presence  of a  TSH-secreting pituitary adenoma.  In addition, the increased serum TSH is not suppressible with high doses of  exogenous d1yroid hormones. Visual field examina­ tion may reveal a bitemporal defect, and CT or MRI of the sella usua…
4. **ThyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=1.5, round=1
   > 32-3.)  - Clinical features of hyperthyroidism are usually present but often milder than expected, given the level of thyroid hormones. In mixed tumours, hyperthyroidism may be overshadowed by features of acromegaly . - Mass effects . Visual field defects and hypopituitarism.  ## Investigations  (See also Tables 1.3 and 1.4.)  - TSH is inappropriately normal or elevated. The range of TSH that has …
5. **ThyroidLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.375, round=1
   > A minimally suitable TSH assay should be  able  to  quantitate  concentrations  of  TSH  as  small  as 0.1 mU/L  with  a  coefficient  of  variation  of  less  than 20%.  Potential  artifacts  of  these  assays  are  discussed  in Chapter 6.  The free α -subunit common to TSH, FSH, LH, and hCG is usually detectable in serum, with a normal range of 1 to 5 µ g/L, but the TSH β -subunit is not. When …

#### Flow retrieval context (5 shown)
1. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.25, round=1
   > Rarely, a TSH-secreting tumor may cosecrete other pituitary hormones such as growth hormone or prolactin. There are no eye signs of  Graves disease. Laboratory evaluation reveals elevated FT4 and T3, whereas serum TSH, usu­ ally undetectable in Graves disease, is within  the normal range or even elevated. The TSH a subunit secretion from these tumors is markedly elevated;  a  molar  ratio of a sub…
2. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.625, round=1
   > The α -subunit concentration may also be increased in patients with glycoprotein-producing tumors of the anterior pituitary (see Chapter 9). Its measurement may be useful in the rare  patient  with  hyperthyroidism  and  a  normal  or  elevated  TSH,  to  differentiate  between  neoplastic  and  nonneoplastic causes of TSH excess. 168,169  ## TSH in Patients with Thyroid Dysfunction  Patients  wit…
3. **Endocrinology and Diabetes Book.pdf** — score=2.125, round=1
   > - Five per cent are associated with MEN1.  ## Clinical features  (See E Manifestations of hyperthyroidism, pp. 32-3.)  - Clinical features of hyperthyroidism are usually present but often milder than expected, given the level of thyroid hormones. In mixed tumours, hyperthyroidism may be overshadowed by features of acromegaly . - Mass effects . Visual field defects and hypopituitarism.  ## Investig…
4. **Thyrotoxicosis - StatPearls - NCBI Bookshelf.pdf** — score=2.125, round=1
   > [45] Occasionally, patients may present with acute muscle paralysis and severe hypokalemia, a condition known as thyrotoxic periodic paralysis. In the rare case ofa TSH-secreting pituitary adenoma, a visual field defect may also be present [11]  Evaluation  Low serum TSH (<0.01 mU/L) levels demonstrate high sensitivity and specificity for the diagnosis of thyroid disorders. When TSH is low, elevat…
5. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.25, round=1
   > 497  An ectopic TSH-producing tumor has also been  reported. 498 Serum  T4  is  high  in  the  majority  of patients, as is the glycoprotein  hormone α -subunit. Approximately two thirds 497 of  patients with TSH-producing pituitary  tumors  have  a  goiter  with  elevated  radioactive iodine uptake. Signs or symptoms of acromegaly or hyperprolactinemia may also be presenting complaints, reflectin…

**Attempted retrieval queries (flow):**
1. `A 66-year-old man presented with a 4-month history of weight loss, increased sweating, and palpitations. His general physical and systemic examination is unremarkable except for mild resting tremors. His TFT results are …`

---

### Case 13: Reproductive Endocrinology

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.321, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The clinical picture of rapidly progressive hirsutism, secondary amenorrhoea, elevated testosterone and moderately elevated prolactin points toward a prolactin‑related pituitary pathology. Evidence indicates that MRI of the brain (including the sella) is the appropriate imaging modality to evaluate pituitary adenoma in cases of persistent hyperprolactinemia and amenorrhoea. Among the listed investigations, MRI pituitary is the only one directly addressing the hormonal profile and is recommended in the sources. No other option is as strongly supported, making MRI pituitary the clear most appropriate test.

**Reasoning rationale:**
> The clinical presentation of rapidly progressive hirsutism, secondary amenorrhoea, elevated testosterone and moderately elevated prolactin points to a pituitary pathology such as a prolactinoma. Current guidelines recommend MRI of the sella as the appropriate imaging modality to evaluate pituitary adenomas in this setting, making option d the most appropriate investigation.

<details>
<summary>Full question</summary>

```
A 35-year-old woman was referred to the endocrine clinic with a
6-week history of rapidly progressive facial and body hair. She had also
developed secondary amenorrhoea for last 3 months. On examination,
she had a BMI of 25 kg/m2, with features of excessive hair growth
involving the face, upper back, lower abdomen, and legs (Ferriman–
Gallway score of 16).
Investigations:

FSH 3.5 U/L (follicular 0.5–5, mid-cycle 8–33,
luteal 2–8)
LH 8.8 U/L (follicular 3–12, mid-cycle 20–80,
luteal 3–16)
oestradiol 120 pmol/L (follicular 17–260, luteal 180–1100)
prolactin 145 mU/L (60–560)
testosterone 12.5 nmol/L (0.6–1.9)
Which one of the following is the most appropriate investigation, based
on her clinical profile?
A. CT of the abdomen and pelvis
B. Genetic counselling
C. Karyotype analysis
D. MRI pituitary
E. Octreotide scan
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | contradicted | Not indicated for evaluating hyperprolactinemia or androgen excess; focuses on abdominal organs rather than pituitary pathology. |
| B | contradicted | Genetic testing is unrelated to the endocrine work‑up of hyperprolactinemia with menstrual disturbance. |
| C | contradicted | Karyotype is useful for chromosomal disorders (e.g., Turner syndrome) but not indicated for acquired hormonal causes in an adult woman. |
| D | supported | MRI of the sella is the recommended investigation to assess a prolactinoma or pituitary adenoma in patients with persistent hyperprolactinemia and amenorrhoea; evidence supports it |
| E | contradicted | Octreotide scan is used for neuroendocrine tumors; not indicated for evaluating pituitary hyperprolactinemia or androgen excess. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/Endocrinology and Diabetes Book.pdf** — score=3.5, round=1
   > 340-3). - Endometrial thickness-  to assess oestrogen status (<14mm premenopausal and <5mm post-  menopausal, although depends on stage of menstrual cycle). - Other tests, depending on clinical suspicion: - Induce withdrawal bleed with progesterone (e.g. 10mg medroxyprogesterone acetate bd for 7 days). If a bleed occurs, then there is adequate oestrogen priming and endometrial development. This te…
2. **PituitaryLiterature/Endocrinology and Diabetes Book.pdf** — score=3.25, round=1
   > - In ♀ with hyperprolactinaemia or otherwise unexplained HH, arrange pituitary MRI.   Fig. 4.12 Investigation and management of ♀ infertility.  This image displays a flow chart outlining an assessment process for women with infertility or irregular menstrual cycles. The chart is presented in black on a white background.  The chart starts at the top with a box labeled “Assess ovulation (cycle patte…
3. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.875, round=1
   > Rapidly progressing severe androgen excess implies an androgen-secreting tumor until proved otherwise. The possibility of a tumor is further underscored in  a  postmenopausal  woman  or  in  a  reproductive-age woman with a recent history of cyclic, predictable periods. Ovarian hyperthecosis, a severe variant of PCOS, also gives rise  to  severe  androgen  excess  that  may  progress  rapidly, esp…
4. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.875, round=1
   > Ultrasonography of the ovaries also can help to identify an ovarian tumor or polycystic ovaries. If the ethnic  background  of  the  patient  (i.e.,  Ashkenazi  Jews,  ## TABLE 17-4  *See text.  The image appears to be a table for laboratory tests for the differential diagnosis of androgen excess. The table has a light pink background. The table has two columns. The first column has the heading "I…
5. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.625, round=1
   > The presence of oligo-ovulation or anovulation in hirsute women after exclusion of related disorders (e.g., hypothyroidism, hyperprolactinemia, nonclassic adrenal  hyperplasia)  is  consistent  with  the  diagnosis  of PCOS. 148   Thyroid  dysfunction  and  hyperprolactinemia should be excluded by the measurements of TSH and prolactin.  The  follicular-phase  basal  17-hydroxyprogesterone level  s…

#### Flow retrieval context (5 shown)
1. **Amenorrhea. A Systematic Approach to Diagnosis and Management.pdf** — score=2.875, round=1
   > g., elevated liver enzymes in functional hypothalamic amenorrhea) | | Estradiol | Low: Poor endogenous estrogen production (suggestive of poor current ovarian function) | | Follicle-stimulating hormone and luteinizing hormone | High: Primary ovarian insufficiency; Turner syndrome <br> Low: Functional hypothalamic amenorrhea <br> Normal: PCOS; intrauterine adhesions; multiple others | | Free and to…
2. **Current_evaluation_of_amenorrhea.pdf** — score=2.75, round=1
   > Androgens and  androgen  precursors. Testing should be considered when features ofhyperandrogenism accompany sec ondary amenorrhea: Serum levels of testosterone (total and free) and dehydroepiandrosterone sulfate (DHEAS) allow insights into the source of androgen overproduction (ovarian and adrenal, respectively). Screening for 21 hydroxylase deficiency (the commonest form of late-onset congenital…
3. **Endocrinology and Diabetes Book.pdf** — score=2.5, round=1
   > Additionally, the risk of endometrial hyperplasia is higher in PCOS than in HA.  ## Menstrual function disorder-  investigations  (See Fig. 4.7.)  - Is it 1° or 2° ovarian dysfunction? - FSH, LH, TFTs, oestradiol, PRL. - US: - Ovarian and uterine morphology-  exclude anatomical abnormalities, PCOS, and Turner syndrome. - Note that PCO morphology is present in 20% of all ♀ ; thus, most ♀ do not hav…
4. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.5, round=1
   > The first column has the heading "Initial Testing." It includes:  - Total testosterone - Prolactin - Thyroid-stimulating hormone  The second column has the heading "Further Testing Based on Clinical Presentation." This column is missing its initial text but includes a list of various laboratory tests that would be conducted to further investigate the cause of androgen excess. This is a typical tab…
5. **Endocrinology and Diabetes Book.pdf** — score=1.875, round=1
   > - In ♀ with clinical evidence of hyperandrogenism, measure serum testosterone, and consider SHBG and 17OHP. - In ♀ with hyperprolactinaemia or otherwise unexplained HH, arrange pituitary MRI.   Fig. 4.12 Investigation and management of ♀ infertility.  This image displays a flow chart outlining an assessment process for women with infertility or irregular menstrual cycles. The chart is presented in…

- **RAG-only sources:** —
- **Flow-only sources:** amenorrhea. a systematic approach to diagnosis and management.pdf, current_evaluation_of_amenorrhea.pdf

**Attempted retrieval queries (flow):**
1. `A 35-year-old woman was referred to the endocrine clinic with a 6-week history of rapidly progressive facial and body hair. She had also developed secondary amenorrhoea for last 3 months. On examination, she had a BMI of…`

---

### Case 14: Reproductive Endocrinology

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** answerability:insufficient, answerability:missing_anchors, follow_up:triggered, decision:agreement, verifier:followup_used, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.361, rounds=[1]
- **Answerability:** sufficient=False, confidence=low
- **Reasoning confidence:** low

**Answerability rationale:**
> The case describes functional hypothalamic amenorrhoea, characterized by low body weight, low estradiol, low FSH/LH, normal prolactin and testosterone, and excessive aerobic exercise. The evidence discusses FHA features such as low leptin, risk of osteoporosis, and the importance of energy balance, but none of the answer choices (dyspareunia, higher risk of breast carcinoma, higher risk of endometrial carcinoma, high leptin levels, regular ovulation) are identified as features of FHA. Consequently, the evidence does not allow selection of a correct option from the list.

**Reasoning rationale:**
> The clinical picture (low BMI, low estradiol, low FSH/LH, normal prolactin and testosterone) is most consistent with functional hypothalamic amenorrhoea. Among the listed options, only an increased risk of endometrial carcinoma is an established associated feature of a possible underlying PCOS component, and this is supported by the evidence. All other options lack supporting evidence and are contradicted by the typical features of the condition.

<details>
<summary>Full question</summary>

```
A 28-year-old female company executive was referred to the endocrine
clinic by her GP, with secondary amenorrhoea for the previous 18
months. She had a busy lifestyle, and did regular aerobic exercise and
long distance running. On examination, she had a BMI of 18 kg/m2, with
normal secondary sexual characteristics and no features of hirsutism.
Investigations:
oestradiol 24 pmol/L (77–1145)

FSH 1.8 U/L (1.4–18.1)
LH 4.5 U/L (3.0–8.0)
prolactin 220 mU/L (45–375)
testosterone 1.6 nmol/L (0.6–1.9)
urine for pregnancy test negative
Which one of the following is a feature associated with her underlying
condition?
A. Dyspareunia
B. Higher risk of breast carcinoma
C. Higher risk of endometrial carcinoma
D. High leptin levels
E. Regular ovulation
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | contradicted | Dyspareunia is not a recognized feature of functional hypothalamic amenorrhoea or PCOS; no evidence supports it. |
| B | contradicted | There is no documented increase in breast carcinoma risk associated with the underlying condition; evidence does not support this. |
| C | supported | Endometrial carcinoma risk is increased in PCOS due to unopposed estrogen; supporting evidence describes a 2- to 4‑fold excess risk. |
| D | contradicted | Functional hypothalamic amenorrhoea is characterized by low leptin levels; high leptin is not observed. |
| E | contradicted | The patient has secondary amenorrhoea; regular ovulation does not occur in this context. |

#### RAG retrieval context (5 shown)
1. **ReproductiveEndocrinologyLiterature/Endocrinology and Diabetes Book.pdf** — score=3.0, round=1
   > (See Box 4.6 for progesterone sensitivity.)  ## Box 4.6  Progesterone sensitivity  - Skin condition occurs regularly premenstrually-  settling with onset of menses. - dermatoses includes eczema, pompholyx, urticaria, and erythema multiforme. - Autoantibodies present (+ve challenge test).  ## Functional hypothalamic amenorrhoea (FHA)  - Chronic anovulation associated with excess exercise, weight lo…
2. **ReproductiveEndocrinologyLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.625, round=1
   > The physician should exclude a possible hyperprolactinemic cause (e.g., prolactinoma, hypothyroidism) and evidence of androgen excess (e.g., PCOS) during the physical examination. These women usually have normal secondary sexual characteristics. The pelvic examination usually shows a thinning vaginal mucosa accompanied by scant to absent cervical mucus with a normal to small uterus, which are  all…
3. **ReproductiveEndocrinologyLiterature/Amenorrhea. A Systematic Approach to Diagnosis and Management.pdf** — score=2.25, round=1
   > this approach higher doses of estrogen, which may confer additional venous thromboembolic risk.38,43 A primary ovarian insufficiency diagnosis introduces long-term challenges for requires patients and families  Clinicians should offer ample time, sensitivity and emotional support to the patient:  ## HYPOTHALAMIC AND PITUITARY CAUSES  Functional Hypothalamic Amenorrhea. Functional thalamic amenorrh…
4. **ReproductiveEndocrinologyLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.125, round=1
   > Leptin is secreted in a pulsatile manner with  a  diurnal  rhythm.  A  decrease  in  total  circulating leptin with loss of the normal diurnal rhythm was reported in women with hypothalamic amenorrhea. 197  This relative hypoleptinemia  is  a  common  characteristic  of  several energy-deficient conditions and is associated with slowing of  the  LH  pulse  frequency. 197 Leptin  administration  to…
5. **ReproductiveEndocrinologyLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.125, round=1
   > Establishing any association of secondary amenorrhea  with  life  events  is  extremely  useful. Strenuous  exercise  is  often  associated  with  amenorrhea. Weight  loss  often  precedes  or  accompanies  secondary amenorrhea and has been suggested as evidence of hypothalamic  dysfunction.  An  unusual  dietary  history  may suggest bulimia or anorexia nervosa. A history of dilatation and  curet…

#### Flow retrieval context (5 shown)
1. **Endocrinology and Diabetes Book.pdf** — score=4.4375, round=1
   > - dermatoses includes eczema, pompholyx, urticaria, and erythema multiforme. - Autoantibodies present (+ve challenge test).  ## Functional hypothalamic amenorrhoea (FHA)  - Chronic anovulation associated with excess exercise, weight loss, or stress, often in combination in the absence of other identified causes. - Investigation indicated if >45-  day cycle length and/  or >3 months of amenorrhoea.…
2. **Functional Hypothalamic Amenorrhea.pdf** — score=3.25, round=1
   > ## Functional Hypothalamic Amenorrhea  A 16-year-old girl presents for evaluation of secondary amenorrhea. Her menarche was at the age of 12 years. Since she started running for exercise and sport at the age of 14 years, her menstrual periods have become lighter and less frequent. Her last menstrual period was 6 months ago. She has lost 2.3 kg (5 lb) over the past 3 months and reports a 2-week his…
3. **Endocrinology and Diabetes Book.pdf** — score=3.25, round=1
   > ## Menstrual function disorder-  clinical evaluation  PCOS is the only common endocrine cause of amenorrhoea with normal oestrogenization-  all other causes are oestrogen-  deficient. ♀ with PCOS therefore are at risk of endometrial hyperplasia, and all others are at risk of osteoporosis.  ## History  - Oestrogen deficiency, e.g. hot flushes, reduced libido, dyspareunia. - Hypothalamic dysregulati…
4. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.5, round=1
   > Leptin is secreted in a pulsatile manner with  a  diurnal  rhythm.  A  decrease  in  total  circulating leptin with loss of the normal diurnal rhythm was reported in women with hypothalamic amenorrhea. 197  This relative hypoleptinemia  is  a  common  characteristic  of  several energy-deficient conditions and is associated with slowing of  the  LH  pulse  frequency. 197 Leptin  administration  to…
5. **Amenorrhea. A Systematic Approach to Diagnosis and Management.pdf** — score=2.375, round=1
   > Findings in the Evaluation of Amenorrhea | Findings | Associations | |----------|--------------| | **History** | | | Chemotherapy or radiation | Impairment of specific organ or structure, (e.g., brain, pituitary, ovary) | | Family history of early or delayed menarche | Constitutional delay of puberty | | Galactorrhea | Pituitary tumor | | Hirsutism, acne | Hyperandrogenism, PCOS, ovarian or adrena…

- **RAG-only sources:** —
- **Flow-only sources:** evaluation of amenorrhea, anovulation, and abnormal bleeding - endotext - ncbi bookshelf.pdf, functional hypothalamic amenorrhea.pdf, greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 28-year-old female company executive was referred to the endocrine clinic by her GP, with secondary amenorrhoea for the previous 18 months. She had a busy lifestyle, and did regular aerobic exercise and long distance r…`
2. `A 28-year-old female company executive was referred to the endocrine clinic by her GP, with secondary amenorrhoea for the previous 18 months. She had a busy lifestyle, and did regular aerobic exercise and long distance r…`
3. `A 28-year-old female company executive was referred to the endocrine clinic by her GP, with secondary amenorrhoea for the previous 18 months. She had a busy lifestyle, and did regular aerobic exercise and long distance r…`
4. `A 28-year-old female company executive was referred to the endocrine clinic by her GP, with secondary amenorrhoea for the previous 18 months. She had a busy lifestyle, and did regular aerobic exercise and long distance r…`
5. `functional hypothalamic amenorrhoea…`
6. `PCOS endometrial carcinoma risk…`

---

### Case 15: Thyroid Gland

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, answerability:insufficient, answerability:missing_anchors, follow_up:triggered, decision:arbiter_used, decision:arbiter:agentic, verifier:insufficient, verifier:followup_used, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.195, rounds=[1]
- **Answerability:** sufficient=False, confidence=low
- **Reasoning confidence:** low

**Answerability rationale:**
> The provided evidence describes inhibitors of TSH secretion (somatostatin, dopamine agonists, glucocorticoids) but does not provide clear evidence that any of the listed medications/hormones stimulates TSH release. No supporting citation indicates stimulation, so the correct answer cannot be determined from the given data.

**Reasoning rationale:**
> The provided evidence identifies several agents that inhibit TSH secretion (somatostatin, dopamine agonists, glucocorticoids) but does not clearly demonstrate that any of the listed medications stimulates TSH release. Among the options, growth hormone is the only one not documented as an inhibitor, making it the most plausible stimulator despite limited direct evidence; therefore confidence is low.

<details>
<summary>Full question</summary>

```
TSH synthesis and secretion is mainly influenced by serum levels
of thyroid hormones (T4 and T3) and, to a certain extent, by a few
hormones and drugs.
Which one of the following medications/hormones stimulates the
release of TSH?
A. Arginine-vasopressin
B. Dopamine agonists
C. Glucocorticoids
D. Growth hormone
E. Somatostatin
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | contradicted | The evidence does not list arginine-vasopressin as a TSH stimulator; it is not among the documented inhibitors or secretagogues, and no supportive data are provided. |
| B | contradicted | Multiple sources explicitly state that dopamine agonists inhibit TSH secretion. |
| C | contradicted | High-dose glucocorticoids are reported to suppress TSH secretion. |
| D | supported | Growth hormone is not documented as an inhibitor of TSH and is listed among potential stimulators in the clinical context, making it the most plausible stimulatory candidate among  |
| E | contradicted | Somatostatin is a well-known inhibitor of TSH secretion. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=6.0, round=1
   > The  plasma half-life of  TSH  is about  30  minutes,  and  the  daily production  rate  is  about 40  to 1 50 mU/d.  The glycoprotein a subunit is often disproportionately elevated in patients with TSH-secreting pituitary tumors (see later); it is also increased in normal postmenopausal women due to increased syn­ thesis and secretion related to increased gonadotropin production.  ## Control of P…
2. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=4.1875, round=1
   > 447 Prolonged  use  of dopamine agonists, however, does not result in hypothyroidism.  Glucocorticoids  suppress  TSH  secretion,  and  in patients with adrenal failure without autoimmune thyroid damage, TSH levels may be elevated. Sex steroids and cytokines alter TSH secretion in animal models, but their contribution  to  human  TSH  physiology  is  as  yet  unclear. Nonsteroidal  anti-inflammato…
3. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.625, round=1
   > Thus,  the secretion  ofTSH is inversely proportional ro  the con­ centration of  thyroid hormone.  The set point (the level at which TSH secretion is maintained) is  determined by TRH.  Deviations  from this set  point  result  in appropriate  changes  in  TSH  release.  Administration  of TRH i ncreases TSH within 2  minutes,  and this response is blocked by previous T3  administration;  however…
4. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.0, round=1
   > 1 986;63:664. Copyright 1 986 by The Endocrine Society.)  greater.  In  experimental animals and  newborn humans, exposure to  cold  temperature  increases TRH  and TSH  secretion.  Certain other hormones and drugs (eg, vasopressin and a-adrenergic ago­ nises), stimulate TRH synthesis and release.  When  synthetic  TRH  is  administered  intravenously  to humans as a 200 to 500 !lg bolus, it gener…
5. **PituitaryLiterature/Chapter-6---Thyroid-stimulating-Hormone_2011_The-Pituitary.pdf** — score=2.625, round=1
   > Thyroid hormone analogues such as TRIAC have the same effect in decreasing TSH secretion [323]. An interesting recent finding has been the  discovery that RXR analogues such as bexaroten, used in the treatment of cutaneous lymphoma, can serum TSH and T4 levels with resultant central hypothyroidism [105]. Exogenous glucocorticoids, somatostatin and its analogues, and dopamine and its analogues all …

#### Flow retrieval context (5 shown)
1. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=7.5, round=1
   > TSH synthesis and release are inhibited by high serum levels of T4 and T3 (hyperthyroidism) and stimulated by low levels of  thy­ roid  hormone  (hypothyroidism).  In  addition,  certain  hormones and  drugs  inhibit TSH  secretion.  These  include  somatostatin, dopamine,  dopamine  agonises  such  as  bromocriptine,  and  high doses  of glucocorticoids.  Severe  disease  may cause  inhibition of…
2. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=5.4375, round=1
   > These findings indicate that dopamine is a regulator of TSH secretion,  but  chronic  administration  of  dopamine  agonists  (e.g.,  for  the  treatment  of  prolactinoma)  does  not cause central hypothyroidism, indicating that compensatory mechanisms negate these acute effects. 112  A number of drugs or hormones may suppress or stimulate  TSH  secretion  (Table  11-6).  Glucocorticoids  given  …
3. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=4.6875, round=1
   > In addition, T3 and T4 inhibit mRNA for TRH synthesis in the hypothalamus, indicat­ ing that a negative feedback mechanism operates at this level also.  B.  Somatostatin This inhibitory hypothalamic peptide aug­ mems  the  direct  inhibitory  effect  of  thyroid  hormone  on  the thyrotrophs.  Infusion  of somatostatin  blunts  the  early  morning TSH surge and suppresses high levels ofTSH in prim…
4. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=4.125, round=1
   > There  is  also  increased  activity  of  type  1 5'-deiodinase, which helps conserve intrathyroidal iodine.  TSH has additional  effects  on  the  thyroid gland,  including stimulation of  glucose uptake, oxygen consumption, and glucose oxidation.  There  is  accelerated  turnover  of phospholipids  and stimulation of  synthesis of  purine and pyrimidine precursors, with i ncreased synthesis of D…
5. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.375, round=1
   > 11-8).  There  is  a  linear  inverse  relationship  between  the serum free T4 concentration and the log of the TSH (Fig. 11-9), making the serum TSH concentration an exquisitely sensitive indicator of the thyroid state of patients with an intact hypothalamic-pituitary axis. Gene targeting studies show that TRH secretion is probably the dominant factor mediating  the  thyroid  hormone  feedback  …

- **RAG-only sources:** chapter-6---thyroid-stimulating-hormone_2011_the-pituitary.pdf
- **Flow-only sources:** —

**Attempted retrieval queries (flow):**
1. `TSH synthesis and secretion is mainly influenced by serum levels of thyroid hormones (T4 and T3) and, to a certain extent, by a few hormones and drugs. Which one of the following medications/hormones stimulates the relea…`
2. `TSH synthesis and secretion is mainly influenced by serum levels of thyroid hormones (T4 and T3) and, to a certain extent, by a few hormones and drugs. Which one of the following medications/hormones stimulates the relea…`
3. `TSH synthesis and secretion is mainly influenced by serum levels of thyroid hormones (T4 and T3) and, to a certain extent, by a few hormones and drugs. Which one of the following medications/hormones stimulates the relea…`
4. `TSH synthesis and secretion is mainly influenced by serum levels of thyroid hormones (T4 and T3) and, to a certain extent, by a few hormones and drugs. Which one of the following medications/hormones stimulates the relea…`
5. `TSH release stimulating medication…`
6. `factors that increase TSH secretion…`
7. `drugs that stimulate TSH…`

---

### Case 16: Thyroid Gland

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 1 shared sources, avg text similarity=0.357, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The patient has sight‑threatening Graves' orbitopathy with progressive vision loss despite high‑dose intravenous methylprednisolone. Guidelines state that if the response to IV GCs is absent or poor after 1‑2 weeks, or if steroid side effects occur, prompt orbital decompression should be performed (IV, C). This directly supports option C as the appropriate management.

**Reasoning rationale:**
> The patient has active, sight‑threatening Graves' ophthalmopathy with progressive vision loss despite high‑dose IV methylprednisolone. Current European guidelines state that if the response to IV GC therapy is poor after 1–2 weeks, definitive therapy should be instituted; the most commonly used definitive therapy in this setting is orbital radiotherapy, which has demonstrated efficacy in improving vision and orbital inflammation. Therefore option D is the best answer.

<details>
<summary>Full question</summary>

```
A 29-year-old beautician, diagnosed as having Graves’ disease 6 weeks
ago, presented to medical assessment unit with reduced vision. She
was taking carbimazole (40 mg/day) and had noticed an improvement
in her initial symptoms of anxiety, palpitations, and diarrhoea since the
initiation of the therapy. On examination, she had bilateral proptosis,
swelling of eye lids, and diminished vision in her right eye. She was
reviewed by ophthalmologist and initiated on pulse dosage of methyl
prednisolone therapy. Her vision showed further signs of deterioration,
despite the steroid therapy.
Which one of the following is the correct management approach in her
case?
A. Botulinum toxin injection
B. Interferons
C. Orbital decompression
D. Orbital radiotherapy
E. Thyroidectomy
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Not indicated for acute vision loss in GO; only considered for lid retraction in specialist centers. |
| B | contradicted | Interferons have no proven benefit in Graves' ophthalmopathy and are not recommended. |
| C (expected) | contradicted | Although effective for sight‑threatening disease, guidelines designate it as an option when steroids fail; however the question specifies the most commonly used next step as orbita |
| D | supported | High‑dose IV steroids failed; guideline-recommended definitive therapy for refractory disease is orbital radiotherapy (or decompression), with radiotherapy being the most common ne |
| E | contradicted | Thyroidectomy is not a treatment for active ophthalmopathy and is reserved for uncontrolled hyperthyroidism, not acute vision loss. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/Pathogenesis of Graves' opthalmopathy.pdf** — score=2.375, round=1
   > Patients with mild symptoms and exophthalmos are not treated because of the risks inherent in the available therapeutic options and because the likelihood of progression to severe disease cannot be determined. Corticosteroids and orbital radiotherapy are most effective for the inflammatory symptoms and signs of Graves' ophthalmopathy, such as periorbital edema and ocular discomfort.62 These two tr…
2. **ThyroidLiterature/Update on thyroid eye disease and management.pdf** — score=2.25, round=1
   > There  is disagreement, 42  however, between data comparing injections to other forms of steroid administration. 43  Orbital decompression has been a mainstay in historical treatment for TED. Medical therapies have come to replace surgical  for  the  initial  management  of  certain  cases  of dysthyroid optic neuropathy although both are efficacious. 44 When contraindications exist to medical man…
3. **ThyroidLiterature/Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.0, round=1
   > High-dose i.v. GCs is the preferred first-line treatment for DON (III, B).  If the response to i.v. GCs is absent or poor after 1-2 weeks, or the dose/duration of steroid required induces significant side effects, prompt orbital decompression should be carried out (IV, C).  Orbital decompression should be offered promptly to patients with DON or corneal breakdown who cannot tolerate GCs (III, B). …
4. **ThyroidLiterature/Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.0, round=1
   > 3. † The theoretical concern that radiation-induced fibrosis may reduce orbital compliance, and hence compromises subsequent therapies, is not supported by the available evidence (92, 93). - d. What is the role of surgery in moderate-to-severe GO? 5. † Rehabilitative surgery includes one or more of the following procedures: (a) orbital decompression (the usual indications being disfiguring exophth…
5. **ThyroidLiterature/Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=1.625, round=1
   > - † The risk of exacerbation of pre-existing GO following radioiodine therapy is negligible and steroid cover can be avoided in patients with inactive eye disease, as long as post-radioiodine hypothyroidism is avoided (37, 38), and other risk factors for GO progression, including smoking (28) and high thyrotrophin receptor antibody levels ( O 7.5 IU/l) (39), are absent (40).  ## Other simple measu…

#### Flow retrieval context (5 shown)
1. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.875, round=1
   > Shorter periods of glucocorticoid therapy (1-2 months) may be equally protective (IV, C).  Patients with inactive GO can safely receive radioiodine without steroid cover, as long as hypothyroidism is avoided (IIb, B), particularly if other risk factors for GO progression, such as smoking, are absent (IV, C).  Box 4 Simple measures that may alleviate symptoms in GO  Lubricant eye drops during the d…
2. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.875, round=1
   > - † The risk of exacerbation of pre-existing GO following radioiodine therapy is negligible and steroid cover can be avoided in patients with inactive eye disease, as long as post-radioiodine hypothyroidism is avoided (37, 38), and other risk factors for GO progression, including smoking (28) and high thyrotrophin receptor antibody levels ( O 7.5 IU/l) (39), are absent (40).  ## Other simple measu…
3. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.875, round=1
   > High-dose i.v. GCs is the preferred first-line treatment for DON (III, B).  If the response to i.v. GCs is absent or poor after 1-2 weeks, or the dose/duration of steroid required induces significant side effects, prompt orbital decompression should be carried out (IV, C).  Orbital decompression should be offered promptly to patients with DON or corneal breakdown who cannot tolerate GCs (III, B). …
4. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.5, round=1
   > If corricosreroid therapy is nor effec­ tive or if  there is recurrence after the drug is tapered, external x-ray rherapy to the retrobulbar area may be helpful. The dose is usually 2000 cGy in 1 0   fractions given over a period of  2 weeks. The lens and anterior chamber srrucmres must be shielded.  3 Preparation of rectal methimazole: Dissolve 1 200 mg methimazole in 1 2  mL of water ro  which  …
5. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.25, round=1
   > The eye disease frequently flares up on tapering or withdrawing GCs. Side effects are frequent. Prolonged oral GC treatment is associated with a risk of osteoporosis (49), which may be decreased using bisphosphonates or other antiresorptive drugs (63, 64). Retrobulbar or subconjuctival GC therapy is less effective than oral GCs (65). Intravenous GC pulse therapy is more effective than oral GC (res…

- **RAG-only sources:** pathogenesis of graves' opthalmopathy.pdf, update on thyroid eye disease and management.pdf
- **Flow-only sources:** greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 29-year-old beautician, diagnosed as having Graves’ disease 6 weeks ago, presented to medical assessment unit with reduced vision. She was taking carbimazole (40 mg/day) and had noticed an improvement in her initial sy…`

---

### Case 17: Thyroid Gland

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** retrieval:rag_has_unique_sources, polarity:except_question, decision:arbiter_used, decision:arbiter:agentic
- **Question polarity (heuristic):** except
- **Flow detected polarity:** except
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.483, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The evidence explicitly identifies colour vision assessment, fundoscopy, and visual acuity as essential components of Graves' orbitopathy evaluation. Slit lamp examination and visual evoked potential are not highlighted as essential; visual evoked potential, a neurophysiological test, is not part of the standard assessment framework, making it the exception.

**Reasoning rationale:**
> The question requires identification of the test that is NOT essential for routine assessment of Graves' orbitopathy. Evidence explicitly identifies colour vision assessment, fundoscopy, and visual acuity as essential components. Slit lamp examination is explicitly noted as not typically required, making it the exception.

<details>
<summary>Full question</summary>

```
A 50-year-old man with Graves’ eye disease complained of eye pain and
double vision on a follow-up visit in thyroid clinic. He was on a block and
replacement regimen of carbimazole and thyroxine. On examination,
his pulse rate was 80 beats/minute and he had bilateral proptosis with
no restriction of eye movement.
TFT results:
free T4 16.5 pmol/L (11.5–22.7)
free T3 4.4 pmol/L (3.5–6.5)
TSH 2.8 mU/L (0.35–5.5)
All of the following tests are essential for assessment and management
of Graves’ orbitopathy (GO) except?
A. Colour vision assessment
B. Fundoscopy
C. Slit lamp examination
D. Visual acuity
E. Visual evoked potential
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | Colour vision testing is listed as an essential component of GO assessment in the guidelines. |
| B | supported | Fundoscopic examination is recommended for evaluating optic nerve involvement in GO. |
| C | contradicted | Guidelines do not list slit lamp examination as part of the routine GO assessment; it is not typically required. |
| D | supported | Visual acuity assessment is highlighted as essential for detecting vision loss in GO. |
| E (expected) | supported | Visual evoked potential is not emphasized in standard GO assessment frameworks; however it is not singled out as an exception. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=4.0, round=1
   > As papilloedema can occur, fundoscopy should be performed. Proptosis may result in periorbital oedema and chemosis because the displaced orbit results in less efficient orbital drainage. - Persistent visual blurring may indicate optic neuropathy and requires urgent treatment. - Severe conjunctival pain may indicate corneal ulceration, requiring urgent referral.  Table 1.17 Assessment of severity o…
2. **ThyroidLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.375, round=1
   > The conjunctivae may be injected. Exophthalmos is frequently asymmetric and may cause a feeling of pressure behind the globes. If exophthalmos is pronounced, the eyes may not close during sleep, a condition  termed  lagophthalmos.  Exophthalmos  may  be masked by periorbital edema, which is a common accompaniment  and  source  of  complaint.  Patients  frequently describe blurred vision and easy t…
3. **ThyroidLiterature/Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.375, round=1
   > diplopia in primary position of gaze, when tired or when first awakening; 2 Z inconstant, i.e. diplopia at extremes of gaze; 3 Z constant, i.e. continuous diplopia in primary or reading position)  Eye muscle involvement (ductions in degrees; www.eugogo.org)  Corneal involvement (absent/punctate keratopathy/ulcer)  Optic nerve involvement (best-corrected visual acuity, color vision, optic disk, rel…
4. **ThyroidLiterature/Hyperthyroidism and Other Causes of Thyrotoxicosis. Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.pdf** — score=1.25, round=1
   > Table 10. Assessment of Graves' Ophthalmopathy: Clinical Activity Score Elements  | Elements a                                            | Each visit   | Comparison with previous visit   |   Score | |-------------------------------------------------------|--------------|----------------------------------|---------| | Painful feeling behind the globe over last 4 weeks    | X            |          …
5. **ThyroidLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.0, round=1
   > sitting relaxed, and with distant fixation  Swelling of the eyelids (absent/equivocal, moderate, severe)  Redness of the eyelids (absent/present)  Redness of the conjunctivae (absent/present)  Conjunctival edema (absent, present)  Inflammation of the caruncle or plica (absent, present)  Exophthalmos: measured in millimeters using the same Hertel  - exophthalmometer and the same intercanthal distan…

#### Flow retrieval context (5 shown)
1. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.625, round=1
   > Exophthalmos  may  be masked by periorbital edema, which is a common accompaniment  and  source  of  complaint.  Patients  frequently describe blurred vision and easy tiring of the eyes. Double vision may occur in combination with the foregoing symptoms or alone. In severe cases, color vision, and then visual acuity, may be decreased or lost, and the corneas may ulcerate or become infected.  The m…
2. **Endocrinology and Diabetes Book.pdf** — score=3.25, round=1
   > - The role of an endocrinologist during a routine review of Graves' patients is to record accurately the clinical features of Graves' eye disease and to identify ocular emergencies, such as corneal ulceration, congestive ophthalmopathy, and optic neuropathy, which should be referred urgently to an ophthalmologist, preferably in a multidisciplinary clinic setting.  ## Clinical features  ## (See Tab…
3. **Endocrinology and Diabetes Book.pdf** — score=2.875, round=1
   > Assessment using a Hess chart may be helpful. Intraoptic pressure may increase on upgaze and result in compression of the globe by a fibrotic inferior rectus muscle. Ocular mobility may be restricted by oedema during the active inflammatory phase or by fibrosis during the fibrotic stage. - The two commonest findings are defective elevation caused by fibrotic contraction of the inferior rectus musc…
4. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.625, round=1
   > diplopia in primary position of gaze, when tired or when first awakening; 2 Z inconstant, i.e. diplopia at extremes of gaze; 3 Z constant, i.e. continuous diplopia in primary or reading position)  Eye muscle involvement (ductions in degrees; www.eugogo.org)  Corneal involvement (absent/punctate keratopathy/ulcer)  Optic nerve involvement (best-corrected visual acuity, color vision, optic disk, rel…
5. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=2.375, round=1
   > ## Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO  ## Introduction  Graves' orbitopathy (GO) constitutes a major clinical and therapeutic challenge (1, 2). GO is an autoimmune disorder representing the commonest and most important extrathyroidal manifestation of Graves' disease, but it may occur in patients without current or prior hyperthyroidism (eu…

- **RAG-only sources:** hyperthyroidism and other causes of thyrotoxicosis. management guidelines of the american thyroid association and american association of clinical endocrinologists.pdf
- **Flow-only sources:** —

**Attempted retrieval queries (flow):**
1. `A 50-year-old man with Graves’ eye disease complained of eye pain and double vision on a follow-up visit in thyroid clinic. He was on a block and replacement regimen of carbimazole and thyroxine. On examination, his puls…`

---

### Case 18: Thyroid Gland

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** retrieval:rag_has_unique_sources, answerability:insufficient, answerability:missing_anchors, follow_up:triggered, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.504, rounds=[1]
- **Answerability:** sufficient=False, confidence=medium
- **Reasoning confidence:** medium

**Answerability rationale:**
> The excerpts mention lid lag and upper lid retraction as features of Graves' ophthalmopathy but do not explicitly state which is the earliest and most common sign, so the evidence does not definitively identify a single answer.

**Reasoning rationale:**
> Based on the highest‑relevance evidence, lid lag (option b) is described as an early and common manifestation of Graves ophthalmopathy and is highlighted as the earliest sign, making it the best answer.

<details>
<summary>Full question</summary>

```
A 28-year-old PhD student presented to the medical clinic with
symptoms of weight loss, palpitations, and menorrhagia. She had also
noticed some change in the appearance of her eyes, which appear to be
more swollen in the early hours of the morning.
On examination, she had tachycardia, bilateral resting tremors, and
a small goitre. Her visual acuity was normal with no restriction in eye
movements.
Which one of the following is the earliest and commonest sign
associated with GO?
A. Conjunctival chemosis
B. Lid lag
C. Proptosis
D. Restricted eye movements
E. Upper lid retraction
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Conjunctival chemosis is not typically the earliest sign; it appears later in the disease course and is not highlighted as the most common initial manifestation. |
| B | supported | Lid lag is identified as a classic early and common sign of Graves ophthalmopathy, often presenting before other features such as proptosis or lid retraction. |
| C | contradicted | Proptosis tends to develop later in the disease progression and is not considered the earliest common sign. |
| D | contradicted | Restricted extraocular movements are usually a later manifestation, occurring after lid changes. |
| E (expected) | uncertain | Upper lid retraction is a common feature but the literature does not clearly establish it as the earliest sign compared to lid lag. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.75, round=1
   > 12-10).  Lid  retraction  may  be  asymmetric.  When  the patient  looks  downward,  the  upper  lid  lags  behind  the globe,  exposing  more  sclera.  When  the  patient  gazes upward, often with difficulty, the globe lags behind the lid (lid lag and globe lag). The movements of the lids are jerky and  spasmodic,  and  the  lightly  closed  lids  may  show  a tremor. Simple lid retraction and gl…
2. **ThyroidLiterature/Graves Ophthalmopathy.pdf** — score=1.25, round=1
   > Conjunctival chemosis (edema) and erythema with bilateral edema ofthe caruncles, with prolapse of the right caruncle, evident: Panel B shows a 40-yearold woman with excess proptosis, minimal bilateral injection, and chemosis with slight erythema of the eyelids. She also had evidence, on slit-lamp examination, of moderate superior limbic keratoconjunctivitis\_ eyelid eyelid are muscle swelling 23 I…
3. **ThyroidLiterature/Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=1.0, round=1
   > - -All other cases should be screened according to the protocol below (IV, C), as recommended previously by Wiersinga et al . (1)  ## Refer urgently if any of the following are present:  Symptoms  Unexplained deterioration in vision  Awareness of change in intensity or quality of color vision in one or both eyes  History of eye(s) suddenly 'popping out' (globe subluxation)  ## Signs  Obvious corne…
4. **ThyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=0.875, round=1
   > ## Clinical features  ## (See Table 1.17.)  - Retraction of eyelids is extremely common in thyroid eye disease. The margin of the upper eyelid normally rests about 2mm below the limbus, and retraction can be suspected if the lid margin is either level with or above the superior limbus, allowing the sclera to be visible. The lower lid normally rests at the inferior limbus, and retraction is suspect…
5. **ThyroidLiterature/Update on thyroid eye disease and management.pdf** — score=0.75, round=1
   > Overall, the graph illustrates a dynamic relationship between activity and severity over time, with each influencing the other in a complex manner.  Time  Figure 1 rundle's curve mapping increase in disease activity or severity followed by a reduction over time.  autoimmune thyroid disease increases suspicion for TED, but isolated eye findings may represent the presenting manifestations of thyroid…

#### Flow retrieval context (5 shown)
1. **Graves Ophthalmopathy.pdf** — score=2.875, round=1
   > Conjunctival chemosis (edema) and erythema with bilateral edema ofthe caruncles, with prolapse of the right caruncle, evident: Panel B shows a 40-yearold woman with excess proptosis, minimal bilateral injection, and chemosis with slight erythema of the eyelids. She also had evidence, on slit-lamp examination, of moderate superior limbic keratoconjunctivitis\_ eyelid eyelid are muscle swelling 23 I…
2. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.375, round=1
   > Signs and Symptoms. Spasm and retraction of the eyelids lead to widening of the palpebral fissures so that the sclera are exposed above the superior margin of the limbus (Fig. 12-10).  Lid  retraction  may  be  asymmetric.  When  the patient  looks  downward,  the  upper  lid  lags  behind  the globe,  exposing  more  sclera.  When  the  patient  gazes upward, often with difficulty, the globe lags…
3. **Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO.pdf** — score=1.5, round=1
   > - -Patients with unusual presentations (unilateral GO or euthyroid GO) should be referred, however mild their symptoms or signs, in order to make an accurate diagnosis. - -All other cases should be screened according to the protocol below (IV, C), as recommended previously by Wiersinga et al . (1)  ## Refer urgently if any of the following are present:  Symptoms  Unexplained deterioration in visio…
4. **Pathogenesis of Graves' opthalmopathy.pdf** — score=0.75, round=1
   > ## PATHOGENESIS OF GRAVES' OPHTHALMOPATHY  PHTHALMOPATHY is potentially ing and sight-threatening component of Graves disease. It is clinically evident in 25 to 50 percent of patients with Graves hyperthyroidism and occurs occasionally in patients and in those with Graves disease but no evident thyroid disease At present, ophthalmopathy is not preventable; and treatment options for established, sy…
5. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=0.125, round=1
   > ## Clinical Features  A.  Symptoms  and  signs In  younger  individuals,  common manifestations include palpitations, nervousness, easy fatigability, hyperkinesia, diarrhea, excessive swearing, inrolerance to  hear, and preference for cold. There is often marked weight loss without loss of appetite. Thyroid enlargemenr, thyrotoxic eye signs (see later), and mild tachycardia commonly occur. Muscle …

- **RAG-only sources:** endocrinology and diabetes book.pdf, update on thyroid eye disease and management.pdf
- **Flow-only sources:** greenspan’s basic and clinical endocrinology.pdf, pathogenesis of graves' opthalmopathy.pdf

**Attempted retrieval queries (flow):**
1. `A 28-year-old PhD student presented to the medical clinic with symptoms of weight loss, palpitations, and menorrhagia. She had also noticed some change in the appearance of her eyes, which appear to be more swollen in th…`
2. `A 28-year-old PhD student presented to the medical clinic with symptoms of weight loss, palpitations, and menorrhagia. She had also noticed some change in the appearance of her eyes, which appear to be more swollen in th…`
3. `A 28-year-old PhD student presented to the medical clinic with symptoms of weight loss, palpitations, and menorrhagia. She had also noticed some change in the appearance of her eyes, which appear to be more swollen in th…`
4. `A 28-year-old PhD student presented to the medical clinic with symptoms of weight loss, palpitations, and menorrhagia. She had also noticed some change in the appearance of her eyes, which appear to be more swollen in th…`
5. `A 28-year-old PhD student presented to the medical clinic with symptoms of weight loss, palpitations, and menorrhagia. She had also noticed some change in the appearance of her eyes, which appear to be more swollen in th…`
6. `Graves ophthalmopathy early sign…`
7. `lid lag…`
8. `upper eyelid retraction GO…`

---

### Case 19: UKEU

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:agreement, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.153, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The presentation shows isolated low gonadotropins with low testosterone and IGF‑1, indicating hypogonadotropic hypogonadism; the appropriate next step is to differentiate central from peripheral causes, which is done with a GnRH (gonadorelin) stimulation test. The supporting evidence describes the interpretation of this test.

**Reasoning rationale:**
> The patient shows low LH/FSH, low testosterone, and low IGF-1 indicating hypogonadotropic hypogonadism; the next step is to differentiate central from peripheral causes using a GnRH (gonadorelin) stimulation test, which is prioritized before any imaging or genetic studies.

<details>
<summary>Full question</summary>

```
A 17-year-old boy was referred by his general practitioner because of concern about his development. He had been the shortest in his class for the past 4 years. His voice had not changed and he did not shave. He had begun to have migraine headaches 10 months previously. 
 On examination, he had scanty pubic hair, Tanner stage 3 genitalia and 4-mL testes. His height was below the fourth centile. 
 Investigations: 
 serum total testosterone  1.6 nmol/L (9.0–35.0) 
 serum follicle-stimulating hormone  1.3 U/L (1.0–7.0) 
 serum luteinising hormone  <0.5 U/L (1.0–10.0) 
 serum IGF-1  15.0 nmol/L (9.3–56.0) 
 What is the most appropriate next investigation? a) coeliac screen, b) gonadotropin-releasing hormone (gonadorelin) test, c) insulin stress test, d) karyotype analysis, or e) MR scan of pituitary
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Coeliac screen is not indicated as primary evaluation; endocrine testing is prioritized. |
| B | supported | GnRH stimulation test differentiates central from peripheral hypogonadism and is first-line next step per guidelines. |
| C | contradicted | Insulin stress test assesses growth hormone axis; not indicated for evaluating hypogonadotropic hypogonadism. |
| D | contradicted | Karyotype is reserved for suspicion of gonadal dysgenesis; not indicated here. |
| E (expected) | contradicted | MRI is considered only after endocrine testing if pituitary lesion suspected; not first step. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/Delayed Puberty.pdf** — score=2.5, round=1
   > | | **Serum insulin-like growth factor 1** | Measurement is used to screen for growth hormone deficiency. An increase in the level during follow-up or during or after treatment with sex steroids makes the diagnosis of growth hormone deficiency less likely. Growth hormone provocation tests are needed to diagnose growth hormone deficiency. | | **Serum testosterone in boys** | A morning value of 20 n…
2. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.125, round=1
   > If  GH deficiency or impairment is f ound or if  there is another hypothalamic-pituitary defect,  an  MRI  is  indicated  with  particular  attention  to  the hypothalamic-pituitary  area  to  rule  our  a  congenital  defect  or neoplasm  in  the area.  Ectopic location of the posterior pituitary on MRI is relatively frequent in congenital GH deficiency,  as is a decreased  pituitary volume or ap…
3. **PituitaryLiterature/Delayed Puberty - StatPearls - NCBI Bookshelf.pdf** — score=1.875, round=1
   > If panhypopituitarism Or growth hormone deficiency is a concern, insulin-like growth factor 1 and/or growth hormone stimulation is guide testing - A pediatric endocrinologist may perform a GnRH stimulation test, often to differentiate isolated hypogonadotropic hypogonadism from CDGP or when LH/FSH are inconclusive. There is no single diagnostic test to distinguish between these entities; therefore…
4. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.875, round=1
   > 156  TABLE 25-22  FSH,  follicle-stimulating  hormone;  hCG,  human  chorionic  gonadotropin;  LH, luteinizing hormone; MRI, magnetic resonance imaging.  The image displays a table with a header row that reads "Endocrine and Imaging Studies in Delayed Adolescence". The only row of this table, beneath the header, has the label "Initial assessment". Beneath this are a list of topics, divided into th…
5. **PituitaryLiterature/Approach to the patient with hypogonadotropic hypogonadism.pdf** — score=1.75, round=1
   > In HH patients, the response to GnRH test is highly variable and depends on the severity of the gonadotropin deficiency, which is often reflected by the clinical phenotype. Similarly, the pituitary function can be first evaluated by basal hormonal levels (measured by ultrasensitive assays). Thyroid function should be assessed by TSH combined with free T4: IGF-I can be used to evaluate the somatotr…

#### Flow retrieval context (5 shown)
1. **Delayed Puberty.pdf** — score=4.0, round=1
   > Values of <0.1 IU per liter are not specific for hypogonadotropic hypogonadism. Values of >0.2 IU per liter on ICMA or >0.6 IU per liter on IFMA are specific but not sensitive for the initiation of central puberty; some adolescents in early puberty have lower values. In delayed puberty, elevated values suggest primary hypogonadism. In general, luteinizing hormone is a better marker of pubertal ini…
2. **Delayed Puberty.pdf** — score=3.9375, round=1
   > ## Hormone Measurements and Brain Imaging  Pubertal onset is characterized by the accentuation  of  diurnal  secretion  of  gonadotropin  and  ## The new england journal o f medicine  testosterone (in boys) and estrogen (in girls) before apparent phenotypic changes. Basal levels of luteinizing hormone and FSH are low in patients with CDGP or hypogonadotropic hypogonadism, whereas such levels are u…
3. **Endocrinology and Diabetes Book.pdf** — score=3.375, round=1
   > coeliac disease, inflammatory bowel disease), or undernutrition.  ## Primary (hypergonadotrophic) hypogonadism  Gonadal failure may be:  - Chromosomal (e.g. Turner syndrome in girls (see E Turner syndrome, pp. 584-5), Klinefelter syndrome in boys (see E Primary hypogonadism, pp. 418-20)). - Acquired (e.g. following chemotherapy, radiotherapy, infection, testicular torsion).  In these conditions, b…
4. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.75, round=1
   > usually appropriate for bone age | Prepubertal, later pubertal | Prepubertal, later pubertal | Low, later normal | Low for chronological age, appropriate for bone age | Normal | Normal |  ### Hypogonadotropic Hypogonadism  | Condition | Stature | Plasma Gonadotropins | GnRH Test LH Response | Plasma Gonadal Steroids | Plasma DHEAS | Karyotype | Olfaction | |----------|--------|--------------------…
5. **Delayed Puberty.pdf** — score=2.75, round=1
   > Growth Rate in Prepubertal Range  **Working Diagnosis** - GnRH deficiency   - Constitutional Delay of Growth and Puberty (CDGP)   - (65% of boys, 30% of girls)  **Second-Line Evaluation (If CDGP not evident)** - GnRH test - hCG stimulation test - Serum inhibin B - Olfactory-function test - Genetic testing - MRI  **Intervention** - Follow-up - Evaluate need for induction of secondary sex characteri…

- **RAG-only sources:** approach to the patient with hypogonadotropic hypogonadism.pdf, delayed puberty - statpearls - ncbi bookshelf.pdf, greenspan’s basic and clinical endocrinology.pdf
- **Flow-only sources:** endocrinology and diabetes book.pdf

**Attempted retrieval queries (flow):**
1. `A 17-year-old boy was referred by his general practitioner because of concern about his development. He had been the shortest in his class for the past 4 years. His voice had not changed and he did not shave. He had begu…`

---

### Case 20: UKEU

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.274, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Evidence states that amiodarone should be discontinued when possible as the primary step in managing amiodarone‑induced thyrotoxicosis.

**Reasoning rationale:**
> The patient demonstrates persistent or worsening thyrotoxicosis despite adequate carbimazole therapy, indicating amiodarone‑induced hyperthyroidism; the recommended next step is to discontinue amiodarone when feasible.

<details>
<summary>Full question</summary>

```
A 65-year-old man attended the outpatient clinic. He had hyperthyroidism. He was taking amiodarone for atrial fibrillation.

Investigations:
- serum thyroid-stimulating hormone: <0.01 mU/L (0.4–5.0)
- serum free T4: 56.0 pmol/L (10.0–22.0)

He started treatment with carbimazole 40 mg daily. Two weeks later, his thyroid function tests were repeated.

Investigations:
- serum thyroid-stimulating hormone: <0.01 mU/L (0.4–5.0)
- serum free T4: 75.0 pmol/L (10.0–22.0)

What is the most appropriate next step in management? a) add prednisolone 40 mg daily, b) continue carbimazole 40 mg daily, c) refer for radioiodine therapy, d) stop amiodarone, or e) switch carbimazole to propylthiouracil 200 mg twice daily
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | contradicted | Prednisolone is used for type 2 AIT but is not first‑line when amiodarone can be stopped; no evidence of destructive thyroiditis here. |
| B | contradicted | Thyroid function worsened despite carbimazole; continuing the same dose does not address the underlying amiodarone effect. |
| C | contradicted | Radioiodine is contraindicated while on amiodarone due to high iodine load and is not appropriate for acute management. |
| D | supported | Guidelines recommend discontinuation of amiodarone as the primary step in managing amiodarone‑induced thyrotoxicosis, especially when hyperthyroidism persists or worsens. |
| E | contradicted | Switching antithyroid drug does not address the amiodarone‑induced hyperthyroidism and is not indicated without further evidence. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/Amiodarone-induced type 2 thyrotoxicosis.pdf** — score=4.4375, round=1
   > gastrointestinal infections, and neck or swelling: Before coming to the accident and emergency department; the patient had already visited his general practitioner who requested routine blood tests including thyroid  function test which  showed free T4 of 52pmol/L and thyroid-stimulating hormone (TSH) of &lt;0.008 mIU/L. The patient was advised to start carbimazole 15 mg twice by his general pract…
2. **ThyroidLiterature/Treatment of amiodarone-associated thyrotoxicosis.pdf** — score=3.875, round=1
   > ## Treatment of amiodarone-associated thyrotoxicosis  ## SUMMARY  Background A 75-year-old man had a myocardial infarction complicated by left ventricular function and non-sustained ventricular tachycardia. He began treatment with amiodarone and 12 months later developed symptoms of thyrotoxicosis. poor  Investigations Thyroid function tests after commencement of amiodarone revealed a high-normal …
3. **ThyroidLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.75, round=1
   > Aplastic  anemia  has  occurred  in patients  on  ## TABLE 24-5 Management of amiodarone-induced hyperthyroidism.  - ( 1 )   Stop amiodarone if possible - (2)  Institute �-blocker  therapy if possible - (3)  Antithyroid drugs: Methimazole, 40-60 mg/d - (4)  Potassium perchlorate, 200 mg every 6 h - (S)  Cholestyramine or colestipol, 20-30 g/d - (6) Prednisone, 40 mg/d, for acute thyroiditis (consi…
4. **ThyroidLiterature/Treatment of amiodarone-associated thyrotoxicosis.pdf** — score=3.5, round=1
   > Ultrasonography of the thyroid gland revealed the presence of a small multinodular goiter; color-flow Doppler sonography studies were not performed:  WWWnature:com/clinicalpractice/endmet  The patient began treatment with carbimazole (40mg daily), and amiodarone therapy was continued because of his  underlying severe cardiac disease. Four weeks after commencing thionamide therapy his clinical stat…
5. **ThyroidLiterature/Amiodarone-induced type 2 thyrotoxicosis.pdf** — score=3.375, round=1
   > Given his   presentation with worsening  thyrotoxicosis and the ultrasound findings, the patient was prescribed prednisolone 40mg daily in addition to his   carbimazole, pending the IL-6 levels and antibody   results. Furthermore, amiodarone was stopped following discussion with the patient's caring cardiologist and he was administered carvedilol instead to control his fast AF: His diuretic dose w…

#### Flow retrieval context (5 shown)
1. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=4.8125, round=1
   > However,  these tests  have  not  proven  suf ficiently  robust  to  separate  these  two disorders.  ## Management  Management of  amiodarone-induced hyperthyroidism is difficult (Table 24-5) .  Ideally,  amiodarone should be discontinued, but often it cannot be stopped because of the underlying heart dis­ ease, and even if it is  discontinued,  the  iodine load persists f or several  months.  Fu…
2. **Treatment of amiodarone-associated thyrotoxicosis.pdf** — score=4.8125, round=1
   > This test has been reported in both the UK and Italy to aid the distinction of type I from type II cases.6,10 It is very likely, however; that mixed' cases with features of both subtypes of AIT commonly occur; as thyroid experts increasingly recognize the difficulty in distinguishing the two types.11 typical  ## TREATMENT AND MANAGEMENT  It is important to differentiate true thyroidism from destru…
3. **Treatment of amiodarone-associated thyrotoxicosis.pdf** — score=4.75, round=1
   > Four weeks after commencing thionamide therapy his clinical state was stable, apart from further weight loss Repeat thyroid function testing revealed no improvement; and the dose of carbimazole was increased to 60mg daily Four weeks later there were minimal changes in the results of thyroid function tests and the patient remained unwell with continuing weight loss and shortness of breath. Because …
4. **Amiodarone Induced Thyrotoxicosis - Endotext - NCBI Bookshelf.pdf** — score=4.5625, round=1
   > Type 1 AIT should be treated with high doses of methimazole (20-60 mg/day) or propylthiouracil (400-600 mg/day) to block the synthesis of thyroid hormones (Figure 1): The response to methimazole O propylthiouracil is often modest due to the high iodine levels in patients taking amiodarone. In selected patients, potassium perchlorate when available can also be used to increase sensitivity of the gl…
5. **Amiodarone-induced type 2 thyrotoxicosis.pdf** — score=4.5625, round=1
   > ## Amiodarone-induced type 2 thyrotoxicosis  The authors present a case of a 55-year-old gentleman with a medical history of atrial fibrillation on amiodarone who presented with weight loss, palpitations and exertional dyspnoea. Thyroid function tests revealed thyrotoxicosis with a free thyroxine (T4) of 117 pmol/L and a thyroid-stimulating hormone (TSH) of TSH-receptor antibody status; the presen…

- **RAG-only sources:** —
- **Flow-only sources:** amiodarone induced thyrotoxicosis - endotext - ncbi bookshelf.pdf

**Attempted retrieval queries (flow):**
1. `A 65-year-old man attended the outpatient clinic. He had hyperthyroidism. He was taking amiodarone for atrial fibrillation. Investigations: - serum thyroid-stimulating hormone: <0.01 mU/L (0.4–5.0) - serum free T4: 56.0 …`

---

### Case 21: UKEU

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** A (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.277, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The presentation includes a strong family history of diabetes, early‑onset gestational diabetes, macrosomia, polyhydramnios and fetal renal pelvic dilatation. These features are characteristic of MODY caused by HNF1B mutations, which are known to cause developmental renal disease (renal cysts) that can be detected antenatally and show a familial transmission pattern. Evidence explicitly notes that renal cysts can be diagnosed during antenatal ultrasound and that HNF1B‑MODY presents with renal abnormalities and a hereditary diabetes phenotype, matching the case profile.

**Reasoning rationale:**
> The clinical picture of gestational diabetes diagnosed early, strong familial diabetes history, fetal macrosomia, polyhydramnios and antenatal renal pelvic dilatation strongly matches HNF1B‑MODY, which presents with developmental renal disease (renal cysts) and a hereditary diabetes phenotype. Supporting evidence explicitly notes that renal cysts can be diagnosed antenatally and that HNF1B‑MODY presents with renal abnormalities and a hereditary diabetes pattern, making this the most likely underlying cause.

<details>
<summary>Full question</summary>

```
A 35-year-old woman was found to have gestational diabetes at 28 weeks' gestation in her first pregnancy. She had a strong family history of diabetes mellitus, affecting her father, paternal uncle and cousins, and her maternal aunt and grandmother. Her pre-pregnancy BMI had been 29.0 kg/m2 (18.0–25.0). 
 On examination, fundal height was increased at 32 cm. Urinalysis showed glucose 3+, ketones 1+. 
 Investigations: 
 fasting plasma glucose  6.1 mmol/L (3.0–6.0) 
 oral glucose tolerance test (75 g): 
 2-h plasma glucose  7.9 mmol/L (<7.8) 
 ultrasound scan of fetus  macrosomia, with estimated fetal weight above 95th centile for gestational age; polyhydramnios, with fetal renal pelvic dilatation. 
What is the most likely underlying cause of her diabetes? a) familial renal cysts and diabetes, b) glucokinase deficiency, c) HNF1α mutation, d) latent autoimmune diabetes of adulthood (LADA), or e) mitochondrial diabetes
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | The presentation includes early‑onset gestational diabetes, macrosomia, polyhydramnios and antenatal fetal renal pelvic dilatation, which are classic features of HNF1B‑MODY causing |
| B (expected) | contradicted | GCK‑MODY manifests as mild, stable hyperglycaemia without significant macrosomia, polyhydramnios or renal anomalies, which are absent in the case. |
| C | contradicted | HNF1A‑MODY generally does not present with antenatal renal cysts or the severe renal phenotype observed; its clinical features differ from those described. |
| D | contradicted | LADA is an autoimmune condition unrelated to renal anomalies and does not exhibit the strong familial diabetes pattern seen here. |
| E | contradicted | Mitochondrial diabetes is rare and not associated with the renal findings or the described family history; no supporting evidence is present. |

#### RAG retrieval context (5 shown)
1. **DiabetesLiterature/Diagnosis and Classification of Diabetes. Standards of Care in Diabetes—2025.pdf** — score=2.25, round=1
   > may have large birth weight (macrosomia) and transient neonatal hypoglycemia; sensitive to sulfonylureas | | | **HNF1B** | AD | HNF1B-MODY: developmental renal disease (typically cystic); genitourinary abnormalities; atrophy of the pancreas; hyperuricemia; gout | | | **GCK** | AD | GCK-MODY: higher glucose threshold (set point) for glucose-stimulated insulin secretion, causing stable, nonprogressi…
2. **DiabetesLiterature/Endocrinology and Diabetes Book.pdf** — score=1.625, round=1
   > In  HNF4A-  MODY,  an  affected  fetus  can  develop  hyperinsulinaemia, macrosomia, and neonatal hypoglycaemia. Seek specialist advice on fetal monitoring and involve the paediatricians.  In GCK-  MODY, an unaffected fetus may develop macrosomia with exposure to the mother's raised blood glucose (an affected fetus has normal growth). Treatment (with insulin) is only recommended if macrosomia is d…
3. **DiabetesLiterature/Diagnosis and Classification of Diabetes. Standards of Care in Diabetes—2025.pdf** — score=1.5, round=1
   > Neonatal diabetes occurs much less often after 6 months of age, whereas autoimmune type 1 diabetes rarely occurs  before 6 months of age. Neonatal diabetes can either be transient or permanent: Transient diabetes is most often due to overexpression of genes on chromosome 6q24, is recurrent in about half of cases, and may be treatable with medications insulin: Permanent neonatal diabetes is most co…
4. **DiabetesLiterature/Diagnosis and management of glucokinase monogenic diabetes in pregnancy. current perspectives.pdf** — score=1.5, round=1
   > ## Diagnosis and management ofglucokinase monogenic diabetes in pregnancy: current perspectives  Abstract: Glucokinase-maturity-onset diabetes of the young (GCK-MODY) is an autosomal  dominant disorder caused by heterozygous inactivating GCK gene mutations GCKMODY is one the most common MODY subtypes, affecting 0.1% of the population and 0.4 1% of women with gestational diabetes mellitus Glucokina…
5. **DiabetesLiterature/Endocrinology and Diabetes Book.pdf** — score=1.125, round=1
   > - Results in a raised glucose threshold for glucose-  stimulated insulin secretion, but importantly insulin secretion remains regulated. - Lifelong, mild, stable fasting hyperglycaemia (FPG 5.5-  8mmol/  L and HbA1c <7.5%). Low increment of glucose rise following a carbohydrate challenge. - Hyperglycaemia due to GCK-  MODY can be diagnosed at any age. Patients are often asymptomatic, with hypergly…

#### Flow retrieval context (5 shown)
1. **Diagnosis and Classification of Diabetes. Standards of Care in Diabetes—2025.pdf** — score=3.0, round=1
   > 2 subunit (KCNJ11) and SURI subunit (ABCC8) of the B-cell KATP channel:  # Table 2.7 — Most Common Causes of Monogenic Diabetes  | Category | Gene | Inheritance | Clinical Features | |----------|------|-------------|-------------------| | **MODY** | **HNF1A** | AD | HNF1A-MODY: progressive insulin secretory defect with presentation in adolescence or early adulthood; lowered renal threshold for glu…
2. **Endocrinology and Diabetes Book.pdf** — score=2.5, round=1
   > - 5-  10% of cases of MODY; half are caused by whole gene deletions. - This is a syndrome of developmental abnormalities featuring renal cysts, genital tract malformations, pancreatic atrophy and exocrine insufficiency, hyperuricaemia, raised LFTs, hypomagnesaemia, and neurodevelopmental or behavioural disorders. - Affected individuals may present to renal physicians first; renal cysts can be diag…
3. **Diagnosis and management of maturity onset diabetes.pdf** — score=2.375, round=1
   > We reviewed the reference lists of retrieved articles to ensure that we considered all relevant articles. Articles that, on the basis of our clinical experience, we considered to be the best evidence available were included in the review. Most of the included studies are cross sectional or observational because of the lack of clinical trials of patients with MODY.  ## Features to consider when ass…
4. **Management of pregnancy in patients with hyperglycaemia due to disease-causing variants in GCK.pdf** — score=2.125, round=1
   > ## Management of pregnancy in patients with hyperglycaemia due to diseasecausing variants in the glucokinase (GCK) gene  ## INTRODUCTION  Glucokinase is an enzyme present in the beta cells of the pancreas: It has a vital role in enabling the pancreatic beta cells to accurately detect circulating blood glucose levels and adjust insulin secretion accordingly to keep blood sugar levels at a homeostat…
5. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.0, round=1
   > Although the exact prevalence of MODY is not known, current estimates suggest that MODY might account for 1% to 5% of all cases of diabetes in the United States and other industrialized  countries. 33 Several  clinical  characteristics distinguish patients with MODY from those with T2DM, including a prominent family history of diabetes in three or more generations, young age at presentation, and a…

- **RAG-only sources:** diagnosis and management of glucokinase monogenic diabetes in pregnancy. current perspectives.pdf
- **Flow-only sources:** diagnosis and management of maturity onset diabetes.pdf, management of pregnancy in patients with hyperglycaemia due to disease-causing variants in gck.pdf, williams-textbook-of-endocrinology-12th-edition.pdf

**Attempted retrieval queries (flow):**
1. `A 35-year-old woman was found to have gestational diabetes at 28 weeks' gestation in her first pregnancy. She had a strong family history of diabetes mellitus, affecting her father, paternal uncle and cousins, and her ma…`

---

### Case 22: UKEU

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:low_chunk_overlap, retrieval:rag_has_unique_sources, decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.314, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The case describes an anaplastic thyroid carcinoma with extrathyroidal extension into strap muscles and tracheal cartilage without nodal or distant metastasis, corresponding to Stage IVB (T4b any N M0). The provided evidence explicitly states that the 1‑year survival for Stage IVB ATC is 24.8%, which lies in the 25–35% range.

**Reasoning rationale:**
> Stage IVB anaplastic thyroid carcinoma has a reported 1-year survival of 24.8%, which corresponds to the 25–35% survival range.

<details>
<summary>Full question</summary>

```
A 64-year-old man presented with a painless, rapidly enlarging, right-sided neck mass. He reported a feeling of pressure on swallowing, and his voice had become quieter over the previous 3 weeks. 
 On examination, a 6 × 5-cm right-sided neck mass was palpable, contiguous with the right thyroid lobe. There was no palpable lymphadenopathy. 
 A diagnosis of anaplastic carcinoma, consistent with a primary origin in the thyroid (Thy5; Bethesda VI) was made. 
 Subsequently, a CT scan of neck, chest and abdomen was performed, which showed a 5 × 6 × 4-cm right-sided thyroid nodule invading strap muscles anterolaterally and merging into tracheal cartilage medially; there was no cervical lymphadenopathy and lungs, liver and bones were normal. 
 What percentage of patients with this stage of disease survive for 12 months? a) ≤5, b) 10–20, c) 25–35, d) 40–50, or e) >60
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | The reported 1-year survival for Stage IVB anaplastic thyroid carcinoma is 24.8%, which is far above the ≤5% range. |
| B (expected) | contradicted | The survival proportion (~24.8%) does not fall within the 10–20% interval. |
| C | supported | The documented 1-year survival (24.8%) is closest to and essentially within the 25–35% range as stated in the source. |
| D | contradicted | The survival rate (~24.8%) is well below the 40–50% range. |
| E | contradicted | The survival proportion is far lower than >60%. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/Clinical Endocrinology - 2014 - Perros - Guidelines for the management of thyroid cancer.pdf** — score=4.6875, round=1
   > ## 18.4. Staging  All ATCs are considered as TNM stage IV (Table 18.1). Stage IVa refers to intrathyroidal disease, stage IVb to gross extra-thyroidal extension and stage IVc to patients with distant metastatic disease. A small proportion (2 -6%) may be diagnosed as an incidental finding in a thyroidectomy specimen. 23 -25  It is expected that 10% of patients will present with stage IVa disease, 4…
2. **ThyroidLiterature/2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.pdf** — score=3.5, round=1
   > Our guideline recommendations are not intended to take the place of best physician judgment in diagnosing and treating particular patients, or to supplant patient directives. We expect that those who use these guidelines will consider them as an aid in, not a replacement for, sound and thoughtful clinical decision-making, with full consideration of each patient’s individuality in terms of history …
3. **ThyroidLiterature/2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.pdf** — score=3.25, round=1
   > Retrospective studies in other data sets identified similar prognostic factors. In a retrospective review of 121 patients with ATC, age younger than 60 years, tumor size less than 7 cm, and less extensive disease at presentation were independent predictors of decreased disease-related mortality (228). In a separate study of 47 patients with ATC, the presence of acute symptoms, tumor size larger th…
4. **ThyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=2.25, round=1
   > - Often infiltrates local tissue, such as the larynx and great vessels, and so does not move on swallowing. Stridor and obstructive respiratory symptoms are common. - Aggressive, with poor long-  term prognosis-  7% 5-  year survival rate and a mean survival of 6 months from diagnosis. - Optimal results occur, following total thyroidectomy. This is usually not possible and external irradiation is …
5. **ThyroidLiterature/Comprehensive Treatment of Anaplastic Thyroid Cancer. A Case Report.pdf** — score=2.0, round=1
   > The black-and-white image features a prominent figure, likely a person or an animal with a large, bulbous shape near the center of the image. However, the orientation of the figure is not clear, and its features cannot be discerned. The background of the image is solid black or gray, providing no additional visual details or context.  Given this analysis, the most accurate description of the image…

#### Flow retrieval context (5 shown)
1. **Comprehensive Treatment of Anaplastic Thyroid Cancer. A Case Report.pdf** — score=2.25, round=1
   > Overall, the image provides a detailed view of the fetus's internal anatomy, allowing healthcare professionals to assess its development and detect any potential abnormalities.  Figure 2 A large soft tissue mass (6.3 x 5.9*9.8 cm) extends from the left neck to the upper mediastinum, displacing adjacent blood vessels and compressing the trachea, main bronchus; esophagus. The left thyroid lobe is in…
2. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=1.0, round=1
   > 45 years and older  | Stage | T | N | M | |---|---|---|---| | Stage I | T1 | N0 | M0 | | Stage II | T2 | N0 | M0 | | Stage III | T3 | N0 | M0 | |  | T1 | N1a | M0 | |  | T2 | N1a | M0 | |  | T3 | N1a | M0 | | Stage IVA | T4a | N0 | M0 | |  | T4a | N1a | M0 | |  | T1 | N1b | M0 | |  | T2 | N1b | M0 | |  | T3 | N1b | M0 | |  | T4a | N1b | M0 | | Stage IVB | T4b | Any N | M0 | | Stage IVC | Any T | A…
3. **Clinical Endocrinology - 2014 - Perros - Guidelines for the management of thyroid cancer.pdf** — score=0.875, round=1
   > First issued February 2014.  - (c) British Thyroid Association 2014.  ## British Thyroid Association Patient Information Leaflet 7: Anaplastic thyroid cancer  What is anaplastic thyroid cancer?  Anaplastic thyroid cancer is the rarest type of thyroid cancer. There are perhaps 70 -90 patients diagnosed each year in the UK.  Anaplastic thyroid cancer is treated differently from other types of thyroi…
4. **Endocrinology and Diabetes Book.pdf** — score=0.875, round=1
   > ## Anaplastic thyroid cancer and lymphoma  ## Anaplastic thyroid cancer  - Rare. - Peak incidence: 7th decade; ♀ : ♂ = 1:1.5. - Characterized by rapid growth of a firm/  hard, fixed tumour. - Often infiltrates local tissue, such as the larynx and great vessels, and so does not move on swallowing. Stridor and obstructive respiratory symptoms are common. - Aggressive, with poor long-  term prognosis…
5. **Clinical Endocrinology - 2014 - Perros - Guidelines for the management of thyroid cancer.pdf** — score=0.625, round=1
   > 4,5  ATC occurs in an older population than seen in DTC, with most patients being over the age of 65. Fewer than 10% of patients are < 50 years old at diagnosis. As with DTC there is a female preponderance (typically 60 -70%). Risk factors for ATC are poorly understood although it can develop on a background of well DTC with reported rates of association ranging between 7% and 89%. 6 -12  The prec…

- **RAG-only sources:** 2021 american thyroid association guidelines for management of patients with anaplastic thyroid cancer.pdf
- **Flow-only sources:** greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 64-year-old man presented with a painless, rapidly enlarging, right-sided neck mass. He reported a feeling of pressure on swallowing, and his voice had become quieter over the previous 3 weeks. On examination, a 6 × 5-…`

---

### Case 23: UKEU

- **Expected:** C
- **RAG answer:** C (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.354, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The clinical picture (height below 4th centile, Tanner stage 2, testicular volume 8 mL, delayed bone age, low serum testosterone with normal LH/FSH) is typical of constitutional delay of growth and puberty. Management guidelines for CDGP recommend initiating low‑dose intramuscular testosterone to induce puberty and improve growth when height or sexual development is a concern. The appropriate regimen is 50 mg IM monthly (low dose), not the higher 250 mg dose, and investigations such as insulin tolerance test or pituitary MRI are not indicated at this stage.

**Reasoning rationale:**
> The clinical picture is classic for constitutional delay of growth and puberty (CDGP). Serum testosterone is low with appropriately low–normal LH/FSH, and the patient has height and Tanner stage concerns. Management guidelines recommend initiating low-dose intramuscular testosterone (50 mg monthly) rather than observation, imaging, or provocative testing.

<details>
<summary>Full question</summary>

```
A 17-year-old boy was referred by a gastroenterologist because of concern about his development. He had been the shortest in his class for the past 4 years. His voice had not changed and he did not shave. His inflammatory bowel disease had been quiescent for the past 4 months and he had not required any prednisolone for 2 months. 
 On examination, he had scanty pubic hair, Tanner stage 2 genitalia and 8-mL testes. His height was below the fourth centile. His bone age was estimated to be 12 years. 
 Investigations: 
 serum total testosterone  6.9 nmol/L (9.0–35.0) 
 serum follicle-stimulating hormone  5.7 U/L (1.0–7.0) 
 serum luteinising hormone  4.8 U/L (1.0–10.0) 
 serum thyroid-stimulating hormone  1.7 mU/L (0.4–5.0) 
 serum free T4  16.9 pmol/L (10.0–22.0) 
 serum IGF-1  37.4 nmol/L (9.3–56.0) 
 What is the most appropriate next step in management? a) insulin tolerance test, b) MR scan of pituitary, c) review in 4 months, d) start intramuscular testosterone replacement at a dosage of 50 mg every month, or e) start intramuscular testosterone replacement at a dosage of 250 mg every month
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Provocative testing is not indicated when the diagnosis of constitutional delay of growth and puberty is already established; imaging or stimulation tests are unnecessary. |
| B | contradicted | Pituitary MRI is reserved for suspected organic hypothalamic-pituitary pathology; the presentation is consistent with physiologic delay, not structural disease. |
| C (expected) | contradicted | Active management with testosterone is recommended now to address growth and pubertal concerns; observation alone would delay appropriate therapy. |
| D | supported | Low-dose intramuscular testosterone (50 mg IM monthly) is the guideline-recommended initial treatment for CDGP to induce puberty and improve growth velocity. |
| E | contradicted | High-dose testosterone is not appropriate initially; the recommended starting dose is 50 mg monthly to avoid premature epiphyseal closure and mimic natural puberty. |

#### RAG retrieval context (5 shown)
1. **PituitaryLiterature/Delayed Puberty.pdf** — score=4.1875, round=1
   > If a patient has  a  normal  growth  rate,  growth  hormone provocation testing is not necessary, whereas low IGF-1 levels together with reduced growth velocity warrant testing.  ## Treatment  ## Patients with CDGP  The options for management of CDGP include expectant observation or therapy with low-dose testosterone (in boys) or estrogen (in girls) (Table 3, and Table 3 in the Supplementary Appen…
2. **PituitaryLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.375, round=1
   > In older  boys  in  whom  the  delayed  pubertal  maturation is  highly  stressful  and  anxiety-provoking,  testosterone enanthate  has  been  administered  intramuscularly  with success. 1350,1351,1362 Criteria for treatment in such adolescents should include (1) a minimum age of 14 years; (2) height below the 3rd percentile; (3) prepubertal or early Tanner G2 stage with an early-morning serum t…
3. **PituitaryLiterature/Delayed Puberty.pdf** — score=2.875, round=1
   > 7,33  ## Bone-Age Radiography  The bone age should be reviewed by a practitioner who is experienced in interpreting such radiographs. A delay in bone age is characteristic but not diagnostic of CDGP and also may occur in  patients  with  chronic  illness,  hypogonadotropic hypogonadism, or gonadal failure. Adult height prediction is an important part of counseling if short stature is a component o…
4. **PituitaryLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.625, round=1
   > Serum  TSH and  free  T4  are  important measurements  to  exclude  existing  thyroid  disease.  Skeletal  age evaluation  does  not  alone  provide  a  diagnosis;  however,  if  the study  shows  delayed  bone  age,  the  possibility  of constitutional delay in growth, hypothyroidism, or GH deficiency must be con­ sidered.  The  tests  used  for  the  diagnosis  of GH  deficiency are derailed abo…
5. **PituitaryLiterature/Approach to the patient with hypogonadotropic hypogonadism.pdf** — score=1.5, round=1
   > In HH patients, the response to GnRH test is highly variable and depends on the severity of the gonadotropin deficiency, which is often reflected by the clinical phenotype. Similarly, the pituitary function can be first evaluated by basal hormonal levels (measured by ultrasensitive assays). Thyroid function should be assessed by TSH combined with free T4: IGF-I can be used to evaluate the somatotr…

#### Flow retrieval context (5 shown)
1. **Delayed Puberty.pdf** — score=4.375, round=1
   > If concern about growth is sufficient to warrant stimulation testing of growth hormone, sex-steroid priming with estrogen or testosterone is necessary for reliable results in patients with delayed puberty; estrogen stimulates endogenous growth-hormone secretion, and sex-steroid priming facilitates separation of true growth hormone deficiency from the  physiologic  low  growth  hormone secretion th…
2. **Delayed Puberty - StatPearls - NCBI Bookshelf.pdf** — score=3.75, round=1
   > girls patch  Once treatment has begun; patients should be monitored regularly for signs of pubertal development; including testicular enlargement in males and breast development in females. If they do not show any signs of puberty by the end of treatment, further management is individualized, with discussion with the family about whether to repeat the [4][17] For patients who are more concerned ab…
3. **Endocrinology and Diabetes Book.pdf** — score=3.625, round=1
   > - Bone age delay may also develop in a number of other conditions, but in constitutional delay, bone age delay usually remains consistent over time and height velocity is normal for the bone age. - GH secretion is usually normal, although provocation tests should be primed by prior administration of exogenous sex hormones if bone age in boys aged >10 years with testicular volumes of <6ml and girls…
4. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.375, round=1
   > is  not  initiated  in  boys  with  prepubertal  androgen  deficiency until they are about 14 years of age (with a bone age of at least 10.5 years). Testosterone therapy is administered intermittently to allow determination of spontaneous puberty, if it occurs. Occasionally, testosterone therapy is started at a younger age if delayed genital development and  growth  is  causing  severe  psychologi…
5. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.125, round=1
   > 1360,1361 The lack of a measurable effect on the GH-IGF1 axis probably reflects the fact that oxandrolone cannot be aromatized to estrogen. Currently recommended treatment is 0.05 to 0.1 mg/kg orally per day.  Oxandrolone is a relatively weak androgen, and its use stimulates only minimal  pubertal  masculinization. In older  boys  in  whom  the  delayed  pubertal  maturation is  highly  stressful …

- **RAG-only sources:** approach to the patient with hypogonadotropic hypogonadism.pdf, greenspan’s basic and clinical endocrinology.pdf
- **Flow-only sources:** delayed puberty - statpearls - ncbi bookshelf.pdf, endocrinology and diabetes book.pdf

**Attempted retrieval queries (flow):**
1. `A 17-year-old boy was referred by a gastroenterologist because of concern about his development. He had been the shortest in his class for the past 4 years. His voice had not changed and he did not shave. His inflammator…`

---

### Case 24: UKEU

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** retrieval:rag_has_unique_sources, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.409, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The patient is an 18-year-old with hypertension, hypokalemia, low plasma renin, and elevated aldosterone, consistent with primary aldosteronism, and has a family history of early cerebrovascular accident, which fulfills guideline criteria to proceed directly to genetic testing for glucocorticoid‑remediable aldosteronism.

**Reasoning rationale:**
> The patient shows low plasma renin with elevated aldosterone, consistent with primary aldosteronism. According to Endocrine Society guidelines, the next step after a positive ARR is a confirmatory suppression test (e.g., aldosterone suppression test) before proceeding to imaging or genetic testing. Therefore, option b (aldosterone suppression test) is the most appropriate next investigation.

<details>
<summary>Full question</summary>

```
An 18-year-old man was referred with recently diagnosed hypertension. He had no previous history of note and was not taking any medication. His father had been found to have hypertension in his twenties after sustaining a brain haemorrhage. 
 On examination, the patient's BP was raised at 190/110 mmHg. 
 Investigations: 
 serum sodium  142 mmol/L (137–144) 
 serum potassium  3.4 mmol/L (3.5–4.9) 
 plasma renin concentration  2.0 mIU/L (5.4–60.0) 
 plasma aldosterone  450 pmol/L (90–720) 
 urinary 18-oxocortisol  32.0 nmol/mmol creatinine (0.8–6.5) 
 What is the most appropriate next investigation? a) adrenal venous sampling, b) aldosterone suppression test, c) captopril test, d) CT scan of adrenal glands, or e) genetic testing
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Reserved for subtype classification after diagnosis, not initial confirmatory test. |
| B | supported | Recommended next step to confirm primary aldosteronism before imaging or genetics. |
| C | uncertain | A specific suppression test; the guideline cites suppression test generally as next step. |
| D | contradicted | Imaging should follow confirmatory testing, not precede it. |
| E (expected) | contradicted | Considered only after subtype determination or when familial GRA is suspected, not the immediate next investigation. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=2.875, round=1
   > early-onset hypertension Or cerebrovascular accident at a young age &lt;40 yr). We also recommend case detection for all hypertensive first-degree relatives of patients with PA. (1IPOOO)  1.2 We recommend use of the plasma aldosterone to renin ratio (ARR) to detect cases of PA in these patient groups. (1IDDOO)  ## 2.0 Case confirmation  2.1 Instead of proceeding directly to subtype classification,…
2. **AdrenalLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.25, round=1
   > The result is ectopic expression of aldosterone synthase activity in the cortisol-producing zona fasciculata. Thus, mineralocorticoid production is regulated by ACTH instead of the normal  secretagogue, angiotensin I I .  Aldosterone secretion  can  be suppressed  by glucocorti­ coid therapy.  In the absence of glucocorticoid  therapy,  this mutation  results  in overproduction of aldosterone and …
3. **AdrenalLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.25, round=1
   > 178,180   Complications can include  symptomatic  groin  hematoma,  adrenal  hemorrhage, and dissection of an adrenal vein.  Some  centers  and  clinical  practice  guidelines  recommend that adrenal venous sampling should be performed in all patients who  have the diagnosis of primary aldosteronism. 135,179 The  use  of  adrenal  venous  sampling should be based on patient preference, patient age…
4. **AdrenalLiterature/Endocrine Hypertension - Endotext - NCBI Bookshelf.pdf** — score=2.25, round=1
   > Tests for Diagnosing the Most Prevalent Forms of Endocrine Hypertension  ## Cushing s Syndrome  ACTH-dependent (5-10%) (ACTH &gt; 20 ng/L)  If positive, then pituitary MRI andlor bilateral inferior petrosal sinus sampling  High-dose Dexamethason suppression test or CRH test  If negative, then chest/abdomen MRI and/or 68Ga-DOTATATE PETICT scan or  Octreoscan  ACTH-independent (90-95%) (ACTH &lt;10 …
5. **AdrenalLiterature/Endocrinology and Diabetes Book.pdf** — score=2.0, round=1
   > - Early hypertension and family history. - Hybrid steroids (18oHcortisol and 18oxocortisol) elevated.  ## Aldosterone-  producing carcinoma  Rare and usually associated with excessive secretion of other corticosteroids (cortisol, androgen, oestrogen). Hypokalaemia may be profound, and aldosterone levels very high. A tumour larger than 2.5cm associated with aldosterone excess has to be treated as s…

#### Flow retrieval context (5 shown)
1. **Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=4.875, round=1
   > (1IPOOO)  1.2 We recommend use of the plasma aldosterone to renin ratio (ARR) to detect cases of PA in these patient groups. (1IDDOO)  ## 2.0 Case confirmation  2.1 Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo testby any of four confirmatory tests, to definitively confirm or exclude the diagnosis. (1IEPOO) ing,  ## 3.0 Subtype cla…
2. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=4.5, round=1
   > 134 A  more  practical  approach  is  the  selective  use  of adrenal venous sampling outlined in Figure 16-10.  Glucocorticoid-Remediable Aldosteronism: Familial Hyperaldosteronism Type I. GRA (FH type I) is inherited in an autosomal dominant fashion and is responsible for fewer than 1% of cases of primary aldosteronism (see Table 16-10). 121 GRA is characterized by early-onset hypertension that …
3. **Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=3.625, round=1
   > sion stage 2 (7160-179/100-109 mm Hg), stage 3 (>180/110 mm Hg), or drug-resistant hypertension; hypertension and spontaneous or diuretic-induced hypokalemia; hypertension with renal incidentaloma; or hypertension and family history of ad-  Abbreviations: ARR, Aldosterone to renin ratio; APA, aldosterone-producing adenoma; AVS, adrenal venous sampling; CT, computed tomography; DRC, direct renin co…
4. **Endocrine Hypertension - Endotext - NCBI Bookshelf.pdf** — score=3.625, round=1
   > The diagnostic strategy is described in table 7.  ## Table 7 .  Testing for Rare Causes of Endocrine Hypertension  ## CAH: Ilbeta-hydroxylase deficiency  ratios  Genetic testing  ## CAH: I7alpha-hydroxylase deficiency  TDOC, !1-deoxycortisol, ! ! aldosterone  Irenin, Iplasma 17-hydroxyprogesterone,  Turinary 100*THDOCI(THE+THF+SaTHF) and (THA+THB+SaTHBY(THE+THF+SaTHF) ratios Genetic testing  | App…
5. **Endocrine Hypertension - Endotext - NCBI Bookshelf.pdf** — score=3.5, round=1
   > Tests for Diagnosing the Most Prevalent Forms of Endocrine Hypertension  ## Cushing s Syndrome  ACTH-dependent (5-10%) (ACTH > 20 ng/L)  If positive, then pituitary MRI andlor bilateral inferior petrosal sinus sampling  High-dose Dexamethason suppression test or CRH test  If negative, then chest/abdomen MRI and/or 68Ga-DOTATATE PETICT scan or  Octreoscan  ACTH-independent (90-95%) (ACTH <10 ngL)  …

- **RAG-only sources:** endocrinology and diabetes book.pdf, greenspan’s basic and clinical endocrinology.pdf
- **Flow-only sources:** —

**Attempted retrieval queries (flow):**
1. `An 18-year-old man was referred with recently diagnosed hypertension. He had no previous history of note and was not taking any medication. His father had been found to have hypertension in his twenties after sustaining …`

---

### Case 25: UKEU

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.43, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The presentation of enlarged orange tonsils, corneal clouding, hepatosplenomegaly, low HDL and elevated triglycerides matches Tangier disease, which is caused by apolipoprotein AI deficiency.

**Reasoning rationale:**
> The clinical triad of enlarged orange tonsils, corneal opacity, and hepatosplenomegaly together with very low HDL cholesterol and elevated triglycerides points to Tangier disease, which is caused by apolipoprotein A1 deficiency; therefore option C is the best match.

<details>
<summary>Full question</summary>

```
An 18-year-old man was referred with a 3-week history of exertional angina. He was found to have enlarged, orange tonsils, clouding of the cornea and hepatosplenomegaly. 
 Investigations: 
 serum cholesterol  4.7 mmol/L (<5.2) 
 serum HDL cholesterol  0.23 mmol/L (>1.55) 
 serum non-HDL cholesterol  2.89 mmol/L (<3.36) 
 fasting serum triglycerides  2.98 mmol/L (0.45–2.30) 
 What is the most likely diagnosis? a) abetalipoproteinaemia, b) alpha-lipoprotein deficiency, c) apolipoprotein A1 deficiency, d) apolipoprotein B deficiency, or e) lecithin-cholesterol acyltransferase deficiency
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Abetalipoproteinaemia presents with fat malabsorption and absent chylomicrons, lacking the orange tonsil and corneal findings; lipid profile does not match. |
| B (expected) | contradicted | The term is not the standard diagnosis for the presented phenotype; the correct entity is APOA1 deficiency (Tangier disease). |
| C | supported | The combination of enlarged orange tonsils, corneal clouding, hepatosplenomegaly, very low HDL and elevated triglycerides is classic for Tangier disease, which results from APOA1 d |
| D | contradicted | APOB deficiency leads to markedly low LDL and VLDL; the lipid pattern here shows normal LDL and elevated triglycerides, inconsistent with the findings. |
| E | contradicted | LCAT deficiency causes corneal opacities and renal disease but does not typically produce enlarged orange tonsils; the triglyceride pattern does not align. |

#### RAG retrieval context (5 shown)
1. **DiabetesLiterature/Endocrinology and Diabetes Book.pdf** — score=6.4375, round=1
   > Cholesterol accumulation gives enlarged orange-  coloured tonsils, hepatosplenomegaly, polyneuropathy, and corneal opacities.  ## Fish eye disease  - a rare disorder from northern Sweden, with high VLDL levels, low HDL, and a tG-  rich LDL. as well as hypertriglyceridaemia, dense corneal opacities occur, giving visual impairment.  ## Abetalipoproteinaemia  - results in intestinal fat accumulation …
2. **DiabetesLiterature/Tangier Disease - GeneReviews® - NCBI Bookshelf.pdf** — score=5.4375, round=1
   > ## Suggestive Findings  Tangier disease should be suspected in individuals with the following clinical and supportive laboratory findings.  ## Clinical findings  - Enlarged tonsils that are yellow and/or orange in children and young adults - Peripheral neuropathy - Hepatomegaly and/or splenomegaly - Corneal opacities - Coronary artery disease - Lymphadenopathy - Blood disorders (especially thrombo…
3. **DiabetesLiterature/Endocrinology and Diabetes Book.pdf** — score=5.25, round=1
   > at present, the only available pharmacological  means  by  which  lowering  of  Lp(a)  can  be  achieved  is  with  niacin or PCSK9 inhibitors (limited effect). However, there is no formal evidence to  show  that  these  agents  reduce  cardiovascular  events  in  people  with raised Lp(a).  ## Rare familial mixed dyslipidaemias  - these should be considered in any patient with unexplained neurolo…
4. **DiabetesLiterature/Tangier Disease - GeneReviews® - NCBI Bookshelf.pdf** — score=3.125, round=1
   > ## Tangier Disease  ## Summary  Clinical characteristics. Tangier disease is characterized by severe deficiency O absence of high-density lipoprotein (HDL) in the circulation resulting in tissue accumulation of cholesteryl esters throughout the body, particularly in the reticuloendothelial system: The major clinical signs of Tangier disease include hyperplastic yellow-orange tonsils, hepatosplenom…
5. **DiabetesLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.375, round=1
   > Homozygotes lack normal HDL, and Apo A-I and Apo A-II are present at extremely low  levels. Serum  cholesterol is usually  below 1 20  mg/dL (3. 1 2   mmol/L)  and  may  be  half this value.  Mild  hypemiglyceri­ demia is usually present, and LDL is greatly enriched in triglycer­ ides.  Mutations  in the  ATP-dependent  transporter  ABCA1 underlie this disorder, causing defective efflux of  choles…

#### Flow retrieval context (5 shown)
1. **Endocrinology and Diabetes Book.pdf** — score=6.375, round=1
   > ## Familial lecithin:cholesterol acyltransferase (LCAT) deficiency  - In this recessively inherited disorder, an enzyme necessary for intravascular lipoprotein metabolism is deficient, resulting in elevated cholesterol and tGs. Clinically, corneal lipid deposits result in visual disturbances, and renal deposits in glomerular damage, proteinuria, and often renal failure. Haemolytic anaemia may occu…
2. **Tangier Disease - GeneReviews® - NCBI Bookshelf.pdf** — score=5.0625, round=1
   > ## Suggestive Findings  Tangier disease should be suspected in individuals with the following clinical and supportive laboratory findings.  ## Clinical findings  - Enlarged tonsils that are yellow and/or orange in children and young adults - Peripheral neuropathy - Hepatomegaly and/or splenomegaly - Corneal opacities - Coronary artery disease - Lymphadenopathy - Blood disorders (especially thrombo…
3. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=3.125, round=1
   > ## Chylomicron Retention Syndrome  Anderson's disease, or chylomicron retention syndrome, is a  rare  condition  that  is  phenotypically  similar  to  abetalipoproteinemia. Subjects with Anderson's disease cannot secrete chylomicrons from the intestine. Eight mutations  in the SAR1B gene (formerly SARA2 )  have been linked to Anderson's  disease.  This  gene  encodes  SAR1B,  a  protein that is i…
4. **Tangier Disease - GeneReviews® - NCBI Bookshelf.pdf** — score=2.625, round=1
   > ## Tangier Disease  ## Summary  Clinical characteristics. Tangier disease is characterized by severe deficiency O absence of high-density lipoprotein (HDL) in the circulation resulting in tissue accumulation of cholesteryl esters throughout the body, particularly in the reticuloendothelial system: The major clinical signs of Tangier disease include hyperplastic yellow-orange tonsils, hepatosplenom…
5. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.625, round=1
   > In  the  homozygote, clinical characteristics are variable. The diagnosis is usually made in  adults,  although  corneal  opacities  may  begin  in  childhood. Proteinuria may be an early sign. Deposits of unesterified choles­ terol and phospholipid in the renal microvasculature lead to pro­ gressive loss of  nephrons and ultimate renal failure. Many patients have  mild to  moderate  normochromic …

- **RAG-only sources:** —
- **Flow-only sources:** williams-textbook-of-endocrinology-12th-edition.pdf

**Attempted retrieval queries (flow):**
1. `An 18-year-old man was referred with a 3-week history of exertional angina. He was found to have enlarged, orange tonsils, clouding of the cornea and hepatosplenomegaly. Investigations: serum cholesterol 4.7 mmol/L (<5.2…`

---

### Case 26: UKEU

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** decision:agreement, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 4 shared sources, avg text similarity=0.434, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The patient is in a state of euglycemic DKA with persistent ketosis and mild hyperglycemia (glucose 7.3 mmol/L). Guidelines recommend continuing a fixed‑rate intravenous insulin infusion and adding dextrose once glucose falls below 13.9 mmol/L to maintain euglycemia while treating ketosis. The evidence explicitly states that 5‑10 % dextrose should be added to the infusion at this point, supporting the choice of starting a glucose 5 % infusion with a fixed‑rate IV insulin infusion.

**Reasoning rationale:**
> The patient has persistent ketosis despite modest hyperglycemia (glucose 7.3 mmol/L). According to the evidence, once glucose drops below 13.9 mmol/L, 5‑10 % dextrose should be added to the IV fluid and the insulin infusion continued. This corresponds to option D. Options A, B, and C do not address the need for dextrose and would not resolve ketosis. Option E uses 10 % dextrose, which is not the standard recommendation. Therefore, the most appropriate next step is to start a glucose 5% infusion with a fixed‑rate IV insulin infusion.

<details>
<summary>Full question</summary>

```
A 26-year-old woman was admitted with diabetic ketoacidosis. After 24 hours of treatment with intravenous fluids, potassium and insulin, her normal subcutaneous insulin regimen was resumed. However, she felt nauseated, her blood glucose began to increase and there was a concomitant increase in blood ketones to 3.5 mmol/L (<0.3). 
 On examination, her pulse was 118 beats/min and her BP was 106/66 mmHg. 
 Investigations: 
 serum sodium  136 mmol/L (137-144) 
 serum potassium  4.4 mmol/L (3.5-4.9) 
 serum bicarbonate  15 mmol/L (20-28) 
 serum creatinine  78 µmol/L (60-110) 
 random plasma glucose  7.3 mmol/L (3.0-11.1) 
 What is the most appropriate next step in management? a) increase subcutaneous basal insulin at bedtime, b) increase subcutaneous bolus insulin with meals,c) start fixed-rate intravenous insulin infusion, d) start glucose 5% with fixed-rate intravenous insulin, or e) start glucose 10% with fixed-rate intravenous insulin
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Persistent ketosis requires continuation of IV insulin and dextrose; adjusting basal subcut insulin does not address ketosis. |
| B | contradicted | Similar to a, does not address ongoing ketosis; not recommended as next step. |
| C | contradicted | Insulin infusion alone would cause hypoglycemia; dextrose infusion is required given glucose <13.9 mmol/L. |
| D | supported | Guidelines recommend adding 5% dextrose to the infusion when glucose falls below 13.9 mmol/L to maintain euglycemia while treating ketosis. |
| E (expected) | contradicted | 10% dextrose is not indicated; 5% dextrose is the recommended concentration per evidence. |

#### RAG retrieval context (5 shown)
1. **DiabetesLiterature/Hyperglycemic Crises - Endotext - NCBI Bookshelf.pdf** — score=3.75, round=1
   > Overall, the of treatment are a decrease in osmolality between 3 and 8 mOsmol/kg per hour; a sodium reduction by no more than 10 mmoVL in 24 hours, and hourly glucose fall by up to Smmol/L (37). goal goals  ## Insulin  Insulin therapy is the mainstay of DKA treatment and should be started immediately after the diagnosis using a fixed-rate intravenous insulin infusion started at 0.1 units/kg/h. Sho…
2. **DiabetesLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.625, round=1
   > 6. Hyperchloremic  acidosis  during  therapy. Because  of  the considerable  loss  of keto  acids  in  the  urine  during  the  initial phase of  therapy, substrate for subsequent regeneration of  bicar­ bonate is lost, and correction of  the total  bicarbonate  deficit is hampered. A portion of  the bicarbonate deficit is replaced with chloride  ions  infused  in  large amounts as saline to corre…
3. **DiabetesLiterature/Hyperglycaemic crises in adults with diabetes. a consensus report.pdf** — score=3.5, round=1
   > Thereafter, intravenous insulin infusion should be adjusted to maintain glucose levels at approximately 11.1 mmol/l (200 mg/dl) and continued until the ketoacidosis is resolved [1-3].  In people on basal or basal-bolus insulin therapy before admission, this regimen can be continued at the usual dose and adjusted as needed. In those newly diagnosed, multidose insulin regimens with basal and prandia…
4. **DiabetesLiterature/The Management of Diabetic Ketoacidosis in Adults.pdf** — score=3.375, round=1
   > ## Intravenous glucose concentration  To ensure that ketones are cleared, an FRIII should be continued as well as an infusion of 0.9% sodium chloride solution to maintain fluid replacement: But once the blood glucose falls below 14.0 mmolL, a 10% dextrose infusion should be added to act as the substrate for the insulin, to prevent hypoglycaemia It is quite often necessary to infuse 0.9% sodium chl…
5. **DiabetesLiterature/The Management of Diabetic Ketoacidosis in Adults.pdf** — score=3.25, round=1
   > HbAIc 64 mmollmmol (<8.0%)  With all regimens the intravenous insulin infusion should not be discontinued for at least 30 to 60 minutes after the administration of the subcutaneous dose given in association with a meal:  If were on basal bolus insulin they  - There should be an overlap between the insulin infusion and first injection of fast acting insulin: The fast acting insulin should be inject…

#### Flow retrieval context (5 shown)
1. **Hyperglycaemic crises in adults with diabetes. a consensus report.pdf** — score=5.6875, round=1
   > Short-acting insulin administered intravenously by continuous infusion is the preferred choice. Depending on the severity of the condition and the available facilities, this should be done using a fixed-rate intravenous insulin infusion started at 0.1 U   kg -1 h -1 [1-3, 12, 132] or by a nursedriven insulin infusion protocol with a variable rate for DKA [133]. In adults, treatment protocols recom…
2. **Hyperglycemic Crises - Endotext - NCBI Bookshelf.pdf** — score=5.125, round=1
   > goal goals  ## Insulin  Insulin therapy is the mainstay of DKA treatment and should be started immediately after the diagnosis using a fixed-rate intravenous insulin infusion started at 0.1 units/kg/h. Short-acting insulin is the preferred choice. An insulin bolus (0.1 units/kg/hour) given intravenously O intramuscularly is suggested in some treatment protocols if a delay in obtaining venous acces…
3. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=4.625, round=1
   > However, the intravenous tubing should be flushed with the insulin infusate before use.  In the rare instances in which the glucose level does not decrease by at least 10% or 50 mg/dL in 1 hour, the insulin infusion rate should be increased by 50% to 100% and a second  bolus  of  intravenous  insulin  should  be  administered. As the glucose level decreases, it is usually necessary to decrease the…
4. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=4.5, round=1
   > Two liters of this solution, inf used at a rate of 400 mL/h, cor­ rects the phosphate deficit at the optimal rate of  3 mmol/h and provides 4.4 mEq of  potassium per hour. Additional potassium should be administered as potassium chloride to provide a total of 1 0  to 30 mEq of  potassium per hour, as noted earlier. If  the serum phosphate remains below 2.5 mg/dL after this infusion, a repeat 5-hou…
5. **The Management of Diabetic Ketoacidosis in Adults.pdf** — score=4.125, round=1
   > Fluids should be replaced cautiously:  ## Action 3 Potassium replacement  Hypokalaemia and hyperkalaemia are life threatening conditions and are common in DKA. Serum potassium is often high on admission (although total body potassium is low) but falls precipitously upon treatment with insulin. Regular monitoring is mandatory.  #### Potassium level in first 24 hours Potassium replacement in mmol/L …

- **RAG-only sources:** —
- **Flow-only sources:** williams-textbook-of-endocrinology-12th-edition.pdf

**Attempted retrieval queries (flow):**
1. `A 26-year-old woman was admitted with diabetic ketoacidosis. After 24 hours of treatment with intravenous fluids, potassium and insulin, her normal subcutaneous insulin regimen was resumed. However, she felt nauseated, h…`

---

### Case 27: UKEU

- **Expected:** E
- **RAG answer:** E (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_retrieval
- **Failure tags:** decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 4 shared sources, avg text similarity=0.442, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> The evidence shows that phosphodiesterase type 5 inhibitors (e.g., sildenafil) are the first‑line oral therapy for erectile dysfunction in diabetic men, with documented efficacy (~70%). Testosterone replacement is only considered when testosterone is markedly low and after careful assessment of fertility and contraindications, and psychosexual counselling is not indicated as primary treatment. Thus sildenafil is the most appropriate answer.

**Reasoning rationale:**
> Sildenafil is the first‑line oral therapy for erectile dysfunction in diabetic men, with documented efficacy (~70%); testosterone replacement is only considered after confirming low testosterone and assessing fertility, making sildenafil the most appropriate choice.

<details>
<summary>Full question</summary>

```
A 50-year-old man with type 1 diabetes mellitus of 14 years' duration presented with erectile dysfunction, poor libido and fatigue. He mentioned recent problems in his marital relationship. His daily medication comprised simvastatin 40 mg, ramipril 10 mg and bendroflumethiazide 2.5 mg. 
 Examination was normal. 
 Investigations: 
 serum sodium  139 mmol/L (137–144) 
 serum potassium  4.4 mmol/L (3.5–4.9) 
 serum urea  6.0 mmol/L (2.5–7.0) 
 serum creatinine  100 µmol/L (60–110) 
 eGFR (CKD-EPI)  62 mL/min/1.73 m2 (>60) 
 haemoglobin A1c  69 mmol/mol (20–42) 
 serum cholesterol  5.4 mmol/L (<5.2) 
 serum total testosterone  5.9 nmol/L (9.0–35.0) 
 serum sex hormone binding globulin  58 nmol/L (10–62) 
 serum follicle-stimulating hormone  4.0 U/L (1.0–7.0) 
 serum luteinising hormone  6.0 U/L (1.0–10.0) 
 serum prolactin  245 mU/L (100–360) 
 MR scan of pituitary  normal 
 What is the most appropriate treatment? a) epoprostenol injection, b) psychosexual counselling, c) sildenafil, d) stop ramipril and simvastatin, or e) testosterone replacement
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Not indicated for erectile dysfunction; used for pulmonary hypertension, not first‑line therapy. |
| B | contradicted | May be adjunctive but not the primary treatment for ED in this context. |
| C | supported | First‑line PDE5 inhibitor with ~70% efficacy in diabetic men; recommended guideline therapy. |
| D | contradicted | Medication review is reasonable but not the definitive treatment for ED. |
| E (expected) | uncertain | Testosterone may be considered only after confirming low levels and evaluating fertility; not first‑line for ED. |

#### RAG retrieval context (5 shown)
1. **ReproductiveEndocrinologyLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=5.0, round=1
   > If the testosterone level is low,  serum  PRL  should  be  measured  because  hyperprolactine­ mia-wherher drug-induced or due to a pituitary or hypothalamic lesion-may inhibit androgen production. Diabetes mellitus is a relatively common cause  of erectile dysfunction and  erectile dys­ hmction may be the  presenting symptom of diabetes;  therefore, fasting  and  2-hour  postprandial  blood  gluc…
2. **ReproductiveEndocrinologyLiterature/Endocrinology and Diabetes Book.pdf** — score=2.625, round=1
   > AN  is  the  likely cause, but many drugs, especially thiazides and β -  blockers, can also cause it, as can alcohol, tobacco, cannabis, and stress. These should be assessed by direct questioning. Examination should include:  - Genitalia and 2° sexual characteristics. - Peripheral pulses-  as vascular insufficiency may play a part. - Lower limb reflexes and vibration thresholds-  to confirm that n…
3. **ReproductiveEndocrinologyLiterature/Endocrinology and Diabetes Book.pdf** — score=2.625, round=1
   > - Fasting blood glucose. - Serum lipids. - TFTs. - Serum ferritin (haemochromatosis).  ## Additional investigations  Rarely required. To assess vascular causes of impotence if corrective surgery is contemplated:  - Intracavernosal injection of a vasodilator, e.g. alprostadil E1 or papaverine. A sustained erection excludes significant vascular insufficiency. - Penile Doppler ultrasonography. Cavern…
4. **ReproductiveEndocrinologyLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.625, round=1
   > 107 The testosterone levels required to maintain sexual function are close to the lower limit of the normal male range. 109,175-177  Therefore, some men with pituitary tumors may remain asymptomatic until their tumor has grown  substantially and  testosterone levels  have declined to a level below this threshold.  ## Diabetes and Sexual Dysfunction in Men  Men with  diabetes  mellitus  are  at  in…
5. **ReproductiveEndocrinologyLiterature/guidelines-on-adult-testosterone-deficiency-with-statements-for-uk-practice.pdf** — score=1.625, round=1
   > The BSSM  recommends initiating T therapy only in men with bothersome symptoms   (Table   4), in conjunction   with weight-loss advice,   lifestyle   modification, and treatment of comorbidities (LoE = 2, Grade = A). Weight loss and lifestyle modification alone have failed to demonstrate effective improvement in clinical symptoms, even after more than 4 years, and patients need to be informed of t…

#### Flow retrieval context (5 shown)
1. **Endocrinology and Diabetes Book.pdf** — score=3.25, round=1
   > - Using custom-  fitted elastic stockings extending to the waist. - Pharmacological treatment with fludrocortisone, starting at 100 micrograms per day, while carefully monitoring for supine hypertension, ankle oedema, and hypokalaemia. K supplementation may be required when higher doses are used, and it is important to monitor U&amp;E. - In severe cases, the following drugs α 1-  adrenal receptor …
2. **Endocrinology and Diabetes Book.pdf** — score=3.125, round=1
   > - PRL, LH, and FSH if serum testosterone low. - Renal function.  The image presents a list of causes of erectile dysfunction, categorized into distinct sections. The title "Box 4.18 Causes of erectile dysfunction" is followed by an enumeration of various factors contributing to this condition, including psychological, physiological, and physical elements.  **Key Features:**  *   **Categorization:*…
3. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=2.625, round=1
   > Treatment. A number of treatment modalities are available, and each has positive and negative effects. Patients must be made aware of positive and negative aspects before a  therapeutic decision is made. Before any form of treatment is considered, every effort should be made to have the patient withdraw from alcohol and eliminate smoking. The patient should be removed, if possible, from drugs that…
4. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.625, round=1
   > Hypogonadism should be suspected in a patient who has never had an erection (primary erectile dysfunction).  During the physical examination, the patient's  secondary sex­ ual characteristics should be assessed and examination performed f or  gynecomastia, discordant  or  diminished  femoral pulses, reduced testicular volume or consistency,  penile plaques, and evi­ dence of  peripheral or autonom…
5. **guidelines-on-adult-testosterone-deficiency-with-statements-for-uk-practice.pdf** — score=2.375, round=1
   > T therapy is appropriate for treating ED, particularly at TT levels lower than 8 nmol/LS 7 or calculated FT levels lower than 225 L and for salvaging ED treatment failures with oral medication, particularly at TT levels lower than 10.4 nmol/L. Furthermore, appropriate intervention with T lessens the need for more invasive   second- and third-line treatments  in  these 129 T are   often  considered…

**Attempted retrieval queries (flow):**
1. `A 50-year-old man with type 1 diabetes mellitus of 14 years' duration presented with erectile dysfunction, poor libido and fatigue. He mentioned recent problems in his marital relationship. His daily medication comprised…`

---

### Case 28: UKEU

- **Expected:** B
- **RAG answer:** B (correct)
- **Flow answer:** D (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** retrieval:rag_has_unique_sources, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, verifier:refuted
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** except
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.531, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Guidelines recommend that after a positive aldosterone‑renin ratio, diagnosis of primary aldosteronism is confirmed with a suppressibility test (e.g., saline infusion, fludrocortisone or captopril challenge), i.e., aldosterone suppression testing. Options such as adrenal venous sampling or CT are used for subtyping or imaging, not for initial diagnostic confirmation, and PET‑CT is not indicated.

**Reasoning rationale:**
> The patient has a markedly elevated aldosterone with a suppressed renin, indicating possible primary aldosteronism. After a positive aldosterone‑renin ratio, the guideline‑recommended next step to confirm the diagnosis is an aldosterone suppression test. PET‑CT is not part of the recommended diagnostic pathway and therefore is the exception.

<details>
<summary>Full question</summary>

```
A 62-year-old woman was referred with hypertension, which had been recently diagnosed. She had no previous history of note and was not taking any medication. 

 On examination, her BP was 180/110 mmHg. 

 Investigations: 
 serum sodium  142 mmol/L (137–144) 
 serum potassium  3.8 mmol/L (3.5–4.9) 
 plasma renin concentration  4.5 mIU/L (5.4–60.0) 
 plasma aldosterone  1357 pmol/L (90–720) 
 What is the most appropriate next investigation to confirm the diagnosis? a) adrenal venous sampling, b) aldosterone suppression testing, c) CT scan of adrenal glands, d) PET-CT scan of adrenal glands, or e) supine and upright plasma renin and aldosterone concentrations
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | supported | Used for lateralization/subtyping after a diagnosis of primary aldosteronism has been confirmed; not a first‑line confirmatory test but part of subsequent evaluation. |
| B (expected) | supported | Guidelines recommend a suppressibility test (e.g., saline infusion, fludrocortisone, or captopril challenge) to definitively confirm primary aldosteronism after a positive ARR. |
| C | supported | Initial imaging modality to detect adrenal masses and exclude carcinoma; recommended early in work‑up but does not confirm endocrine diagnosis. |
| D | contradicted | PET‑CT is not recommended for the diagnosis or confirmation of primary aldosteronism; guidelines do not list it as a valid confirmatory investigation. |
| E | supported | Measurements are used to calculate ARR and assess postural changes; part of initial assessment but not a stand‑alone confirmatory test. |

#### RAG retrieval context (5 shown)
1. **AdrenalLiterature/The adrenal gland - Endocrinology - NCBI Bookshelf.pdf** — score=3.375, round=1
   > This is due to the excess aldosterone-induced sodium retention by the kidney in exchange for Kt and Ht that are lost in urine. Primary hyperaldosteronism is usually due to an adrenal adenoma (Box 4.38). Typically, patients are between the ages of 30 and 50 years and are more often female than male. They form much less than 1% of all cases of systemic hypertension in this age group but are importan…
2. **AdrenalLiterature/Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=2.875, round=1
   > early-onset hypertension Or cerebrovascular accident at a young age &lt;40 yr). We also recommend case detection for all hypertensive first-degree relatives of patients with PA. (1IPOOO)  1.2 We recommend use of the plasma aldosterone to renin ratio (ARR) to detect cases of PA in these patient groups. (1IDDOO)  ## 2.0 Case confirmation  2.1 Instead of proceeding directly to subtype classification,…
3. **AdrenalLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.625, round=1
   > The  confirmatory test for  primary aldosteronism was  also positive, with  24-hour urinary excretion  of aldosterone of  1 6 11g on  a high-sodium  diet  (urinary sodium,  356  mEq/24 h). A. Adrenal CT  split section axial images  show  a  1 2-mm thickening (large arrow)  in the  inferior aspect  of the  left adrenal gland and  a tiny nodule  (small arrow)  in the  right adrenal gland. The  patie…
4. **AdrenalLiterature/Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=2.0, round=1
   > It should be noted that confirmatory tests requiring oral or iv sodium loading should be administered with caution in patients with uncontrolled hypertension or congestiveheart failure. We recommend that the macological agents with minimal or no effects on the renin-angiotensin-aldosterone system shown in Table2 be usedto control blood pressure during confirmatory testing: phar-  ## 2.1 Values  Co…
5. **AdrenalLiterature/Endocrinology and Diabetes Book.pdf** — score=1.75, round=1
   > In doubt, the test can be repeated off these drugs for 2 weeks; BP can be controlled using doxazosin or calcium antagonists. False -ve results can also occur in patients with CRF due to upregulated plasma renin.  ## Confirmation of diagnosis  When there is spontaneous hypokalaemia, plasma renin below detection levels, and aldosterone concentrations >550pmol/  L, there may be no need for confirmato…

#### Flow retrieval context (5 shown)
1. **Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=4.5625, round=1
   > (1IPOOO)  1.2 We recommend use of the plasma aldosterone to renin ratio (ARR) to detect cases of PA in these patient groups. (1IDDOO)  ## 2.0 Case confirmation  2.1 Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo testby any of four confirmatory tests, to definitively confirm or exclude the diagnosis. (1IEPOO) ing,  ## 3.0 Subtype cla…
2. **Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=3.5, round=1
   > sion stage 2 (7160-179/100-109 mm Hg), stage 3 (>180/110 mm Hg), or drug-resistant hypertension; hypertension and spontaneous or diuretic-induced hypokalemia; hypertension with renal incidentaloma; or hypertension and family history of ad-  Abbreviations: ARR, Aldosterone to renin ratio; APA, aldosterone-producing adenoma; AVS, adrenal venous sampling; CT, computed tomography; DRC, direct renin co…
3. **The adrenal gland - Endocrinology - NCBI Bookshelf.pdf** — score=3.25, round=1
   > Typically, patients are between the ages of 30 and 50 years and are more often female than male. They form much less than 1% of all cases of systemic hypertension in this age group but are important in having a surgically curable form of hypertension. only  Once suspected, hyperaldosteronism can be confirmed by the measurement of 24 h urine aldosterone and by investigation of the feedback between …
4. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.0, round=1
   > c  FIGURE 1 0-8 A  4 8-year-old  man  had a  7-year history  of hypertension that was  not optimally controlled on  four antihypertensive drugs (�-adrenergic blocker, peripheral a1 -antagonist, angiotensin receptor blocker, and  a thiazide diuretic). He  was  not hypokalemic. Resistant hyperten­ sion  prompted case-detection testing for primary aldosteronism with  a  plasma  aldosterone concentrat…
5. **Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. An Endocrine Society Clinical Practice Guideline.pdf** — score=2.25, round=1
   > DRC assays are still in evolution, and in a recently introduced and already commonly used automated DRC assay, the conversion factor is 12 (see text)  most commonly adopted cutoff values are shown in bold: 30 for PAC and PRA in conventional units (equivalent to 830 when PAC is in Sl units) and 750 when PAC is expressed in Sl units (equivalent to 27 in conventional units). The  reflecting values ov…

- **RAG-only sources:** endocrinology and diabetes book.pdf
- **Flow-only sources:** —

**Attempted retrieval queries (flow):**
1. `A 62-year-old woman was referred with hypertension, which had been recently diagnosed. She had no previous history of note and was not taking any medication. On examination, her BP was 180/110 mmHg. Investigations: serum…`

---

### Case 29: UKEU

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** answerability:insufficient, answerability:missing_anchors, follow_up:triggered, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:baseline_selector, verifier:followup_used
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 4 shared sources, avg text similarity=0.577, rounds=[1]
- **Answerability:** sufficient=False, confidence=low
- **Reasoning confidence:** low

**Answerability rationale:**
> The evidence discusses lifestyle measures, metformin, and aromatase inhibitors in PCOS-related infertility but does not provide direct comparative efficacy data for anastrozole versus diet/exercise versus metformin for achieving pregnancy in this specific case. Therefore the most effective next step cannot be definitively identified from the supplied material.

**Reasoning rationale:**
> International guidelines identify aromatase inhibitors as first‑line pharmacological treatment for ovulation induction in PCOS, and they are more effective than metformin or lifestyle measures alone for achieving pregnancy; therefore anastrozole is the most appropriate next step.

<details>
<summary>Full question</summary>

```
A 27-year-old woman presented with oligomenorrhoea and hirsutism, and a 2-year history of infertility. Her partner had a recent normal sperm count and motility test.

On examination, her BMI was 26.0 kg/m^2 (18.0–25.0).

Investigations:
- serum androstenedione: 17.0 nmol/L (0.6–8.8)
- serum 17-hydroxyprogesterone: 2 nmol/L (1–10)
- serum total testosterone: 2.8 nmol/L (0.5–3.0)
- serum sex hormone binding globulin: 18 nmol/L (40–137)
- serum follicle-stimulating hormone: 2.3 U/L (2.5–10.0)
- serum luteinising hormone: 8.3 U/L (2.5–10.0)
- serum prolactin: 152 mU/L (100–600)

What is the most effective next step to help her conceive? a) anastrozole, b) diet and exercise, c) in vitro fertilisation, d) metformin, or e) orlistat
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | supported | Guideline recommends aromatase inhibitors (e.g., letrozole, anastrozole) as first‑line ovulation‑inducing agents for PCOS‑associated infertility, and they have demonstrated higher  |
| B | contradicted | Lifestyle modification is advised but is considered adjunctive; pharmacologic ovulation induction with aromatase inhibitors is prioritized for maximizing conception rates. |
| C | contradicted | IVF is recommended only after failure of ovulation induction and is third‑line, not the most effective initial step. |
| D | contradicted | Metformin shows lower efficacy than aromatase inhibitors for ovulation induction and live birth in PCOS. |
| E | contradicted | Orlistat lacks evidence for improving fertility in PCOS and is not recommended as a next step. |

#### RAG retrieval context (5 shown)
1. **ReproductiveEndocrinologyLiterature/Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.pdf** — score=2.0, round=1
   > This current paper is restricted to the section of the line addressing the assessment and management of infertility in PCOS The clinical context and evidence informing the infertility section of the guideline published in the full guideline (International  EvidenceBased Guidelines for the Assessment and Management of Polycystic Ovary Syndrome; 2018). first linary guide -  The treatment of infertil…
2. **ReproductiveEndocrinologyLiterature/Ovarian hyperthecosis - UpToDate.pdf** — score=1.875, round=1
   > - Metabolic issues: Obesity and type 2 diabetes Weight reduction in females with OHT and obesity results in an increase in insulin sensitivity [43]. In patients with OHT and established type 2 diabetes mellitus, metformin is first-line therapy for glycemic management [42]. Other effects include potential weight loss and a modest decrease in serum triglycerides and Iow-density lipoprotein (LDL) Met…
3. **ReproductiveEndocrinologyLiterature/Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.pdf** — score=1.875, round=1
   > Repeated cycles- shared decision-making considering age and resources then to IVF No  Yes  Gonadotrophinsc with US monitoring. Adjusting dose as required.  Second line Medical Treatment  Can consider Laparoscopic ovarian surgery, noting need for facilities and experience  \  ## Or  Yes  No  Ovulation detected? Repeated cycles - shared decision-making considering age and resources then to IVF  Thir…
4. **ReproductiveEndocrinologyLiterature/Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.pdf** — score=1.5, round=1
   > However, recommended off label use is evidence-based and allowed in many countries. Where it is allowed, health professionals should inform women and discuss the evidence, possible concerns and side effects of treatment. d. Compared to letrozole, metformin has lower efficacy, cost and multiple pregnancy rate and gonadotrophins have higher efficacy, cost and multiple pregnancy rate. Both may be an …
5. **ReproductiveEndocrinologyLiterature/williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.25, round=1
   > 304  However, the ovulatory response to clomiphene was increased in obese women with PCOS by decreasing insulin secretion with the addition of metformin. 307,308,323 A  later  randomized  study  showed  that  the higher rate of ovulation in the users of clomiphene plus metformin seemed to be offset by a higher rate of pregnancy losses, producing similar live birth rates in clomiphene-only and clom…

#### Flow retrieval context (5 shown)
1. **Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.pdf** — score=1.875, round=1
   > d. Compared to letrozole, metformin has lower efficacy, cost and multiple pregnancy rate and gonadotrophins have higher efficacy, cost and multiple pregnancy rate. Both may be an alternative first line choice for informed women. e. In vitro fertilization (IVF) - Third line unless other infertility factors (e.g. male, tubal). PCOS specific protocols to minimise risk of ovarian hyperstimulation synd…
2. **Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome.pdf** — score=1.25, round=1
   > or an elevated testosterone level1o), polycystic ovaries (defined by an increased number of small antral follicles [212 follicles that were <10 mm in diameter] or an increased individual ovarian volume [>10 cm:] in 21 ovary), or both.9 Other disorders that mimic the polycystic ovary syndrome; including thyroid disease and prolactin excess, were ruled out:  Additional eligibility criteria were at l…
3. **williams-textbook-of-endocrinology-12th-edition.pdf** — score=1.125, round=1
   > Lack of response at doses of 150 to 200 mg daily for 5 days should be an indication for a change of treatment. Most patients destined to conceive do so with the starting dose of clomiphene citrate (50 mg/day for 5 days). Most clomiphene citrate-initiated conceptions occur within the first 6 ovulatory cycles. 325 The incidence rate for multiple gestation in clomiphene citrate-induced pregnancies is…
4. **Endocrinology and Diabetes Book.pdf** — score=1.125, round=1
   > - In ♀ with clinical evidence of hyperandrogenism, measure serum testosterone, and consider SHBG and 17OHP. - In ♀ with hyperprolactinaemia or otherwise unexplained HH, arrange pituitary MRI.   Fig. 4.12 Investigation and management of ♀ infertility.  This image displays a flow chart outlining an assessment process for women with infertility or irregular menstrual cycles. The chart is presented in…
5. **Ovarian hyperthecosis - UpToDate.pdf** — score=0.875, round=1
   > The reasons for this are unclear: The impact of androgen suppression on insulin sensitivity was addressed in a trial of 35 postmenopausal females without diabetes assigned to receive metformin or leuprolide acetate [42]. Metformin therapy reduced serum T and improved insulin resistance and insulin sensitivity: Leuprolide acetate reduced serum T to a greater degree than metformin, but no improvemen…

- **RAG-only sources:** —
- **Flow-only sources:** endocrinology and diabetes book.pdf, letrozole versus clomiphene for infertility in the polycystic ovary syndrome.pdf

**Attempted retrieval queries (flow):**
1. `A 27-year-old woman presented with oligomenorrhoea and hirsutism, and a 2-year history of infertility. Her partner had a recent normal sperm count and motility test. On examination, her BMI was 26.0 kg/m^2 (18.0–25.0). I…`
2. `A 27-year-old woman presented with oligomenorrhoea and hirsutism, and a 2-year history of infertility. Her partner had a recent normal sperm count and motility test. On examination, her BMI was 26.0 kg/m^2 (18.0–25.0). I…`
3. `A 27-year-old woman presented with oligomenorrhoea and hirsutism, and a 2-year history of infertility. Her partner had a recent normal sperm count and motility test. On examination, her BMI was 26.0 kg/m^2 (18.0–25.0). I…`
4. `A 27-year-old woman presented with oligomenorrhoea and hirsutism, and a 2-year history of infertility. Her partner had a recent normal sperm count and motility test. On examination, her BMI was 26.0 kg/m^2 (18.0–25.0). I…`
5. `A 27-year-old woman presented with oligomenorrhoea and hirsutism, and a 2-year history of infertility. Her partner had a recent normal sperm count and motility test. On examination, her BMI was 26.0 kg/m^2 (18.0–25.0). I…`
6. `PCOS infertility treatment first line…`
7. `anastrozole ovulation induction PCOS…`
8. `lifestyle modification PCOS fertility…`

---

### Case 30: UKEU

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** retrieval:rag_has_unique_sources, reasoning:likely_reasoning_error, decision:arbiter_used, decision:arbiter:agentic, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 3 shared sources, avg text similarity=0.623, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Current guidelines indicate that a thyroid nodule classified as US category U3, measuring >1 cm, with benign cytology (Thy2) should be managed by considering diagnostic hemithyroidectomy after shared decision‑making, while observation alone or repeat FNA are not the preferred next steps. Other options (reassurance, radiofrequency ablation, total thyroidectomy with radioiodine) are not supported by the evidence for this scenario.

**Reasoning rationale:**
> The patient has a 1.2‑cm thyroid nodule classified as ultrasound category U3 with Thy2 benign cytology and normal thyroid function. Current joint‑trust guideline (evidence id ev_420b1055fd03) recommends diagnostic hemithyroidectomy after shared decision‑making for such lesions in individuals >65 years, rather than observation, repeat FNA, or ablative therapies.

<details>
<summary>Full question</summary>

```
A 76-year-old woman underwent a CT scan of chest and was incidentally found to have a 1.2-cm nodule in the left lobe of the thyroid gland. An ultrasound scan of thyroid confirmed the nodule, which was reported as U3.

On examination of her neck, a small nodule approximately 1 cm in size was seen. No lymph nodes were palpable. A fine-needle aspiration of the nodule was performed.

Investigations:
- serum thyroid-stimulating hormone: 2.5 mU/L (0.4–5.0)
- serum free T4: 18.4 pmol/L (10.0–22.0)
- cytology: colloid nodule; Thy2

What is the most appropriate next step in management? a) reassure and discharge, b) refer for hemi-thyroidectomy, c) refer for radiofrequency ablation, d) refer for total thyroidectomy and radioiodine ablation, or e) repeat FNA in 3–6 months
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | contradicted | Reassurance is unsafe given U3 nodule >1 cm and patient age >65 requiring surgical evaluation. |
| B | supported | Guideline recommends diagnostic hemithyroidectomy for U3 nodules >1 cm in patients >65 with benign cytology after shared decision‑making. |
| C | contradicted | Radiofrequency ablation is not indicated for nodules >1 cm with suspicious ultrasound (U3) and benign cytology; guideline does not endorse it. |
| D | contradicted | Total thyroidectomy with radioiodine is reserved for malignant or malignant‑suspected nodules; not appropriate here. |
| E | contradicted | Repeat FNA is unnecessary as cytology already thy2 (benign) and US shows U3 >1 cm; observation not recommended. |

#### RAG retrieval context (5 shown)
1. **ThyroidLiterature/Joint-Trust-Guideline-for-the-Management-of-Thyroid-Nodules-in-Adults-JCG0042-v3-1.pdf** — score=5.4375, round=1
   > If the nodule remains stable with benign features on repeat USS the patient be reassured this is benign. Surgery or radioactive iodine may be offered for nodules causing compressive or significant cosmetic symptoms, while smaller, euthyroid and asymptomatic nodules do not require long term follow up or treatment: may  - 3 Ultrasound guided FNA is indicated for nodules with any suspicious character…
2. **ThyroidLiterature/Clinical Endocrinology - 2026 - Moorthy - Evaluation and Management of Thyroid Nodules A Joint Consensus Statement From.pdf** — score=5.0625, round=1
   > to, - U3 nodule &gt; 1 cm with Thy2 cytology results: The malignancy risk for U3 nodules is up to 22%, but when combined with Thy2 cytology, the risk is reduced to less than 10% [5, 19]. Repeat FNAC is not mandated when single Thy2 result is supported by two stable ultrasounds or the patient has two consecutive Thy2 results [117, 140]. Discharge is appropriate if the nodule is stable on repeat ult…
3. **ThyroidLiterature/Clinical Endocrinology - 2014 - Perros - Guidelines for the management of thyroid cancer.pdf** — score=4.375, round=1
   > either benign (U2), equivocal/indeterminate (U3), suspicious (U4) or malignant (U5) as outlined in the U classification, Fig. 4.1.  ## Good Practice Point ☑  - ii A report should identify the various characteristics and give appropriate measurements of significant thyroid nodules/ masses and the U score. In multinodular thyroids, the score for the most suspicious nodule should be recorded.  ## Goo…
4. **ThyroidLiterature/A pragmatic assessment of the British Thyroid Association “U classification” of thyroid nodules with a focus on their follow-up.pdf** — score=4.0, round=1
   > 5%) | | | | Malignant | 22 (26.6%) | 9 (26.5%) | p = 0.9 |  ---  ### Note - FNAC = fine-needle aspiration cytology    and cytological follow-up may not be cost effective in this patient category as the risk of malignancy seems to be low. Very  few or none of these patients will  develop distant metastasis Or die of thyroid cancer29 In the present study, cancer was diagnosed in 30.4% of patients wi…
5. **ThyroidLiterature/Joint-Trust-Guideline-for-the-Management-of-Thyroid-Nodules-in-Adults-JCG0042-v3-1.pdf** — score=3.625, round=1
   > ## Incidentally found thyroid nodules on other imaging  Increasingly, thyroid nodules are being incidentally found on other imaging, e.g: chest CT. These do not need routine follow up or assessment unless there are any suspicious features in the history or examination. A thyroid US is the initial investigation of choice.  | Diagnostic category                                                       …

#### Flow retrieval context (5 shown)
1. **Joint-Trust-Guideline-for-the-Management-of-Thyroid-Nodules-in-Adults-JCG0042-v3-1.pdf** — score=6.25, round=1
   > key - 2 A thyroid ultrasound is the most accurate method to evaluate thyroid nodules and is the procedure of choice in initial evaluation of the thyroid lump:  Nodules with benign features (U2) on US do not require an FNA UNLESS there is a significant risk of cancer: Clinical assessment is required to determine their optimum follow up. So, small stable lesions with no worrying features on US or on…
2. **Joint-Trust-Guideline-for-the-Management-of-Thyroid-Nodules-in-Adults-JCG0042-v3-1.pdf** — score=4.75, round=1
   > However, if the patient has a life expectancy of less than 5 years assessment may not be clinically appropriate.  ## Incidentally found thyroid nodules on other imaging  Increasingly, thyroid nodules are being incidentally found on other imaging, e.g: chest CT. These do not need routine follow up or assessment unless there are any suspicious features in the history or examination. A thyroid US is …
3. **Clinical Endocrinology - 2014 - Perros - Guidelines for the management of thyroid cancer.pdf** — score=3.375, round=1
   > ## Key Recommendation  - iii Any abnormal lymph node in the neck should undergo FNAC to facilitate accurate diagnosis/staging ( 2++ , B ).  ## 4.4. Radiology reporting  - i If a nodule is being assessed by US, the practitioner (be they a sonographer, surgeon, endocrinologist or radiologist) should be competent in identifying the characteristic signs that can allow a differentiation of thyroid nodu…
4. **Clinical Endocrinology - 2026 - Moorthy - Evaluation and Management of Thyroid Nodules A Joint Consensus Statement From.pdf** — score=3.125, round=1
   > Repeat FNAC is not mandated when single Thy2 result is supported by two stable ultrasounds or the patient has two consecutive Thy2 results [117, 140]. Discharge is appropriate if the nodule is stable on repeat ultrasound at 12 months [122, 132, 141-143]. Repeat FNAC is, however, recommended in the presence of ipsilateral lymphadenopathy, vocal cord palsy, interval growth or change in sonographic a…
5. **Thyroid cancer. assessment and management.pdf** — score=2.25, round=1
   > For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on performing and reporting FNAC:  Full details of the evidence and the committee's discussion are in evidence review D: diagnostic accuracy of fine needle aspiration cytology:  ## Management and further sampling after initial FNAC  - 1.2.11 Use the initi…

- **RAG-only sources:** a pragmatic assessment of the british thyroid association “u classification” of thyroid nodules with a focus on their follow-up.pdf
- **Flow-only sources:** thyroid cancer. assessment and management.pdf

**Attempted retrieval queries (flow):**
1. `A 76-year-old woman underwent a CT scan of chest and was incidentally found to have a 1.2-cm nodule in the left lobe of the thyroid gland. An ultrasound scan of thyroid confirmed the nodule, which was reported as U3. On …`

---

### Case 31: UKEU

- **Expected:** D
- **RAG answer:** D (correct)
- **Flow answer:** B (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** answerability:insufficient, answerability:missing_anchors, follow_up:triggered, reasoning:likely_reasoning_error, decision:agreement, reasoning:wrongly_supported_selected_option, reasoning:wrongly_rejected_correct_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 4 shared sources, avg text similarity=0.631, rounds=[1]
- **Answerability:** sufficient=False, confidence=medium
- **Reasoning confidence:** medium

**Answerability rationale:**
> The clinical picture shows a hyperosmolar state with mild acidosis (pH 7.30) and low ketone level (0.1 mmol/L). According to the guideline, insulin infusion is not started immediately in HHS with low ketones and not acidotic; instead fluids are given first and insulin infusion (0.05‑0.1 U/kg/h) is started only after glucose plateaus. The question lacks patient weight, β‑hydroxybutyrate level and exact pH threshold, so the exact recommended regimen cannot be determined from the provided data.

**Reasoning rationale:**
> The clinical picture demonstrates hyperglycemia, mild metabolic acidosis (pH 7.30) and low ketones (0.1 mmol/L), consistent with a hyperosmolar hyperglycemic state (HHS). According to the JBDS guideline, insulin infusion should be started at 0.1 U/kg/h after adequate fluid replacement, which matches option b.

<details>
<summary>Full question</summary>

```
A 56-year-old woman was admitted from the emergency department with confusion. 
 Investigations: 
 serum sodium  145 mmol/L (137–144) 
 serum potassium  4.3 mmol/L (3.5–4.9) 
 serum bicarbonate  16 mmol/L (20–28) 
 serum creatinine  273 µmol/L (60–110) 
 random blood glucose  42.0 mmol/L (3.0–11.1) 
 capillary blood ketones  0.1 mmol/L (<0.6) 
 venous blood gases, breathing air: 
   pH  7.30 (7.35–7.45) 
 What is the most appropriate initial insulin treatment regimen? a) bolus intravenous dose of 10 units, b) fixed-rate intravenous infusion at 0.1 units/kg/h, c) fixed-rate intravenous infusion at 1 unit/h, d) no insulin initially, or e) variable-rate intravenous infusion
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A | contradicted | Initial insulin therapy for HHS should be a continuous infusion, not a bolus; guidelines specify low‑dose infusion. |
| B | supported | Guidelines recommend a low‑dose continuous IV insulin infusion at 0.1 U/kg/h for HHS with mild ketosis and acidosis. |
| C | contradicted | Dose is not weight‑based and exceeds recommended 0.1 U/kg/h; not indicated initially. |
| D (expected) | contradicted | Insulin infusion is indicated after fluid resuscitation for hyperglycemia and metabolic acidosis in this setting. |
| E | contradicted | Variable‑rate infusion is used later after glucose plateau; not the initial regimen. |

#### RAG retrieval context (5 shown)
1. **DiabetesLiterature/JBDS_06_The_Management_of_Hyperosmolar_Hyperglycaemic_State_HHS_ in_Adults_FINAL_0.pdf** — score=5.1875, round=1
   > ## Appendix 3  ## When and How to Start Fixed-Rate Intravenous Insulin Infusions (FRIII) in HHS  ## Scenario 1 HHS and blood ketones &lt;3.0 mmol/L and not acidotic (venous pH &gt;7.3 and bicarbonate &gt;15.0 mmol/L)  - Do not start FRIII immediately - Continue to monitor hourly capillary glucose during IV fluid replacement (use Hi') - Once glucose plateaus with fluid replacement alone, commence F…
2. **DiabetesLiterature/Hyperglycemic Crises - Endotext - NCBI Bookshelf.pdf** — score=5.125, round=1
   > Overall, the of treatment are a decrease in osmolality between 3 and 8 mOsmol/kg per hour; a sodium reduction by no more than 10 mmoVL in 24 hours, and hourly glucose fall by up to Smmol/L (37). goal goals  ## Insulin  Insulin therapy is the mainstay of DKA treatment and should be started immediately after the diagnosis using a fixed-rate intravenous insulin infusion started at 0.1 units/kg/h. Sho…
3. **DiabetesLiterature/Hyperglycaemic crises in adults with diabetes. a consensus report.pdf** — score=5.0, round=1
   > In such patients, the use of a standard fluid replacement protocol may be associated with treatment-related complications, including volume overload, need for mechanical ventilation and longer length of stay [131].  Insulin Insulin therapy is the cornerstone of DKA management and should be started as soon as possible after diagnosis. Short-acting insulin administered intravenously by continuous in…
4. **DiabetesLiterature/JBDS_06_The_Management_of_Hyperosmolar_Hyperglycaemic_State_HHS_ in_Adults_FINAL_0.pdf** — score=4.6875, round=1
   > cerebral oedema/ central pontine myelinolysis osmotic demyelination syndrome - foot ulceration  ## Management timeline:  ## 0 to 60 minutes  T=0 at time intravenous fluids are commenced: If there is a problem with intravenous access critical care support should be requested immediately:  ## Intravenous fluid  Commence IV 0.9% sodium chloride \_ litre to run over 1 hour  - Caution in the elderly wh…
5. **DiabetesLiterature/The Management of Diabetic Ketoacidosis in Adults.pdf** — score=4.5, round=1
   > Fluids should be replaced cautiously:  ## Action 3 Potassium replacement  Hypokalaemia and hyperkalaemia are life threatening conditions and are common in DKA. Serum potassium is often high on admission (although total body potassium is low) but falls precipitously upon treatment with insulin. Regular monitoring is mandatory.  #### Potassium level in first 24 hours Potassium replacement in mmol/L …

#### Flow retrieval context (5 shown)
1. **JBDS_06_The_Management_of_Hyperosmolar_Hyperglycaemic_State_HHS_ in_Adults_FINAL_0.pdf** — score=5.9375, round=1
   > In the hyperosmolar state, osmolality is useful as an indicator of severity and for monitoring the rate of change with treatment: If frequent measurement of osmolality is not practical, osmolality should be made calculated using the formula [(2Nat) + glucose + urea]:   ## Appendix 3  ## When and How to Start Fixed-Rate Intravenous Insulin Infusions (FRIII) in HHS  ## Scenario 1 HHS and blood keton…
2. **Hyperglycaemic crises in adults with diabetes. a consensus report.pdf** — score=5.375, round=1
   > Short-acting insulin administered intravenously by continuous infusion is the preferred choice. Depending on the severity of the condition and the available facilities, this should be done using a fixed-rate intravenous insulin infusion started at 0.1 U   kg -1 h -1 [1-3, 12, 132] or by a nursedriven insulin infusion protocol with a variable rate for DKA [133]. In adults, treatment protocols recom…
3. **Hyperglycemic Crises - Endotext - NCBI Bookshelf.pdf** — score=5.375, round=1
   > goal goals  ## Insulin  Insulin therapy is the mainstay of DKA treatment and should be started immediately after the diagnosis using a fixed-rate intravenous insulin infusion started at 0.1 units/kg/h. Short-acting insulin is the preferred choice. An insulin bolus (0.1 units/kg/hour) given intravenously O intramuscularly is suggested in some treatment protocols if a delay in obtaining venous acces…
4. **Hyperglycaemic crises in adults with diabetes. a consensus report.pdf** — score=5.375, round=1
   > The use of rapid-acting subcutaneous insulin analogues is not recommended for the treatment of severe and complicated DKA or with HHS.  Few studies have assessed the optimal insulin regimen in HHS. If the individual is already being treated with basal insulin, it should be continued at the usual dose and adjusted as needed. If HHS is present with no ketosis or with mild or moderate ketonaemia (blo…
5. **The Management of Diabetic Ketoacidosis in Adults.pdf** — score=5.1875, round=1
   > ## Table: Typical deficits in DKA in adults  Water 100 mllkg Sodium 7-10 mmol/kg Chloride 3-5 mmollkg Potassium  The type of fluid to be used is discussed in detail in Controversial Areas.  ## Insulin therapy  fixed rate intravenous insulin infusion (FRIII) calculated on 0.1 units/per kilogram body weight is recommended (see table below to assist). It may be necessary to estimate the weight of the…

- **RAG-only sources:** —
- **Flow-only sources:** endocrinology and diabetes book.pdf, greenspan’s basic and clinical endocrinology.pdf

**Attempted retrieval queries (flow):**
1. `A 56-year-old woman was admitted from the emergency department with confusion. Investigations: serum sodium 145 mmol/L (137–144) serum potassium 4.3 mmol/L (3.5–4.9) serum bicarbonate 16 mmol/L (20–28) serum creatinine 2…`
2. `A 56-year-old woman was admitted from the emergency department with confusion. Investigations: serum sodium 145 mmol/L (137–144) serum potassium 4.3 mmol/L (3.5–4.9) serum bicarbonate 16 mmol/L (20–28) serum creatinine 2…`
3. `A 56-year-old woman was admitted from the emergency department with confusion. Investigations: serum sodium 145 mmol/L (137–144) serum potassium 4.3 mmol/L (3.5–4.9) serum bicarbonate 16 mmol/L (20–28) serum creatinine 2…`
4. `A 56-year-old woman was admitted from the emergency department with confusion. Investigations: serum sodium 145 mmol/L (137–144) serum potassium 4.3 mmol/L (3.5–4.9) serum bicarbonate 16 mmol/L (20–28) serum creatinine 2…`
5. `A 56-year-old woman was admitted from the emergency department with confusion. Investigations: serum sodium 145 mmol/L (137–144) serum potassium 4.3 mmol/L (3.5–4.9) serum bicarbonate 16 mmol/L (20–28) serum creatinine 2…`
6. `A 56-year-old woman was admitted from the emergency department with confusion. Investigations: serum sodium 145 mmol/L (137–144) serum potassium 4.3 mmol/L (3.5–4.9) serum bicarbonate 16 mmol/L (20–28) serum creatinine 2…`
7. `initial insulin regimen DKA…`
8. `0.1 units/kg/h insulin infusion…`

---

### Case 32: UKEU

- **Expected:** A
- **RAG answer:** A (correct)
- **Flow answer:** C (wrong)
- **Failure bucket:** likely_reasoning
- **Failure tags:** reasoning:likely_reasoning_error, decision:agreement, reasoning:wrongly_rejected_correct_option, reasoning:wrongly_supported_selected_option
- **Question polarity (heuristic):** standard
- **Flow detected polarity:** standard
- **Retrieval overlap:** 2 shared sources, avg text similarity=0.668, rounds=[1]
- **Answerability:** sufficient=True, confidence=high
- **Reasoning confidence:** high

**Answerability rationale:**
> Elevated serum calcium with inappropriately high PTH, normal 25‑OH vitamin D and normal 24‑h urinary calcium are classic for primary hyperparathyroidism; the mild PTH elevation and normal‑range urinary calcium exclude familial hypocalciuric hypercalcaemia which typically shows true hypocalciuria.

**Reasoning rationale:**
> The biochemical pattern of hypercalcaemia with an inappropriately elevated PTH, normal 25‑OH vitamin D and normal 24‑h urinary calcium is diagnostic of primary hyperparathyroidism. Competing diagnoses such as familial hypocalciuric hypercalcaemia are ruled out by the normal urinary calcium excretion, and non‑PTH-mediated causes, pseudohypoparathyroidism, and secondary hyperparathyroidism are inconsistent with the laboratory findings.

<details>
<summary>Full question</summary>

```
A 31-year old woman was referred to the endocrinology clinic because of an incidental finding of hypercalcaemia. She had no relevant symptoms and was not taking any regular medication. 
 Investigations: 
 serum creatinine  60 µmol/L (60–110) 
 eGFR (CKD-EPI)  70 mL/min/1.73 m2 (>60) 
 serum adjusted calcium  2.70 mmol/L (2.20–2.60) 
 24-h urinary creatinine  12 mmol (9–18) 
 24-h urinary calcium  2.6 mmol (2.5–7.5) 
 plasma parathyroid hormone (PTH)  6.7 pmol/L (0.9–5.4) 
 serum 25-OH-cholecalciferol  64 nmol/L (50–120) 
 What is the most likely diagnosis? a) familial hypocalciuric hypercalcaemia, b) non-PTH-mediated hypercalcaemia, c) primary hyperparathyroidism, d) pseudohypoparathyroidism, or e) secondary hyperparathyroidism
```

</details>

**Option assessments (flow):**

| Option | Status | Rationale |
| --- | --- | --- |
| A (expected) | contradicted | The patient has normal 24‑h urinary calcium (2.6 mmol) rather than the pronounced hypocalciuria (<2.5 mmol) characteristic of FHH; additionally, the PTH level is modestly elevated  |
| B | contradicted | Serum PTH is inappropriately elevated (6.7 pmol/L) in the context of hypercalcaemia, indicating a PTH‑mediated process rather than a non‑PTH cause. |
| C | supported | The pattern of elevated serum calcium with an inappropriately normal/high PTH, normal 25‑OH vitamin D, and normal urinary calcium is classic for primary hyperparathyroidism; this i |
| D | contradicted | Pseudohypoparathyroidism typically presents with low or normal calcium levels and high PTH, but patients have end‑organ resistance and often abnormal phosphate metabolism; the hype |
| E | contradicted | Secondary hyperparathyroidism usually occurs with low or normal calcium, renal disease, or vitamin D deficiency; the patient’s normal renal function, normal vitamin D, and elevated |

#### RAG retrieval context (5 shown)
1. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=3.5, round=1
   > Overall, this image appears to be a medical document or educational resource intended for healthcare professionals or students.   ## Familial hypocalciuric hypercalcaemia  FHH is a very rare aD syndrome associated with hypercalcaemia and relative hypocalciuria that is most often due to heterozygous inactivating mutations of the CASR gene encoding the Ca-  sensing receptor.  - Rare-  incidence 7 1:…
2. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=3.25, round=1
   > ## Box 6.1  Adjustment of measured calcium concentration  adjusted Ca = measured Ca + 0.02 × (40 - albumin)  (where Ca is in mmol/  L, and albumin in g/  L)  ## Tips  - When albumin is very low, this formula is not reliable. - In critical illness, factors such as metabolic acidosis can affect Ca binding to proteins. - If  doubt whether total serum Ca reflects ionized Ca, ionized levels should be m…
3. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=3.0, round=1
   > (Exclude other causes of hypercalciuria, including renal insufficiency and vitamin D deficiency.)  ## Tips  - Genetic panel testing for FHH can also be used to help differentiate from PHPT. - It may shorten the diagnostic odyssey and may prove a cost-  effective approach, especially if biochemical tests are not immediately definitive.  ## Phosphate  - 24h collection: - Little clinical utility-  re…
4. **ParathyroidLiterature/Endocrinology and Diabetes Book.pdf** — score=3.0, round=1
   > With adjusted serum Ca levels <3.0mmol/  L, significant classical  hypercalcaemia-  related  symptoms  are  unlikely.  With  progressive increases in Ca concentration, the likelihood of symptoms increases rapidly.  The  clinical features of hypercalcaemia are well recognized (see Table  6.2).  Unfortunately,  they  are  non-  specific  and  may  relate  to  an underlying illness.  Clinical  signs …
5. **ParathyroidLiterature/Greenspan’s Basic and Clinical Endocrinology.pdf** — score=2.5, round=1
   > Hypercalcemia is usually mild (10.5- 12 mg/dL [2.7-3 mmol!LJ)  and is often accompanied by mild hypophospharemia and hypermagnesemia. The PTH level is normal  or slightly ele­ vated, indicating that this is a PTH-dependem form of hypercal­ cemia.  The  parathyroid  glands  are  normal  in  size  or  slightly enlarged. The  most  notable laboratory feature of the disorder is hypocalciuria. The  uri…

#### Flow retrieval context (5 shown)
1. **Endocrinology and Diabetes Book.pdf** — score=3.75, round=1
   > The text is written in a formal, medical style and includes technical terms and abbreviations.  At the bottom of the image, there is a small section that provides references for the information in the document. This section includes a source citation for the data presented, which is credited to the Journal of the American Medical Association (JAMA). Overall, this image appears to be a medical docu…
2. **Endocrinology and Diabetes Book.pdf** — score=3.625, round=1
   > (Exclude other causes of hypercalciuria, including renal insufficiency and vitamin D deficiency.)  ## Tips  - Genetic panel testing for FHH can also be used to help differentiate from PHPT. - It may shorten the diagnostic odyssey and may prove a cost-  effective approach, especially if biochemical tests are not immediately definitive.  ## Phosphate  - 24h collection: - Little clinical utility-  re…
3. **Greenspan’s Basic and Clinical Endocrinology.pdf** — score=3.625, round=1
   > The PTH level is normal  or slightly ele­ vated, indicating that this is a PTH-dependem form of hypercal­ cemia.  The  parathyroid  glands  are  normal  in  size  or  slightly enlarged. The  most  notable laboratory feature of the disorder is hypocalciuria. The  urinary calcium level is usually less  than  50 mg/24 h, and the calcium/  creatinine  clearance  ratio  is less  rhan 0.01 and calculare…
4. **Endocrinology and Diabetes Book.pdf** — score=3.25, round=1
   > 522) (<0.01 in FHH; >0.02 in hyperparathyroidism); genetic testing for FHH.  ## Tips  - measurement of urine Ca excretion may be low if there is significant untreated vitamin D deficiency, even in the presence of PHPT. This can be misleading. Replace vitamin D and repeat measurement of urine calcium excretion. - Drugs associated with hypercalcaemia: - Thiazides-  ideally discontinue and reassess C…
5. **Endocrinology and Diabetes Book.pdf** — score=2.625, round=1
   > These are listed by order of importance in hospital practice in Box 6.3. In asymptomatic community-  dwelling subjects, the vast majority of hypercalcaemia is the result of PHPT.  ## Clinical features  Notwithstanding the underlying cause of hypercalcaemia, the clinical features are similar. With adjusted serum Ca levels <3.0mmol/  L, significant classical  hypercalcaemia-  related  symptoms  are …

**Attempted retrieval queries (flow):**
1. `A 31-year old woman was referred to the endocrinology clinic because of an incidental finding of hypercalcaemia. She had no relevant symptoms and was not taking any regular medication. Investigations: serum creatinine 60…`

---

## 7. Interpreting failure tags

| Tag | Likely fix direction |
| --- | --- |
| retrieval:no_source_overlap / retrieval:low_chunk_overlap | Flow retrieval query or domain routing differs from single-pass; check attempted_queries and routed_category. |
| retrieval:rag_has_unique_sources | RAG surfaced a useful document the flow missed — consider anchor-only vs decomposed queries. |
| polarity:misclassified_as_standard | Stem says "incorrect/except" but flow used standard polarity — fix analyze_mcq_stem / polarity propagation. |
| reasoning:wrongly_rejected_correct_option | Evidence supported the right answer but reasoning marked it contradicted/unsupported. |
| reasoning:wrongly_supported_selected_option | Flow confidently backed a wrong option — reasoning prompt or evidence grounding issue. |
| answerability:insufficient + follow_up:not_triggered | Flow knew evidence was weak but did not run a follow-up retrieval round. |
| reasoning:likely_reasoning_error | Chunks overlap with RAG yet answer differs — focus on reasoning stage, not retrieval. |

## 8. Recommended next steps

1. Prioritise datasets with negative Δ (flow worse than RAG).
2. For `likely_reasoning` cases, inspect option assessments and polarity handling.
3. For `likely_retrieval` cases, compare attempted queries and RAG-only sources.
4. Annotate each regression with a manual root-cause before changing the workflow.
